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Abstract 
The advent of advanced modern nanotechnology techniques offers new and exciting 
opportunities to develop novel nanotech-derived antimalarial nanodrugs with enhanced 
selective and targeting abilities that allow for lower effective drug dosages, longer drug 
persistence and reduced drug degradation within the body. Using a nanodrug approach also 
has the advantage of avoiding drug resistance problems that plague reconfigured versions of 
already-existing antimalarial drugs. In this study recombinant triosephosphate isomerase 
enzymes from Plasmodium falciparum (PfTIM) and Humans (hTIM) were recombinantly 
expressed, purified and characterised. PfTIM was shown to have optimal pH stability at pH 
5.0-5.5 and thermal stability at 25°C with Km 4.34 mM and Vmax 0.876 µmol.ml-1min-1. For 
hTIM, these parameters were as follows: pH optima of 6.5-7.0; temperature optima of 30°C, 
with Km 2.27 mM and Vmax 0.714 µmol.ml-1min-1. Recombinant TIM enzymes were subjected 
to inhibition studies using polyvinylpyrrolidone (PVP) stabilised silver nanoparticles 
(AgNPs) of 4-12 nm in diameter. These studies showed that the AgNPs were able to 
selectively inhibit PfTIM over hTIM with an 8-fold greater decrease in enzymatic efficiency 
(Kcat/Km) observed for PfTIM, as compared to hTIM, for kinetics tests done using 0.06 µM of 
AgNPs. Complete inhibition of PfTIM under optimal conditions was achieved using 0.25 µM 
AgNPs after 45 minutes while hTIM maintained approximately 31% of its activity at this 
AgNP concentration.  
The above results indicate that selective enzymatic targeting of the important, key metabolic 
enzyme TIM, can be achieved using nanotechnology-derived nanodrugs. It was demonstrated 
that the key structural differences, between the two enzyme variants, were significant enough 
to create unique characteristics for each TIM variant, thereby allowing for selective enzyme 
targeting using AgNPs. If these AgNPs could be coupled with a nanotechnology-derived, 
targeted localization mechanism – possibly using apoferritin to deliver the AgNPs to infected 
erythrocytes (Burns and Pollock, 2008) – then such an approach could offer new 
opportunities for the development of viable antimalarial nanodrugs. For this to be achieved 
further research into several key areas will be required, including nanoparticle toxicity, drug 
localization and testing the lethality of the system on live parasite cultures.  
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1.	Literature	review	
1.1 Malaria 
Malaria is a potentially fatal, yet treatable infectious disease, which kills hundreds of 
thousands of people every year, most of whom are children in Africa (Aregawi et al., 2011; 
Miller et al., 2002). It is caused by protozoan parasites of the genus Plasmodium. The disease 
is transmitted through female Anopheles mosquitoes. There are approximately 60 known 
species of Anopheles that act as hosts, with about 30 species being considered as highly 
important, of which only four can infect humans under natural conditions: P. falciparum, P. 
vivax, P. ovale and P. malariae. Of these it is only Plasmodium falciparum which results in 
severe and potentially fatal malaria (Tuteja, 2007; Miller et al., 2002). According to the 
World Health Organisation (WHO) 2011 report on malaria, an estimated 3.3 billion people 
are at risk of being exposed to malaria, with 1.2 billion deemed to live in high risk locations. 
In 2010 there were approximately 216 million cases of infection and between 537000 and 
907000 deaths, of which approximately 91% occurred  in Africa with 86% being children 
below the age of 5 (Aregawi et al., 2011). While it is true that the fight against malaria is 
showing signs of succeeding with a reduction in observed cases by approximately 17% since 
the year 2000 and a decrease in mortality by 26%, these figures are significantly lower than 
the targeted values of 50% fewer cases by 2010 (Aregawi et al., 2011).  
1.2 Fighting malaria 
The WHO currently recommends a wide variety of approaches for malaria control and 
treatment. These methods target two main aspects of the disease (a) the vector of the disease, 
mosquitoes and (b) the parasite itself. To limit vectors for the disease, the use of insecticide-
treated mosquito nets and indoor residual sprays (IRS) to treat walls and ceilings is currently 
recommended. Targeting insecticides to areas where mosquitoes typically land before and 
after feeding, limits vector spreading and overall pesticide usage. Pyrethroids, 
organophosphates and organochlorines, including Dichlorodiphenyltrichloroethane (DDT), 
are typically used as chemical insecticidal agents (Aregawi et al., 2011). While the 
pyrethroids are the most widely used insecticides - due to their low toxicity, cost and long-
levity - increasingly more toxic alternatives, such as DDT, are seeing a comeback.   
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The use of DDT is still controversial, but the potential benefits of its use, are often seen as a 
good enough reason to disregard scientific findings linking it to ill health effects. DDT 
exposure has shown links to various serious medical conditions such as; pancreatic cancer, 
breast cancer, non-hodgkins lymphoma and other cancers. Other concerning medical issues 
include; reproductive related problems, impaired lactation, androgen receptor antagonism 
linked to testicular cancers and low sperm counts, neurological poisoning effects such as; 
hypersensitivity, dizziness, irritability, tremors and convulsions (Longnecker et al., 1997; 
Snedeker, 2001). Yet other research and statistical analysis has called many of these findings 
into question (Longnecker et al., 1997). Nevertheless, DDT was initially banned in the 
1970's, and is currently banned in many countries (Rogan and Chen, 2001). 
Strategic monitoring for the spread of insecticide resistance is part of the WHO antimalaria 
program and 78 countries currently monitor for resistance. In sub-Saharan Africa, 27 
countries have reported pyrethroid resistance (Aregawi et al., 2011).  
Monitoring includes a promotion of research into the mechanisms of insecticide resistance 
within the mosquitoes and, so far, two main mechanistic methods of resistance development 
in mosquitoes have being identified. These are target site resistance and metabolic resistance. 
Target site resistance typically involves modifications that prevent insecticide binding at 
target sites of the mosquitos’ central nervous system. Such mutations have been shown to 
occur in acetylcholinesterase (the target of organophosphates and carbamates) and voltage-
gated sodium channels (the target of pyrethroids and DDT). On the other hand, metabolic 
resistance mechanisms observed usually involve an increase in expression and regulation of 
detoxifying enzymes that prevent insecticides reaching their target sites (Aregawi et al., 
2011).  
For treatment and prevention the WHO recommends that suspected malaria cases should 
undergo parasitological confirmation tests either via microscopy or with the use of rapid 
diagnosis tests that have been developed. For confirmed cases the recommended treatment is 
Artemisinin based combination therapy (ACT). In addition to this, a complete withdrawal of 
Artemisinin based monotherapies (AMT) is recommended. These AMT treatments are 
suspected of creating and harbouring the spread of Artemisinin-resistant parasites, which 
decrease the effectiveness of ACT’s (Dondorp et al., 2009; Aregawi et al., 2011). As of 
November 2011, 28 pharmaceutical companies were still manufacturing the monotherapies, 
39 fewer than in 2010. Limiting the production and sale of the monotherapies AMT has been 
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difficult due to weak regulation of the pharmaceutical industry. A greater collaboration in this 
regard is thus required (Aregawi et al., 2011).   
Since ACT currently represents the frontline in the fight against malaria and is often the drug 
of choice, the spread of resistance by using AMT’s is a significant problem. ACT generally 
has the greatest success when compared with other commercially available drugs. In 
Cambodia however resistance to ACT is present and spreading (Dondorp et al., 2009; 
Aregawi et al., 2011). Seeing as ACT’s are recommended as the replacement to older 
treatments, of quinine, chloroquine and sulfadoxine-pyrimethamine, to which there is a 
relatively widespread resistance, and since no better alternatives are currently available, 
resistance to ACT is likely to become more widespread in the future.  
The rapid spread of resistance to relatively new drugs is possible, and has been seen in the 
past with other anti-parasitic drugs. Programs are in place to monitor and test for resistance 
and, where possible, intervene with more drastic measures like insecticide spraying when 
detected. These efforts to limit the spread of resistance will likely maximise the lifetime of 
the currently-available drugs but resistance to new drugs also threatens to unravel much of 
the successes achieved so far (Aregawi et al., 2011). The WHO therefore actively encourages 
malaria research so as to ensure that new drugs, and methods for tackling this disease, will be 
available in the future. For this goal to be achieved malaria research needs to be an on-going 
field of research. Novel drugs, with new mechanisms of action, are required to ensure that 
new drugs have a useful life-span and are unaffected by currently-spreading resistance 
mechanisms.  
1.3 The malarial life cycle and targeting it 
Of all the malaria causing parasites, P. falciparum poses the greatest risk of death and severe 
morbidity. The life cycle of this interesting parasite is extremely complex and a detailed 
understanding of this life-cycle is required if new anti-parasitic drug targets are to be 
identified. The parasite expresses a variety of different, often specialised proteins, which are 
critical to its survival in the different cell lines and environments in which it lives (Tuteja, 
2007). To survive the parasite progresses through several distinct life cycle stages (Figure 
1.1) that are outlined in detail in the following pages. 
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Figure 1.1: The life cycle of malaria parasites P. falciparum and P. malariae. Taken from the Centres 
for Disease Control website (CDC, 2010). 
 
Infection starts with a mosquito taking a blood meal, during which sporozoites are injected 
from the mosquitos’ salivary glands into subcutaneous tissues and, less frequently, into the 
blood system of the human host (Miller et al., 2002). The sporozoites travel directly to the 
liver for P. falciparum and P. malariae where they infect liver hepatocytes. Studies (Mota et 
al., 2001), have shown that the sporozoites are capable of traversing through different cell 
types in a process that involves piercing the cells plasma membrane of the cell, using special 
proteins to achieve entry. Unlike bacteria and most other parasites, which enter cells without 
disrupting the plasma membrane, malarial sporozoites make use of a parasitophorous vacuole 
to enter the cell (Mota et al., 2001). Utilizing this process enables the parasite to reside freely 
within the cytosol and to exit the cell at a later stage, again by piercing its way out. The 
process results in leakage from effected cells due to entry and exit ‘wounds’ that can spill 
cytoplasmic fluids until they are able to close. This ability of the parasite to bore in and out of 
cells, allows it to traverse cellular barriers and penetrate through tough layers of skin cells, 
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which is necessary for it to reach its target, the liver hepatocytes (Mota et al., 2001). It has 
been shown that the sporozoites tend to migrate through several hepatocytes within the liver 
before settling inside one of these cells, to start the next phase of the life cycle. This process 
has been shown to be essential in the parasites life cycle. The factor that triggers the decision 
to switch between entry mechanisms is unknown (Miller et al., 2002; Tuteja, 2007). Once it 
has been triggered, the parasite alters its cell entry technique, to one using a parasitophorous 
vacuole for hepatocyte invasion. This is achieved using conventional receptor mediated 
endocytosis (Entzeroth et al., 1998; Mota et al., 2001; Kaiser et al., 2003). The receptors 
involved in this process have been studied in detail. On the surface of the parasite, 
thrombospodin domains of the circumsporozite protein, along with the thrombospodin-related 
adhesive protein, interact with heparan sulphate proteo-glycans of the host hepatic cells to 
achieve cellular invasion via endocytosis (Frevert et al., 1993).  
Once this occurs, the sporozoites undergo several phases of asexual reproduction in the liver 
hepatocytes for between 9-16 days. This phase is known as exo-erythrocite schizogony 
(Figure 1.1A) and it results in the production of schizonts. In the case of P.ovale and P.vivax, 
a delayed schizogony phase may also occur. This is achieved by the production of dormant 
liver hypnozoites, which can remain dormant in the liver for several weeks or longer and will 
result in relapsing malaria in the patient, if untreated. Once inside the hepatocyte, sporozoites 
produce tens of thousands of merozoites, each capable of infecting a red blood cell (Miller et 
al., 2002; Tuteja, 2007). Studies have shown that the parasite then induces cell death and 
detachment of the host hepatocyte. This is followed by budding of parasite-filled vesicles 
called merosomes which travel through pores into the lumen of sinusoidal blood vessels in 
the liver. During merosome budding from the hepatocyte, the parasite also simultaneously 
suppresses the expression of phosphatidylserine by the host. Suppression is achieved active 
accumulation, in the merozoite, of intracellular Ca2+ ions, which are normally released by the 
dying hepatocyte.  This prevents the production of phosphatidylserine, an enzyme on the 
outer plasmid membrane merosomes, which functions as a cellular recognition signal for 
destruction to phagocytes. However, since the merosome membranes are derived from the 
host cell, and the production of phosphatidylserine by infected host cells is being suppressed 
by the parasite. Merosomes are therefore able to effectively avoid detection by host 
phagocytes and to safely enter into the blood stream (Miller et al., 2002; Sturm et al., 2006).  
Once in the blood stream, the merosomes release merozoites directly into circulation (Sturm 
et al., 2006). This represents the beginning of the erythrocytic cycle (Figure 1.1B), which is 
6 
 
primarily responsible for the symptoms of the disease (Frevert et al., 1993; Tuteja, 2007). As 
such, and due to its complexity, this part of the life cycle has been identified as a good target 
for the development of drug interactions that may inhibit it (Frevert et al., 1993). Merozoites 
enter the erythrocytes in a four-stage process. First, there is a reversible recognition and 
attachment to the outer membrane of the erythrocytes. Second, this is followed by a 
reorientation which then leads to irreversible binding and reorganisation of the parasite, 
forming a parasitophorous vacuole and allowing entry into the erythrocyte. Third, 
invagination of the merozoite occurs, in a process that simultaneously removes the 
merozoites surface coating - which protected it in the blood stream. Fourth, the invasion 
process is finalised by the resealing of the erythrocyte and the parasitophorous vacuole 
membranes (Tuteja, 2007). Within this process a series of cellular signalling reactions occur. 
These prepare the parasite and host cell for further development. The process is extremely 
complicated and not fully understood. It is known that it involves a set of protein interactions 
between host and parasite enzymes that allow for the parasitic takeover of the host’s 
biochemical machinery (Miller et al., 2002; Tuteja, 2007).  
Asexual replication of the parasite within host erythrocytes then begins, starting with the 
characteristic 'ring form' of the trophozoite, which can be easily identified for diagnosis, 
using a microscope (Figure 1.1B). The reproduction process continues with trophozoite 
enlargement, which is accompanied by a highly active metabolism, using glycolysis. During 
this process the parasite uses its own glycolytic enzymes and actively imports glucose from 
the blood to satisfy its energy needs (Sherman, 1979). The parasite lacks a functional 
tricarboxcylic acid (Krebs) cycle and is thus entirely dependent on glycolysis for energy 
production (Parthasarathy et al., 2002). This means that the glycolysis enzymes of the 
parasite are potentially good targets for drug development (Miller et al., 2002; Ravindra and 
Balaram, 2005; Tuteja, 2007; Shekinah and Rajadurai, 2008; Gerdes and Overbeek, 2012). 
As the trophozoite enlarges and the replication continues, the parasite ingests host cell 
cytoplasm and uses proteolysis to break down haemoglobin in the red blood cells, forming 
free amino acids needed to feed the massive level of replication. A by-product of this 
digestion is the production of free heme, which is potentially toxic to the parasite. This toxic 
waste is dealt with by polymerizing it into hemozoin which then crystalizes and is stored 
within the parasite’s food vacuole to form what is known as malaria pigment (Miller et al., 
2002; Tuteja, 2007). Inhibition of this process is considered as the mechanism of action of 
most of the currently-used antimalarial drugs, including Chloroquine and Artemisinin (Robert 
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et al., 2001). Resistance to this mechanism of action has also been described in detail (Sidhu 
et al., 2002). Replication ends with multiple rounds of nuclear division and the construction 
of schizonts. In P. falciparum the whole erythrocytic cycle takes approximately 48 hour and 
the subsequent release of the merozoites occurs simultaneously throughout the body. This 
simultaneous rupture and release of red blood cell contents into the blood stream, results in 
the production of cytokines such as the tumour necrosis factor among others. Together, these 
cause the clinical manifestations (fever, and shakes) of malaria. The repetition of this process 
causes massive accumulation of toxins and destruction of red blood cells that ultimately 
results in malaria-associated death (Miller et al., 2002; Sturm et al., 2006; Tuteja, 2007).  
A small percentage of the merozoites in red blood cells go on to form micro- and macro-
gametocytes which later become male and female forms of the parasite, for the sexual 
reproduction phase, which occurs in the mosquito (Figure 1.1C). After these gametocytes are 
ingested by a mosquito they have no further function in the human host. After a mosquito has 
taken a blood meal from an infected individual, the gametocytes move into the mosquito's 
mid-gut, where they form into sexual micro- and macro- gametes. These gametes fuse 
together, creating a fertilized zygote, which transforms into an ookinete and then infects a 
mid-gut cell of the mosquito before developing into an oocyst (Tuteja, 2007). The malaria 
gamete surface antigen Pfs230 has been identified during this process. This is critical for the 
recognition and binding to exflagellating human red blood cells that contain the male parasite 
and form into exflagellation clusters, which release individual microgametes. The process has 
been shown to be a critical step in oocyst formation (Eksi et al., 2006). Sporogony then 
occurs within the oocyst, producing many sporozoites that migrate to the mosquitos’ salivary 
glands when the oocyts ruptures. The cycle is completed by the mosquito taking a blood meal 
from a new host (Figure 1.1A), (Tuteja, 2007; Miller et al., 2002). Gaining a detailed 
understanding of this lifecycle is a critical step that will aid in finding drug targets for the 
development of the new drugs, required for the on-going efforts to fight malaria. 
1.4 Triosephosphate isomerase (TIM) 
Triosephosphate isomerase (TIM) is a well-studied homodimeric enzyme which was first 
discovered by Otto Meyerhof (considered one of the fathers of modern biochemistry) in 1935 
(Meyerhof, 1935). TIM is a critical enzyme of glycolysis that catalyses the inter-conversion 
of dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde-3-phosphate (D-G3P). 
Glycolysis is one of two basic energy-producing enzymatic cycles, along with the 
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tricarboxylic acid cycle or ‘Krebs cycle’. These cycles produce cellular energy, by oxidative 
phosphorylation, in the form of ATP and NADH/NADPH, which are energetic biochemical 
agents required in the metabolism of all living organisms (Voet and Voet, 2003).  
The enzyme TIM is therefore very old and has become highly evolved over time. It has been 
described as an enzyme honed to perfection, by the selective pressures of evolution (Knowles 
and Albery, 1977). The human TIM (hTIM) is a good example of this enzyme, shown in its 
loop-open and loop-closed forms in Figure 1.2 below. 
 
Figure 1.2: PDB images showing hTIM in loop-open (a) and loop-closed (b) forms, with bound 
substrate. The mobile loop is coloured in green (diagrams constructed with PyMol®). 
 
1.4.1 Mechanism of action 
The enzyme reaction occurs through the creation of a cis-enediol (intermediate), by the 
mediation of the protonation and deprotonation for two enol structures (Figure 1.3), 
(Knowles, 1991).  
 
(a) (b) 
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Figure 1.3: Diagram of the inter-conversion of DHAP (a) to the enediol intermediate (b) to D-G3P (c) 
via a catalytic acid/base proton abstraction involving Glu-165 and His-95 of TIM. Image from 
(Knowles, 1991). 
 
How TIM achieves this mode of action has been extensively studied (Knowles, 1991; Joseph 
et al., 1990; Pompliano et al., 1990; Knowles et al., 1972; Banner et al., 1975; Lolis and 
Petsko, 1990). Three main functional components are in operation in TIM and will be 
discussed in detail. The first of these is a protein loop (residues 166-177), in which the subset 
residues (of 168-173) are highly conserved and form a rigid lid that moves ~7 Å in a hinge-
like action from its open state (with no ligand present) to its closed position (with a substrate 
or inhibitor present), see (Figures 1.2 and 1.4), (Knowles et al., 1972; Banner et al., 1975; 
Joseph et al., 1990; Lolis and Petsko, 1990; Pompliano et al., 1990). While many enzymes 
have similar structures, the mechanisms of how such enzymes work are not always fully 
understood. It has been suggested that these structures move in an 'induced fit' mechanism 
upon substrate binding. A similar well-studied example of such a mechanism is that of lactate 
dehydrogenase (LDH). In LDH it has been shown that, upon binding of its substrate, loop 
movement is induced. LDH has a similar peptide loop, which contains a highly conserved 
catalytic Arg109 residue that is responsible for polarizing a carbonyl group on the substrate 
and stabilizing its transition state (Clarke et al., 1986).  
C1 
C2 
C1 
C2 
(b) (c) (a) 
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Figure 1.4: Models of wild-type and mutant TIM, with residues of the mobile loop 168-177 in (light 
blue) and the rest of the protein in (dark blue). The bound inhibitor phosphoglycolohydroxamate is in 
orange. (a) Wild-type TIM in open loop conformation, (inhibitor shown for visual reference only). (b) 
Wild-type in closed/liganded conformation with inhibitor bound. (c) Mutant TIM (lid 170-173 
deletion) in open loop conformation (again inhibitor shown for visual reference only). (d) Mutant (lid 
170-173 deletion) in closed/liganded conformation with inhibitor bound. Image from (Pompliano et 
al., 1990). 
 
As with LDH, in TIM the mobile loop appears to clamp down on the bound 
substrate/inhibitor complex. In TIM, unlike LDH, no new catalytic residues are brought into 
action. Instead it appears to effectively sequester the substrate from the solvent (Figure 1.5) 
and is thought to help stabilize the substrate through transition intermediary states. 
Crystallographic work has also shown these highly conserved lid residues 170-173, the main 
chain NH group of Gly171, creates at least one, and possibly two, hydrogen bonds with 
oxygen atoms on the substrate or inhibitor’s phosphate group (Pompliano et al., 1990). An 
example of this in Plasmodium falciparum (PfTIM) is shown in Figure 1.5. This stabilises the 
substrate for TIM ensuring a tight fit as the enolization reaction transitions through its 
different states (Figures 1.2 and 1.3) (Pompliano et al., 1990). 
(c) 
(a) (b) 
(d) 
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Figure 1.5: The hinged loop of PfTIM, (pdb code: 1LZO), in closed conformation, forming a 
hydrogen bond of 2.7 Å, with its backbone Gly171 -NH group and an oxygen atom of the inhibitor 
complex 2-phosphoglycolate. Bond lengths shown are in angstroms. Image made using PyMol 
version 1.3. 
 
The 'induced fit' hypothesis is acceptable for TIM as shown by crystallography data and 
computer simulation studies done by Joseph et al., 1990, which indicates that residues 166-
168 and 174-176, which are not conserved, act as the 'hinges' for the loop movement. The 
study points out that during the interaction between the substrate and the catalytic Glu165 
residue, the residue shifts towards the substrate, in a relatively substantial positional change 
of ~3 Å from open to closed loop forms. This shift in turn induces further pseudo-dihedral 
angle changes between residues 166-168, which in turn weaken a hydrogen bond between 
Trp168 and Tyr164, causing a shift in the indole functional group of Trp168. The indole 
group then interacts with Glu129 and causes a cascade of dihedral angle changes that 
culminate in the bond angle changes of residues 174-175, ‘the other hinge’, which closes the 
loop. The study also notes that the loop is rigid throughout its movement. This is due to intra-
loop hydrogen bonds and stacked ‘van der Waals’ forces between conserved loop residues. 
As the loop closes residues 173 and 176 form additional hydrogen bonds with the rest of the 
3D protein structure as the loop clamps down (Figure 1.3), while residue 171 forms hydrogen 
bonds with the substrate (Figure 1.5). These help to lock the mobile-loop or ‘lid’ down, 
ensuring a tight fit and limiting substrate movement within the active site (Joseph et al., 
1990). Due to the complexity of this process, it is theorised that any conformational changes 
in overall TIM protein structure may have drastic effects on activity.      
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The next two components used by TIM for its reaction are, a catalytic base and a catalytic 
acid, which mediate the two enolization steps in each direction, (Figures 1.6a and 1.6b) 
respectively (Knowles, 1991). The catalytic base, responsible for the removal of the pro-R 
proton of C1 in DHAP (Figure 1.3), is the carboxylate group from Glu165 (Figures 1.3 and 
1.6a). Isotope and crystallographic studies have shown this mechanism to be bi-dentate, 
meaning it is also capable of removing the proton from C2 in D-G3P (Figure 1.3). This is 
catalytically required for the reverse reaction (Knowles et al., 1972; Banner et al., 1975; Lolis 
and Petsko, 1990; Bash et al., 1991; Knowles, 1991).  
For the above to occur, strategic and extremely precise placing of the Glu165 residue relative 
to the substrate is required. Indeed it’s been theorised that the reason proteins are often so 
much larger than their substrates, is simply to supply the necessary scaffolding required for 
such precision-placing of the catalytically active groups (Knowles, 1991). The removal of 
Glu165, or its substitution with alanine or glycine, has been shown to reduce catalytic activity 
by over a million fold (Knowles, 1991). The final active chemical component of this enzyme 
is a catalytic acid, which acts as an electrophile and aids in the enolization steps. Again it is 
the strategic placing of His95 that places its imidazole rings, NH group, precisely in-between 
and approximately 2.9 Å from each of the two possible substrate, C1 and C2 oxygen groups 
(Figures 1.3 and 1.6b). This allows for the creation of a hydrogen bond which aids in the 
chemical destabilisation of both substrate conformations DHAP and D-G3P, and aids in their 
catalytic inter-conversion. Mutations of His95 are known to decrease catalytic activity by a 
factor of nearly 400 fold, when compared to the wild type enzyme (Bash et al., 1991; 
Nickbarg et al., 1988). Essentially, it is the strategic and precise positioning of catalytic base 
and acid groups by the two α-helixes that hold these residues (Figures 1.6c, d) respectively, 
as well as the snug fit within the active site — which is further aided by the stabilisation of 
the substrate molecule by mobile lid closure — that makes this enzyme so efficient. The 
isomerisation reaction can therefore be said to function in a catalytic pull-push acid/base 
mechanism which relies on the precise positioning of active residues and a snug substrate fit.  
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Figure 1.6: The catalytic residues of the active site in TIM. (a) The catalytic base of Glu165 (yellow) 
acts as a proton acceptor with the tightly-fit substrate (red). (b) The catalytic acid from the NH group 
of His95 acts as the electrophile. (c) The α-helix that stabilises the imidazole ring of His95. (d) The α-
helix stabilising the lid over the phosphate group of the phosphoglycolohydroxamate (inhibitor). Note: 
the dots surfaces are at the van der Waals' radii. Image from (Knowles, 1991). 
 
Understanding the remarkable chemical mechanisms involved in these catalytic events, 
which occur within angstrom distances allows one to form a deeper understanding of the 
enzyme TIM and how it functions. This information can then be used to aid in the design of 
new enzyme inhibiting drugs. The ability to selectively target a specific variant of such an 
important enzyme could be used to design antimetabolite drugs capable of disrupting this 
mechanism of action. To further investigate this possibility for the design and development of 
P. falciparum TIM targeted therapeutic agents, the genetic variation and unique structural 
features of this enzyme should be studied.  
PfTIM is one of the better-studied variants of TIM and is known to have several significant 
important differences, compared to its human host counterpart, version hTIM. These 
differences are discussed in detail in the following section. In this research it is assumed that 
nanoparticle interactions that could induce conformational changes in target PfTIM would 
likely inhibit activity, because even a relatively small shift in residue positioning would 
(c) 
HN 
O 
(a) 
(b) (d) 
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probably have strong effects on activity, due to the precise redox chemistry and nature of how 
TIM operates. 
1.4.2 TIM from Plasmodium falciparum (PfTIM) as a drug target  
Critical evaluation of the specific genetic variations in PfTIM reveals several key differences 
with the hTIM variant. Exploitation of these differences could make PfTIM an excellent 
target for selective enzyme inhibition.   
As previously mentioned, P. falciparum lacks a functional energy-producing Krebs cycle, 
making it entirely dependent on glycolysis for energy production (Velanker et al., 1997; 
Ravindra and Balaram, 2005; Tuteja, 2007; Gerdes and Overbeek, 2012). This, coupled with 
the parasite’s massive energy demands during asexual, blood-stage, reproduction (Sherman, 
1979), means that the parasites glycolytic enzymes are potentially good drug targets. 
Disrupting this cycle will starve the parasite of the cellular energy it needs to survive and 
reproduce. The sheer scale of the parasites reproduction process puts a huge strain on the 
host’s system and the ability to slow this process down, could make the difference between 
life and death.  
The parasite’s use of its own glycolysis enzymes offers an opportunity to identify genetic 
differences between it and its human host. DNA sequencing and X-Ray crystallographic 
studies have helped identify PfTIM as having several notable genetic and structural 
differences that may be useful for targeted drug development (Velanker et al., 1997; 
Parthasarathy et al., 2003; Ravindra and Balaram, 2005).   
The search for therapeutic agents against pathogens, targeting key enzymes that only exist 
within the pathogens themselves, is usually the best option. If this is not possible, selectively 
targeting analogous parasite enzymes is also a possibility (Maithal et al., 2002; Ravindra and 
Balaram, 2005). Two methodological approaches have been used for this purpose. The first 
approach is to design benign inhibitors that compete for the active site. Ideally, these 
inhibitors will remain in the active site or, in some cases, may even modify the active site 
chemically. This method is only useful, however, when there aren't any important host 
analogues to the target enzyme. The approach involves designing inhibitor peptides that 
specifically target the active site of the enzyme. If analogous enzymes are present, similarities 
with the homologous host enzyme’s active site usually limit the use of this approach, because 
the residues within active sites of analogues are usually highly conserved. In such cases a 
better strategy is to target dimer interfaces, if present, which are typically less conserved and 
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often exhibiting clear genetic and structural differences. In this case the approach is to target 
non-conserved, but functional, interface residues for disruption. This can also be done using 
synthetic peptides, or by covalently modifying reactive surface residues that could disrupt the 
oligomeric state of the protein ( Smith et al., 1975; Gómez-Puyou et al., 1995;  Maithal et al., 
2002). As demonstrated (Gómez-Puyou et al., 1995), this approach worked well when 
targeting the blood parasite Trypanosoma brucei TIM (TbTIM), which shares many 
similarities in enzymatic structure with Plasmodium (Greenbaum et al., 2004; Velanker et al., 
1997). TbTIM features a subunit interface cysteine residue, in position 14 (Cys14), which 
was shown to be influential in subunit binding. Gómez-Puyou et al. (1995) were able to 
selectively inhibit TbTIM using a methyl methanethiosulfonate to derivatize its Cys14 into a 
methyl sulphide. The treatment showed dramatic inhibition on other TIMs that featured 
interface Cys14 residues. TIMs without this variation showed only low levels of inhibition. 
For rabbit TIM a 20% decrease in activity was observed and in yeast TIM the inhibition was 
negligible (Gómez-Puyou et al., 1995). 
In the case of PfTIM, the enzyme is known to only be fully active in its dimeric form 
(Maithal et al., 2002). In addition it also features dimer-interface cysteine residues, in this 
case at position 13 (Cys13), while in hTIM this residue is methionine. Methionine is similar 
to cysteine, as it also has a sulphur atom within its side chain, but its sulphur atom is shielded 
by a terminal CH3 group, which makes it less reactive. The presence of this mutation makes 
selective enzyme inhibition of PfTIM an attractive option, as targeting of TIM dimer 
cysteines has already been successfully demonstrated for selective inhibition (Gómez-Puyou 
et al., 1995). PfTIM contains four cysteine residues per subunit at positions 13, 126, 196 and 
217 (Figure 1.7b). Disruption of the interface Cys13 of PfTIM or its removal (C13D mutant) 
results in a significant, 7-fold, decrease in catalytic activity and reduces dimer stability. In 
addition to this, Cys196, of PfTIM, is also located on the enzyme surface and opposite to the 
active site (Figures 1.7b, c). Maithal et al., 2002 demonstrated that this residue is the most 
accessible and reactive of the cysteine residues, presenting its sulphur atom in the surface 
structure (Figure 1.7c). This provides an external site for chemical targeting of cysteine 
sulphur atoms with nanoparticle-based nanodrugs (Maithal et al., 2002; Malabadi et al., 
2012).  
The presence of the reactive sulphur atoms in the cysteines side chain is what makes these 
mutations of such interest. Sulphur is a known reactive element in this amino acid, and is 
responsible for the creation of disulphide bonds and strong ‘van der Waals’ forces, which are 
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highly influential in enzymatic folding and structure conformation. Sulphur atoms are also 
known to form bonds with gold and silver atoms and are used to interface gold and silver 
surfaces, or nanoparticles, in various biotech applications, such as biosensor design, peptide 
metallic interfacing and nanoparticle stabilisation (Willner et al., 2007; Malabadi et al., 
2012). 
Of the four cysteine residues, X-ray crystallography has shown that both Cys196 and Cys217 
are surface-accessible for PfTIM. Additionally, the sulphur atom of Met248 is also exposed 
on the surface (Figures 1.7a and 1.7c).   
 
            
      
 
 
 
 
 
 
 
 
 
 
Figure 1.7: PyMol (v1.3) representations of PfTIM (a,b,c) and hTIM (d) with sulphur atoms in 
yellow. (PDB codes: 1YDV and 1HTI respectively). (a) PfTIM monomer, showing Mobile-loop 
above the active site, the sulphur atom of the dimer interface Cys13 and surface accessible sulphur 
atoms of Cys217 and Met248. (b) PfTIM dimer showing surface of chain A, with sphere 
representations for the 4 cysteines and the one methionine 248, (note Cys13 at dimer interface). (c) 
Reverse side of PfTIM showing surface accessible Cys196 sulphur atom. (d) Surface structure of 
hTIM showing mobile-loop, active site with bound inhibitor (2-phosphoglycolic acid - C2H5PO6) and 
the only surface accessible sulphur atom on Cys217.  
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(d) (c) 
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Maithal et al., 2002 performed a sophisticated evaluation of PfTIM cysteine residues by 
differentially labelling the residues using iodoacetic acid and iodoacetamide. This was 
followed by electron spray ionization, mass spectroscopy and tryptic fragment digestion 
analysis, to determine the positioning of the labels. These data indicated that the accessibility 
of the cysteine residues is as follows: Cys196>Cys13>>Cys217 and Cys126. This correlated 
well with crystallography data which shows Cys126 buried inside the enzyme and while 
Cys217 was largely covered; only partly exposing its sulphur atom (Figures 1.7a, b). 
Likewise Cys196 is highly available on the reverse side of the structure (Figure 1.7c). 
Interestingly, while the crystallography data indicates Cys13 has a generally-limited 
accessibility, due to dimer formation, labelling experiments indicated otherwise, with Cys13 
undergoing relatively rapid modification, indicating access by the labelling residues is 
possible and therefore possibly by other interfering agents. Due to the proximity of Cys13 to 
the active site, labelling of this residue was also accompanied by loss in enzyme activity 
(Maithal et al., 2002).  
1.5 Medical Nanotechnology  
The field of nano-medicine using nanoparticles is relatively new and, to date, few nanodrugs 
have been tested in humans (Chen et al., 2008; De Jong and Borm, 2008; Lévy et al., 2010; 
Sperling et al., 2008). Recent research has however shown progress in this field with 
developments involving transition metal complexes as therapeutic agents, used to treat 
carcinomas, lymphomas, control infections, as anti-inflammatory agents, neurological 
disorders, and diabetes (Rafique et al., 2010). Many challenges that face conventional 
therapeutic agents, such as poor bioavailability and intrinsic toxicity, often compromise or 
seriously limit the abilities of otherwise beneficial drugs. Nanotechnology has allowed the 
creation of nanoscopic systems which can be altered through the addition of various 
functional surface molecules thereby altering pharmacological and therapeutic properties. 
These designed systems are capable of overcoming many of the limitations associated with 
conventional treatments (Chen et al., 2008; De Jong and Borm; 2008, Lévy et al., 2010). 
Drug delivery with nanotechnology is designed to exploit pathophysiological conditions and 
anatomical changes that often exist within diseased tissues. This allows for the creation of 
site-specific targeted therapeutics (Sahoo et al., 2007).   
Nanosystem selective targeting allows for the accumulation of higher concentrations of 
therapeutics at targeted sites, and lower concentrations elsewhere in the body. This enhances 
18 
 
bioavailability and reduces systemic toxicity. Incorporation of the drugs into nanosystems 
also overcomes solubility issues that are often associated with otherwise-effective functioning 
drugs. Nanosystems also allow therapeutic drugs to bypass immune detection, during 
circulatory transportation to target locations. This enables targeting sites that are hard to 
reach, such as the brain, which offers an additional challenge due to the blood brain barrier 
(Sahoo et al., 2007). Chen et al (2008), outline several nanosystems and their targets, which 
have been developed and are currently in use. It is important to note that nanotechnology-
derived drugs are usually custom designed yet often make use of the same base nanoparticle 
system, such as gold or silver nanoparticles. It is the various modifications and 
functionalising of these systems that creates modern, highly specific and capable 
nanodrugs/nanosystems (Chen et al., 2008). The nanosystems are typically less than 100 nm 
in size, thus allowing delivery through capillaries and uptake by cells. Drugs coupled to 
nanosystems also generally benefit from longer circulation times and less loss of therapeutic 
potential during circulation (Sahoo et al., 2007). For drug delivery, nanosystems can employ 
encapsulation, entrapment, adsorption, and attachment, and are even able to dissolve active 
agents into or onto the nanoparticle matrix. This can be used to allow for the creation of 
targeted release mechanisms, or triggers, which greatly aid in limiting toxicity and increased 
concentrating at target sites (Sahoo et al., 2007; Chen et al., 2008; Lévy et al., 2010).  
Regulation of protein activity has important biomedical applications and can be used to 
influence the processes of signal transduction, DNA replication and other key metabolic 
systems (Toogood, 2002; Gadek and Nicholas, 2003). Nanoparticles can be made in the same 
size range as enzymes and have several key advantages when considering therapeutic agents. 
They have large relative surface areas for interactions and attachments, they easily enter into 
cells, and their synthesis can now be performed relatively easily to make various sizes and 
shapes with alterable surface properties (Conte et al., 1999; Wu et al., 2009). These abilities 
allow for more than just cellular targeting and make selective enzymatic targeting both a 
viable and attractive option in modern therapeutic development.  
Due to these multi-capabilities that can be attributed through such modifications, the modern 
nanodrug development trend is to create multifunctional nanoparticle systems to fulfil 
virtually all the drug requirements of selective delivery, biocompatibility, solubility, and 
limited toxicity. An example of such a system is the use of polymeric micelles, developed by 
Nasongkla et al. (2006), which target cancer cells, deliver drugs, and allow magnetic 
resonance imaging (MRI) for tracking.  
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1.5.1 Medical applications for transition metals using nano-technology 
Many nanomedical applications involve the use of transition metals, which have several 
unique properties that make them useful. Transition metals all have unfilled d-orbitals and 
occupy groups 3-12 on the periodic table. This allows them to have various reactive oxidative 
states, giving them both oxidation and reduction capabilities. They are capable of forming 
many different types of bonds of varying strength, usually with negatively charged molecular 
groups. This confers transition metal complexes with promising pharmacological properties 
and has spurred a great deal of interest and research into investigating the development of 
compounds that use the transition metals (Rafique et al., 2010). Transition metal medical 
applications come in many forms, from modified single atom/ion enhanced ligand structures, 
which can be new or may just improve older therapeutics, to complex functionalised 
nanoparticles. 
An example of the use of transition metals in medical antimalarial research is the 
modification of chloroquine using Fe ions to create ferroquine, which was synthesised and 
tested in-vitro on live parasites resistant to chloroquine. The new synthetic organometallic 
analogue was shown to be 5.3 times more active against the chloroquine resistant parasite 
than chloroquine (Atteke et al., 2003). 
1.5.2 Gold and silver nanoparticles 
Gold nanoparticles (AuNPs) are one of the more studied nanoparticle variants for use in 
nanomedical and nanosensing applications. Properties of AuNPs include biocompatiblity, 
bioavailability, photo-optical activity, and easy functionalization. Applications such as 
diagnostic imaging, biosensing, and various cancer therapeutic techniques have greatly 
benefited from these unique properties. In addition to this there are various delivery methods 
for gold nanoparticles that can target diseased tissues (Chen et al., 2008). Silver is in the 
same group (Group 11) on the periodic table as gold. Indeed gold and silver share the same 
outer electron orbital valences’ and consequently this means that silver (Ag) and gold (Au) 
nanoparticles tend to have similar chemical reactive properties when reacted with the same 
elements or compounds (Kholoud et al., 2010). This effect is noted with special reference to 
bond length properties when reacting with sulphur containing compounds as indicated by 
Sellers et al., (1993). 
Gold nanoparticles have been used in photothermal therapies by exiting AuNPs at 650-900 
nm which then transform absorbed energy into heat in a photothermal ablation technique 
20 
 
used to kill targeted cancer cells (Chen et al., 2008). The technique demonstrated effective 
destruction of the cancer cells, although the cell targeting techniques that were used lacked 
selectivity (Huang et al., 2006; Chen et al., 2007).  
Silver nanoparticles (AgNPs) have also shown a wide variety of uses and can be synthesised 
in many ways. They have commonly been used as disinfectant and antibacterial agents 
(Kholoud et al., 2010; Guzmán et al., 2008). One area of silver nanoparticle research that has 
been widely explored is nanoparticle-virus interactions. Elechiguerra et al. (2005), showed 
that silver nanoparticles, of sizes ranging from 1-10 nm, are able to interact with the HIV-1 
virus, through exposed sulphur atoms that were present on HIV glycoprotein (gp) knobs of 
gp120. The AgNP-gp120 binding also demonstrated viral inhibition by preventing host cell 
entry.  
Applications of silver have a long history of therapeutic uses and silver has being extensively 
studied for its antimicrobial and antiviral properties. Silver has seen applications as 
nanoparticles for water treatment and sterilization, as nanoparticles or nano-crystalline silver 
in dressings, gels and creams have being used to treat burn wounds and reduce bacterial 
infections in chronic wounds among other treatments and have generally being found to be 
non-toxic to humans in minute concentrations but have shown cytotoxicity to some cell lines 
depending on nanoparticle size (Rai et al., 2009). The manner in which silver nanoparticles 
obtain such desired properties is being investigated and is not yet fully understood. It has 
being shown that size and shape of the silver nanoparticles is important however with 
generally the smaller range of approximately <20 nm generally exhibiting higher efficacy and 
greater biocompatibility (Kim et al., 2007; Rai et al., 2009). Studies have shown that AgNPs 
interact with the lipopolysaccharides in the exterior cellular membranes of bacteria, causing 
structural changes and degradation that leads to increased cell membrane permeability and 
ultimately cell death (Sondi and Salopek-Sondi, 2004; Kim et al., 2007; Rai et al., 2009). A 
study investigating by Hao and Schatz (2004) indicates that as the size (particularly below 
100 nm) and shape of silver nanoparticles change, corresponding changes in the 
electromagnetic field and surface Plasmon resonance of AgNPs are observed. These changes 
allow for differences in electrostatic interactions resulting in dipole and tripole moments 
between nanoparticles that are notably different. The effect these altered field states and 
strengths may have on interactions with complex molecules, such as proteins, is unknown but 
it is fair to assume that if they appear to notably affect characteristics of simpler NP-NP 
interactions, the effect on more complex molecules - such as proteins – will be presumably 
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more notable and definitely far more complex. This may potentially explain the variability in 
toxicity effects observed in various studies (Sondi and Salopek-Sondi, 2004; Kim et al., 
2007; Rai et al., 2009). 
A demonstrated application of AuNPs is in biosensor design, where redox enzymes typically 
lack the direct electrical conductivity required to ‘wire’ them into amperometric sensors with 
high sensitivities able to detect the binding of microscopic levels of target compounds that 
require detection. By using enzyme-nanoparticle hybrid systems, gold nanoparticles can be 
tethered to gold nano-electrodes using cross-linkages to form dithiol bridges with ligand-
linked detector enzymes. The AuNPs mediate electron charge transport, thereby increasing 
the amperometric detector efficiency (You et al., 2005; Willner et al., 2007).  
1.5.3 Biomolecular nanoparticle engineering 
Biomolecules, like proteins, antibodies, antigens and small DNA segments, offer the reactive 
potential to design unique nanoparticle-biomolecule hybrid systems. In terms of scale, these 
building blocks are of a size which allows for them to be attached to nanoparticles and travel 
with them, allowing them to complement the nanoparticles by conferring the unique 
properties they possess and thereby creating novel nanoscale substances with diverse 
capabilities. The engineering of nanosystems capable of molecular recognition and selective 
binding to target cells and enzymes, is a relatively new field of research with exciting 
prospects in biomedical applications (You et al., 2005). Fischer et al. (2002), demonstrated 
an engineered NP-enzyme interaction capable of recognizing and inhibiting α-chymotrypsin. 
This system used monolayer-protected nanoparticles with functionalized anionic termini for 
recognition and inhibition, similar to the generic sample shown in Figure 1.8b. 
Being able to engineer the nanoparticle protein interactions is a critical step in the 
methodology of designing multi-capable nanomedical systems. Typically, two 
fundamentally-different approaches are used to conjugate proteins to nanoparticles. These are 
direct covalent linkage of the protein to the nanoparticle surface, which can be done in 
several different ways, or the use of non-covalent interactions between the protein and 
nanoparticle to generate supra-molecular assemblies (Rana et al., 2010).  
In the direct conjugation approach, multiple protein side chains may potentially be involved 
in interactions. In such cases conditions that limit non-specific binding are often sought, as it 
has been shown that direct conjugation interactions may often result in the loss of enzyme 
activity, usually due to conformational changes in protein structure. A commonly-used 
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method for direct conjugation is the use of a single cysteine residue for monovalent 
attachment. This approach is also plagued by protein denaturation but it may be useful for 
protein targeting, where enzyme denaturation and loss of activity may be desired. The ability 
of cysteine to directly conjugate to metallic nanoparticles makes it a useful bio-
nanotechnology tool, which can be used as a functionalizing nanoparticle linkage or for direct 
protein-nanoparticle interactions, if present on a target enzyme surfaces (Rana et al., 2010; 
Majzik et al., 2009).  
Another direct conjugation method relies on the engineering of custom ligands for 
nanoparticle conjugation and functionalization. This method generally has had greater 
success, due to its wide range of modification possibilities and easy development methods 
available. Some common attachment methods are outlined in Figure 1.8 (Rana et al., 2010). 
 
Figure 1.8: Three examples from Rana et al. (2010), for direct protein-nanoparticle attachment. (a) 
Direct attachment using a thiol groups on the proteins surface. (b) Amine-carboxylate coupling 
linking NP carboxylate and protein amine groups. (c) An alkyne-azide Huisgen ‘click’ reaction, which 
uses a catalyst to aid linking the azide tagged NP and the alkyne tagged protein to achieve high yields. 
 
An example of the application and possibilities of modern nanoparticle drugs has been 
demonstrated recently, as highlighted by (Sheridan 2012; Hrkach et al., 2012). This passed 
Phase 1 human drug trials for a clinical cancer nanodrug and the nanodrug is currently 
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undergoing further testing. The study done by BIND Biosciences of Cambridge, 
Massachusetts (Hrkach et al., 2012) provided positive evidence for the progressive 
development and clinical application of new nanomedicines. The nanodrug system that was 
used consisted of a hydrophobic nanoparticle core, with polylactide polymers encapsulating 
the cytotoxic drug docetaxel. This was surrounded by a hydrophilic corona of polyethylene 
glycol bound to a small designed molecule, (S-2-[3-35-amino-1-carboypentyl]-ureido]-
pentanedioic acid), which targets the prostate-specific membrane antigen that is known to be 
overexpressed in most solid cancer tumours (Hrkach et al., 2012). A computer-generated 
image of this molecule is shown in Figure 1.9a (Sheridan, 2012). 
 
Figure 1.9: (a) Theoretical image of the anti-cancer nanoparticle drug under human clinical trials 
developed by BIND Biosciences. The nanoparticle drug functions as a targeting and safe drug 
delivery vessel by utilising layers of peptides to confer different functionality to the overall nanodrug 
system (Sheridan, 2012; Hrkach et al., 2012). (b) A general schematic of a common ligand system 
used as a linker to help maintain structure and function of linked proteins (Rana et al., 2010). 
 
The second, non-covalent method, using supramolecular interactions is also commonly used 
for the creation of bioconjugates (Shang et al., 2007). With this approach it has been shown 
that either ‘naked’ or fully functionalised NPs, generally interact in a similar manner as 
normal protein-protein interactions. This occurs through the evolution of a loosely attached 
protein ‘corona’ around the nanoparticles, which varies depending on the environment it is in, 
as well as the concentration and type of proteins present (Rana et al., 2010). The ‘naked’ 
nanoparticles tend to irreversibly bind and deform an initial layer of biomolecules which 
form the first ‘corona’ layer, while functionalized NPs, which already have an irreversible 
bound initial layer, act similarly by also loosely binding available biomolecules (Rana et al., 
(a) (b) 
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2010; Lynch and Dawson, 2008). This is further discussed in section 1.5.5, Non-
functionalized protein-nanoparticle interactions.   
1.5.4 Nanoparticle toxicity 
Nanoparticle toxicity has been investigated under various conditions and have being found to 
be both benign and toxic depending of circumstances (Hao and Schatz 2004; Kim et al., 
2007; Chen et al., 2008; Rai et al., 2009; Lasagna-Reeves et al., 2010). Size similarities of 
nanoparticles with other biological components, such as enzymes, have raised concerns about 
the ability of nanoparticles to be disguised and pass through natural cellular barriers. This can 
lead to undesired cellular entry into otherwise healthy cells, with unknown effects. Yet this 
ability is also a potential benefit, allowing for drug delivery in hard-to-reach places, like the 
brain and cell nuclei (Connor et al., 2005; De Jong and Borm, 2008). To investigate cellular 
toxicity, Pan et al. (2007), studied the size-dependent nature of NP cytotoxicity, using 
triphenylphosphine-stabilised, AuNPs. Four different mammalian cell lines were tested, 
including human Hela cells. They found that AuNPs of 1-2 nm in size showed cytotoxic 
effects, with IC50 values in the high micro-molar range, while AgNPs of 15 nm in size were 
determined to be generally nontoxic, even at 60 fold higher concentrations than the small 
NPs. 
Figure 1.10: Gold nanoparticles functionalized with cationic and anionic side chains used in toxicity 
studies. Image from Chen et al. (2008), original study done by Goodman et al. (2004).  
 
25 
 
Other investigations by Goodman et al. (2004), have shown that toxicity is influenced by the 
nature of the functionalizing and stabilising side chains. Cationic side chains tended to have 
low cytotoxic levels, while anionic side chains were shown to be generally nontoxic (Figure 
1.10). 
Current literature generally supports the notion that nanoparticles are generally nontoxic. 
However, size, composition and the way in which they are functionalized can strongly 
influence their toxicity. Additional research in this field is required to further understand and 
define nanoparticle toxicology (Chen et al., 2008; De Jong and Borm, 2008). 
1.5.5 Non-functionalized protein-nanoparticle interactions 
Nanoparticles and the study of their interactions with various enzymes, in-vitro and in-vivo, 
has created a new field of nanomedicinal studies in which these interactions are being 
characterised and potential medical applications are being investigated (Lynch and Dawson, 
2008).  
Early studies on protein-nanoparticle interactions revealed that proteins often become 
distorted upon adsorption with various surfaces. Protein adsorption onto various materials is 
generally well studied, with interactions being generally defined by electrostatic and 
hydrophobic forces. Understanding this process and how it relates to protein nanoparticle 
interactions is somewhat more difficult, due to the complexity of size-to-surface ratios. Yet 
this is critical in understanding how adsorbed protein layers function and even mediate other 
enzymatic interactions around them (Lynch and Dawson, 2008). Protein-nanoparticle 
interactions typically involve highly curved surfaces, with NPs often on the scale of the 
enzymes themselves. This curvature adds a complex new dynamic that is often overlooked, 
when trying to understand nanoparticle-protein interactions (Lynch and Dawson, 2008).  
In material biology any material that comes in contact with a physiological environment is 
generally considered to become almost immediately saturated in biological matter, consisting 
mostly of proteins (Lynch and Dawson, 2008). This phenomenon requires careful 
consideration in the case of non-functionalized protein-nanoparticle interactions. 
Physiological environments, like blood plasma, typically contain over 3000 proteins (Omenn, 
2007). Such a variety of proteins represents a wide range of association and dissociation 
constants, each with different affinities and exchange times. One way of studying this 
phenomenon can be to consider the nanoparticle as surrounded by a protein corona. This 
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‘corona’ is in a constant state of change, dependent on its environment and the proteins 
present in it (Lynch and Dawson, 2008).  
Protein adsorption studies, using AuNPs with self-adsorbed monolayers of 
mercaptoundecanoic acid, have focused on adsorption with bovine serum albumin (BSA), 
myoglobin, and cytochrome c. All three of these proteins were shown to form adsorption 
layers with both irreversibly- and reversibly- bound fractions (Kaufman et al., 2007), 
highlighting the observation that protein adsorption onto solid surfaces is a complex process, 
involving structural changes of protein surfaces, dehydration of sections of the protein, and 
new direct electrostatic interactions, including hydrogen bonding and van der Waal 
interactions (Kaufman et al., 2007).  
Protein 3D structure is tightly controlled through the composition and conformation of α-
helixes and β-sheets. The positioning of hydrophobic residues is also influential and they are 
usually localized to the protein core. The overall tertiary protein structure is more than just a 
scaffold for the active site as it helps determine solubility, stability and longevity of the 
molecules in various sensitive cellular environments (Word et al., 1999). Due to the 
sensitivity and a relatively low number of stabilising bonding reactions, such as disulphide 
bonds, proteins are often considered as only marginally stable entities that tend to get 
replaced relatively regularly, due to their inherent instabilities. As such, a strong interaction –
even with the surface of a protein – has the potential to easily disrupt their fragile 
conformational state. Such disruption will usually result in some form of deformation and the 
likely loss of enzyme activity/function (Word et al., 1999; Lynch and Dawson, 2008). In 
addition to active disruption, it has been shown that once a protein’s conformational state is 
altered, it may often remain deformed, even after the removal or desorption of the disrupting 
agent. This depends on the particular protein and some proteins are able to refold better than 
others. Still other proteins are aided in folding by chaperones that encourage a desired protein 
conformation. For example, Sabatino et al. (2007) demonstrated that BSA undergoes 
irreversible conformation changes upon adsorption and desorption with an asbestos surface.  
Similar effects were also shown on BSA using polystyrene nanoparticles. This indicated that 
BSA is susceptible to irreversible adsorption and desorption changes (Sweryda-Krawiec et 
al., 2004). It can thus be assumed that adsorption and desorption of nanoparticles in a 
selective manner, that targets one particular variant of otherwise identically-functioning 
enzymes, may result in a selective inhibition effect on the target protein that underwent 
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stronger nanoparticle adsorption. This requires the identification of a target interaction site 
for adsorption.  
The influence of protein cysteine residues on non-functionalized nanoparticles has been 
shown to be very important. In one study by Shen et al., (2007), Raman spectra results 
indicated that the sulphur atoms on cysteine residues in haemoglobin were able to form direct 
chemical bonds with cadmium sulphide nanoparticles under a normal physiological pH of 
7.43. The functionalization of gold nanoparticles using cysteine residues is well established, 
as previously discussed (Majzik et al., 2009). It should also be noted that gold, silver and 
copper are all known to form bonds with sulphur atoms due to their grouping on the periodic 
table, which makes them attractive nanoparticle choices for protein-nanoparticle interactions 
of this type. The malarial TIM (PfTIM), shown (Figures 1.7a, b, c, d), has several exposed 
surface sulphur residues that are not present on the hTIM variant. This offers an opportunity 
for such selective nanoparticle targeting. 
1.6 Conclusions 
The malarial triosephosphate isomerise enzyme has a potential as a nanoparticle enzyme 
target. First, it has been identified as a biomedical target due to its importance in energy 
production for Plasmodium falciparum. Second, it has key amino acid, and structural, 
differences from its human host counterpart. These offer potential targets for gold and silver 
nanoparticle interactions due to their ability to associate with sulphur atoms of accessible 
cysteine and methionine residues (Figures 1.7 a, b, c, d). Finally, the selective inhibition of 
the Trypanosoma brucei TIM variant, which is known to be similar in structure to PfTIM, has 
been demonstrated by targeting cysteine residues that are also present in PfTIM and has being 
shown to be fatal for T. brucei. This indicates that, if successful, this methodology has the 
potential to be fatal to P. falciparum, as it was to T. brucei (Gómez-Puyou et al., 1995; 
Velanker et al., 1997; Parthasarathy et al., 2002; Parthasarathy et al., 2003). 
1.7 Hypothesis 
Due to amino acid sequence and structural differences between human and Plasmodium 
falciparum triosephosphate isomerases, silver nanoparticles, of less than 20 nm in size, will 
selectively inhibit the parasite enzyme over its human counterpart. 
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1.8 Research objectives 
1. Obtain cDNA for recombinant expression of human and Plasmodium falciparum 
triosephosphate isomerases. 
2. PCR amplify and sub-clone these genes into the pET28(b+) expression plasmid. 
3. Transform this plasmid into E. coli BL21(DE3) cells for protein over-expression.  
4. Purify large quantities of highly pure recombinant enzymes using Ni-Affinity 
chromatography and test enzyme activity, using a suitable assay. 
5. Assess and characterise the recombinant enzyme kinetics and activity and establish 
enzyme stability under different temperature and pH conditions. 
6. Synthesize and characterise silver nanoparticles, assessing their stability, size and 
shape using transmission electron microscopy and spectrophotometry. 
7. Interact the recombinant enzymes with the silver nanoparticles and monitor for 
changes in catalytic activity.  
8. Suggest a theorised mechanism for differences in activity that may be observed in 
data.  
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2.	Gene	cloning	and	verification	
2.1 Introduction  
The aims of this chapter was to sub-clone the gene sequences for hTIM and PfTIM into the 
pET28(b+) expression vector and transform the plasmids into the appropriate cell lines for 
recombinant protein overexpression. These were E. coli BL21(DE3) cells for hTIM and E. 
coli BL21(DE3), with the pRARE2 plasmid for PfTIM, since P. falciparum is AT-rich and 
uses rare codons (Su et al., 1996; Baca and Hol, 2000). To achieve this goal several 
molecular techniques were used.  For molecular DNA cloning, plasmid vectors were used as 
they have several natural advantages. First, typically they are small in size making them easy 
to purify and manipulate. Second, they can replicate independently of host cells as they have 
their own origin of replication. Third, they can have a multiple copy number, meaning several 
copies can reside within a single cell, which is advantageous when plasmid propagation is 
required. Fourth, selectable agents such as antibiotics can be incorporated, which simplifies 
screening and isolation. Fifth, commercial plasmids incorporate many easy-to-use restriction 
endonuclease sites, allowing for easy cutting and ligating of genes (Madigan and Martinko, 
2006).   
To obtain the PfTIM gene from the malarial parasite, complementary DNA (cDNA) was 
obtained from the ‘Malaria Research and Reference Reagents Resource Center’, (MR4), a 
part of the American Type Culture Collection (ATCC), and the PfTIM gene was amplified 
using polymerase chain reaction (PCR). This technique makes use of two PCR primers that 
flank, or are a part of, the target sequence. Therefore, some knowledge of the gene sequence 
being acquired is necessary. Primers can then be designed and tested, using several modern 
bioinformatics tools, and then ordered pre-synthesised from a company such as Integrated 
DNA Technologies. The design of primers typically also incorporates the restriction 
endonuclease sites, which are used to manipulate the amplified DNA during sub-cloning 
procedures and for cutting and ligating the gene sequence into an expression vector. PCR 
works through repetitive heating and cooling cycles. First, the double stranded DNA is 
denatured by heating, at high temperatures such as 95°C or 98°C, separating the dsDNA into 
two ssDNA sequences. Second, the sample is cooled to allow the primer sequences to 
‘anneal’ to the ssDNA at their specific target sites. At this stage DNA replication is also 
initiated, when a thermally stable DNA polymerase enzyme, such as Taq or Pfu, binds the 
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double stranded primer and template sequence segment. The polymerase then replicates the 
template DNA, downstream of the primer binding site, over a period of time known as the 
extension time. This process typically involves a slight increase in temperature and an 
increase in the replication speed of the DNA polymerase. However, this may not always be 
necessary or advisable for AT-rich genes, as it could result in DNA separation. These 
processes are typically optimised for use, with the sequence being amplified. Once extension 
is complete the sample is heated again to separate the now-double-stranded DNA and the 
process repeated 35 to 40 times, each time theoretically doubling the amount of target DNA 
isolated by the two primers (Wilson and Walker, 2005).  
Once DNA is obtained through PCR, and sub-cloned into a vector for further propagation, it 
can be sequenced. DNA sequencing is now fully automated but essentially works in the same 
manner as the original un-automated systems. Two methods have been developed. The first 
was the Maxam and Gilbert method that made use of chemical reactants to achieve base-
specific cleavage of DNA strands, although this method has now been replaced by the chain-
terminator method, which makes use of modified dNTP’s. The second sequencing method is 
known as the Sanger procedure, which exploits the use of a DNA polymerase from E. coli to 
synthesise complementary DNA from ssDNA without the need of primers. In both 
sequencing methods the chain-terminator sub-method may be used. This works by 
incorporating natural deoxynucleotides and 2’,3’-dideoxynucleotide analogues (at a lower 
concentration); these lack a hydroxyl group, which causes the termination of DNA strand 
elongation after they are inserted. A radiolabelled dNTP analogue (e.g. α35S-dATP) is also 
included, and the reactions are run four times, once for each base. If done correctly, the DNA 
elongation is terminated at all possible bases and can be imaged using autoradiography after 
running denaturing (SDS-PAGE). The banding patterns of the four sequences are read 
together and the sequence can be directly deduced from this method. Similarly, fluorescent-
dye-labelled substrates can also be used for more rapid (real-time) DNA sequence detection, 
using capillary polyacrylamide gels. This illustrates how modifications to essential basic 
techniques (i.e. PCR and gel electrophoresis) can result in entirely new powerful applications 
of such procedures. Indeed the many different forms of gel electrophoresis and 
chromatography techniques, that all essentially work on basic principles, have allowed for the 
development of an astounding number of unique and extremely powerful molecular and 
biochemical methods (Karp, 2005; Ratledge and Kristiansen, 2006).   
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In this chapter the experimental work, used to obtain both the hTIM and PfTIM genes in an 
expression-ready form, is outlined. This involved DNA amplification techniques, using PCR 
and plasmid sub-cloning in E. coli JM109 cell lines for gene propagation. For hTIM the 
optimised gene was sub-cloned from the pMK-T plasmid into the pET28(b+) vector. While 
for PfTIM samples, the PCR product was ligated into the pJET1.2 vector for propagation and 
then sub-cloned into the pET28(b+) vector. Once both genes had being sub-cloned into the 
pET28(b+) cvector making pET28(b+) expression ready plasmids, the plasmids were 
transformed into the E. coli BL21(DE3) expression ready cells for protein overexpression.  
2.2 Materials and methods 
A full list of reagents is also supplied (Appendix A) as well as a list of buffer preparation 
procedures of common buffers used (Appendix B). When kits were used they all included the 
necessary reagents. An Eppendorf bench-top micro-centrifuge was used for the centrifugation 
steps, unless otherwise stated.  
For double digestion reactions the Thermo scientific Fermentas double digest tool, available 
on their website, was used (http://www.fermentas.com/en/tools/doubledigest). Plasmid DNA 
extraction was done using the Bioflux, Biospin plasmid DNA extraction kit, Cat#BSC01S1, 
available from (www.bioer.com.cn). DNA extractions made use of the Bioflux, Biospin gel 
extraction kit from Bioer Cat#BSC02S1, available at (www.bioer.com.cn). The CloneJET™ 
PCR Cloning Kit Ref #K1231, sold by Inqaba Biotechnology (part of ThermoScientific), was 
used. The kit is available on their website at http://www.fermentas.com/. Extracted plasmid 
DNA was sent into Inqaba biotechnology (http://www.inqababiotec.co.za/) for DNA 
sequencing with the pJet1.2 sequencing primers provided in the plasmid kit. 
2.2.1 DNA ligations 
Three DNA ligation reactions were required in this project: One to ligate the PfTIM PCR 
product into the pJET 1.2 vector, and two more to ligate both hTIM and PfTIM into the 
pET28(b+) vector. All reactions were designed (using Equations 2.2.1 and 2.2.2) to calculate 
the optimal concentrations of vector DNA, to insert DNA for efficient ligation reactions using 
50 ng of vector DNA (Table 2.1). 
 
Equation 2.2.1  
Insert concentration = 50 ng(vector DNA) x insert DNA size 
               Size of vector used 
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Equation 2.2.2 
 Volume of vector required = concentration of vector after restriction analysis   
           50 ng of vector needed 
For ligation reactions, the unknown concentrations of the pET28(b+) and/or pJET1.2 vectors, 
as well as for the hTIM and PfTIM genes, were determined using a Nanodrop 2000c 
spectrophotometer (ThermoScientific), after the double-digest restriction analysis (Section 
2.2.5) using EcoRI, NdeI and XhoI and gel purification. The determined DNA concentration 
data, was used to calculate reaction reagent concentrations (Equations 2.2.1 and 2.2.2) for the 
ligation reactions. The calculated values are indicated in Table 2.1.  
Table 2.1: Ligation reactions for hTIM and PfTIM ligation into the pET28(b+) vector and the PfTIM 
PCR product into the pJET1.2 vector. 
Reagents hTIM in 
pET28(b+) 
PfTIM in 
pET28(b+) 
PfTIM in 
pJET 1.2 
Linearized pET28(b+) 1.8 µl 3 µl - 
pJET 1.2 (50 ng/µl) - - 1 µl 
DNA insert 0.5 µl 3.2 µl 3.8 µl 
Ligase buffer 1 µl 1 µl - 
T4 DNA Ligase 1 µl 1 µl 1 µl 
Nuclease free H2O 5.7 µl 1.8 µl 4.2 µl 
pJET1.2 (ligase buffer) - - 10 µl 
Total Volume 10 µl 10 µl 20 µl 
  
Ligation reactions were performed overnight (approximately 12-16 hours) at 4°C, except for 
the pJET1.2 ligation, which was incubated at room temperature for 5 min before being 
immediately transformed into E. coli JM109 cells. 
2.2.2 Preparation of competent cells  
A procedure outlined by Inoue et al. (1990) was used for the preparation of competent cells 
and transformation with prepared plasmids. The preparation of competent cells was 
performed three times to make competent E. coli JM109 cells and E. coli BL21(DE3) cells 
for propagation/expression, and again on a selection of E. coli BL21(DE3) transformed with 
the pRARE2 plasmid, to allow for expression of PfTIM, which contained rare codons. 
For growth media, super optimal broth (SOB), super optimal broth with catabolite 
suppression (SOC) and luria broth (LB), were prepared as described by Hanahan (1983) 
(Appendix B). For selection and screening of transformed E. coli JM109 cells, LB agar plates 
were prepared with relevant antibiotics, when necessary. These included, ampicillin 100 
µg/ml (pJET1.2), kanamycin 30 µg/ml [pMK-T or pET28(b+)] and chloramphenicol 34 
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µg/ml (pRARE2 plasmid), where the concentrations here represent the final concentration 
present in the prepared agar, or broth, solution.  
Frozen cell stocks were thawed, streaked on LB agar plates, and cultured overnight at 37°C. 
A swipe of large colonies was isolated using a platinum loop and inoculated in 250 ml of 
SOB medium in a 1 litre flask. This was grown overnight (~8-10 hours) at 18-20°C, with 
shaking at ~150-200 rpm, until an OD600 of ~0.55 was obtained. This broth was then removed 
from the incubator and immediately placed on an ice/water slurry for 10 min. The culture was 
transferred into a 500 ml centrifuge bottle and centrifuged (2500 x g; 10 min; 4°C). The pellet 
was resuspended using 80 ml of ice-cold TB buffer and incubated on ice for a further 10 min. 
After incubation it was centrifuged again, as described above. The cell pellet was gently 
resuspended in 20 ml of TB buffer, and 1.5 ml DMSO was added and gently swirled to 
facilitate mixing. The sample was placed on ice for a final 10 min, distributed as 100 µl 
aliquots in 1.5 ml sterile tubes, and then rapidly frozen in liquid nitrogen. Samples were then 
stored at -80°C until use. 
2.2.3 Transformation procedure 
Previously prepared competent cells of E. coli JM109 or Bl21(DE3) were thawed at on ice 
and 10 µl of extracted ligation mixture/plasmid was added. Tubes were gently tapped to mix, 
and incubated on ice for 20 min. Samples were then heat-shocked by putting them in a heat 
block at 42°C for 40-60 sec, then immediately placing them in an ice water slurry for 2 min. 
Thereafter, 250 µl of SOC media was added and samples were incubated at 37°C for 1 hour. 
Cells were centrifuged (2500 x g; 5 min). The supernatant was decanted until 100 µl was left 
and the pellet was resuspended by gently pipetting the volume up and down several times. 
The resuspended sample was then spread-plated onto selective LB-Agar plates with 
appropriate relevant antibiotics: kanamycin (30 µg/ml) for transformations using pET28(b+) 
and pMK-T plasmids, and ampicillin (100 µg/ml) for transformations using the pJet1.2 
plasmid. Chloramphenicol (34 µg/ml) was also used when transformations were done using 
cell cultures that contained the pRARE2 plasmid. Samples were then grown overnight (for 
12-16 hours) and individual colonies picked and grown in LB with relevant antibiotics (for 
12-16 hours) before restriction analysis screening (Inoue et al., 1990).  
2.2.4 Plasmid DNA extraction 
The standard protocol provided with the Bioflux, Biospin plasmid DNA extraction kit, is 
described as follows. Broth cultures continuing plasmid were grown for 16 hours. From this 2 
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ml was centrifuged (10000 rpm; 30 sec), the supernatant discarded and the process repeated 
once more. The pellet was resuspended, using 250 µl resuspension buffer, and vortexed. To 
this 250 µl of lysis buffer was added and sample inverted 4-6 times, followed by the addition 
of 350 µl of neutralization buffer, followed by inversion (for mixing). This was centrifuged at 
13000 rpm for 10 min, the supernatant added to a spin column, and then centrifuged for 1 
min at 6000 rpm. Flow-through was discarded and 650 µl of wash buffer was added, and the 
solution centrifuged at 12000 rpm for 1 min, discarding the flow-through. This process was 
then repeated once. Sample columns were then transferred to sterile 1.5 ml tubes, 50 µl of 
elution buffer was added, and the tubes incubated at 37°C for 15 min. Finally, plasmid DNA 
was collected by centrifuging the elution buffer through the column at 12000 rpm for 1 min 
and collecting the flow-through in 1.5 ml tubes. 
2.2.5 DNA double digestion reactions 
Double digestion reactions were performed on plasmid DNA samples extracted as described 
in Section 2.2.4. By performing double digestion reactions, target genes could be screened for 
on agarose gels (Section 2.2.6) and cleaned from the gel for downstream cloning (Section 
2.2.7). In total, three double digestion reactions were performed, as outlined in Table 2.2, 
using ‘Fermentas’ reagents. The double digestion reactions for the pMK-T and pJET1.2 
plasmids resulted in sticky-end gene sequences for ligation into the pET28(b+) expression 
plasmid. Generally, 10 µl double digestion reaction repeats of these reactions were done for 
screening purposes. 
 
Table 2.2: Double digestion reactions performed on the pMK-T, pET28(b+) and pJET1.2 plasmids. 
Reagent pMK-T  
& hTIM  
pET28(b+) 
& hTIM 
pJET1.2   
& PfTIM 
pET28(b+) 
& PfTIM 
Buffer R 5 µl 1 µl - - 
Buffer O - - 1 µl 2.5 µl 
XhoI 2.5 µl 0.2 µl - - 
NdeI 5 µl 0.4 µl 0.5 µl 1 µl 
EcoRI - - 0.5 µl 1 µl 
Plasmid DNA 30 µl 8.4 µl 4 µl 20.5 µl 
Sterile H2O 7.5 µl - 4 µl - 
Total volume 50 µl 10 µl 10 µl 25 µl 
 
Double digestion reactions were incubated at 37°C for 1-3 hours though in some cases the 
reaction was run overnight. The overall volumes of reactions did vary between individual 
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experiments, but the relative concentration ratios of reagents always remained as indicated 
(Table 2.2). 
2.2.6 Agarose gels 
All agarose gels were made as 0.8% by mixing 0.8 g agarose with 100 ml of 1 x TAE buffer 
(Appendix B). This was microwaved for approximately 1-2 min until all agarose was 
dissolved and the liquid appeared clear. This was allowed to cool to approximately 55°C and 
4 µl of ethidium bromide (10 mg/ml) was added. The sample was swirled several times to 
mix, then poured into a Bio-Rad® gel system and electrophoresed (90 V, 60 min). Samples 
loaded in the gel wells were mixed with 1 µl, 6 x loading dye (ThermoScientific), per 4 µl of 
sample, and loaded into the gel wells (typically 10 µl). 
2.2.7 Agarose gel DNA extraction 
Agarose gels were visualised on a gel doc (Vilber Lourmat) under 365 nm UV light to limit 
DNA denaturation. Samples were loaded with GeneRuler DNA Ladder marker, supplied by 
Inqaba biotechnology, but a product of ThermoScientific, which were used to help identify 
the relevant bands to be excised from the gel, using a sterile scalpel. Gel slices were placed in 
2 ml tubes and weighed, then 3 x their weight of extraction buffer was added and samples 
were incubated at 50°C for 10 min and periodically vortexed until the gel had melted. For 
pET28(b+) samples 1 x gel weight of isopropanol was also added. The sample was 
transferred to the supplied spin columns and centrifuged at 6000 rpm for 1 min and the flow-
through discarded. This was repeated until all samples had been loaded onto the columns. An 
additional 500 µl of extraction buffer was added and centrifuged at 12000 rpm for 30 sec, 
discarding the flow-through. Wash buffer was added (750 µl) and allowed to stand for 5 min. 
It was then centrifuged for 1 min at 12000 rpm and the column transferred to a 1.5 ml tube. 
To this, 50 µl of elution buffer was added and the sample was incubated for 15 min at 37°C. 
Finally, the DNA was eluted by centrifugation at 12000 rpm for 1 min.  
Extracted DNA (plasmid or gene) was quantified using a Nanodrop 2000c spectrophotometer 
(ThermoScientific), (Section 2.2.1). 
2.2.8 Preparation of glycerol stocks 
To prepare glycerol stocks a swipe of transformed colonies was taken and grown for 12-16 
hours in LB broth containing relevant antibiotics (kanamycin 30 µg/ml, and/or 
chloramphenicol 34 µg/ml). Aliquots were then taken from this broth and stored in 1.5 ml 
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tubes containing 1 ml of cultured cells and 0.5 ml of a sterile 50% glycerol solution. Stocks 
were then frozen at -80°C, for later use.     
2.2.9 PCR primer design  
Plasmodium falciparum 3D7, blood-stage, cDNA obtained from the Malaria Reference 
Reagents and Resource Center (MR4), a part of the American Type Culture Collection 
(ATCC), was used as a template for PCR to amplify the PfTIM gene sequence. To do this the 
PfTIM gene sequence in the cDNA needed to be known so that a suitable pair of PCR 
primers could be designed. The entire genome and mRNA of P. falciparum has being 
sequenced and, as such, the cDNA sequence, which is in fact a complementary strand of 
mRNA made using reverse transcriptase, could be downloaded from the National Centre for 
Biotechnology Information (NCBI). Website:  (http://www.ncbi.nlm.nih.gov/genbank/), 
Sequence #XM_001348516.2. Using the mRNA sequence also has the benefit of not having 
to remove the introns, as this has already been done by the parasite’s biochemical machinery 
during mRNA expression. The sequence listed here was 1486 bp in length, of which positions 
318-1064 (inclusive) were identified by the NCBI website as being the coding sequence. This 
meant that the target sequence for PCR was 747 bp in length (Appendix C).  To target this 
sequence, the following forward and reverse primers were designed, tested, and analysed 
using the pDraw32 program as well as the Integrated DNA Technologies (IDT), website-
based, primer design tool at: (http://eu.idtdna.com/analyzer/Applications/OligoAnalyzer/). 
For further details of these designed primers, the target sequence, and analysis of primers - 
including melting temperatures (Tm), and BLAST primer analysis - see Appendix C. 
 
 
Primer sequences designed to bind to PfTIM cDNA for PCR 
 
Forward primer (binding sequence)     
5’-ATGGCTAGAAAATATTTTGTCGCAGC-3’     (26 bp) 
 
Reverse primer (binding sequence) 
5’-TTACATAGCACTTTTTATTATATCAACAAAAGATTC-3’   (36 bp) 
 
After designing the binding primer sequence (above), they were redesigned to incorporate 
restriction endonuclease sites for NdeI (forward) and EcoRI (reverse). This allowed for easy 
sub-cloning of the gene into the pET28(b+) expression vector via restriction analysis:  i.e. the 
‘double digest’ reactions (Section 2.2.5). The redesigned primers, with restriction sites, also 
function to forcefully introduce the restriction sites during PCR at the right points and in the 
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right reading frame for problem-free DNA manipulations. The redesigned primers are 
indicated below, with restriction sequences highlighted: NdeI (CATATG) and EcoRI 
(GAATTC). These redesigned sequences (below) were synthesised, by IDT whom also 
provided analysis of the ordered primer sequences – see Appendix C.  
 
Final primer sequences designed for PCR amplification of PfTIM from P. falciparum cDNA 
Forward primer (ordered sequence)     
5’-CATATGGCTAGAAAATATTTTGTCGCAGC-3’    (29 bp) 
 -NdeI 
 
Reverse primer (ordered sequence) 
5’-GAATTCTTACATAGCACTTTTTATTATATCAACAAAAGATTC-3’  (42 bp) 
 -EcoRI 
2.2.10 Optimized PCR Protocol  
The PCR procedure underwent many optimisations (Appendix D) before a functioning 
procedure was developed. One paper in particular, by Su et al., (1996), was used extensively 
as an aid for customising and optimising the PCR protocol, as it focuses extensively on 
dealing with highly AT-rich genes. Troubleshooting guidelines from the manual for Pfu high 
fidelity DNA polymerase were also extensively used to develop optimisations that allowed 
this PCR to work. The highly AT-rich nature of the Plasmodium falciparum genome rendered 
several common PCR protocols and DNA polymerase enzymes completely ineffective (for P. 
falciparum cDNA). Eventually, a completely redesigned optimized PCR protocol was 
developed (see Table 2.3, with cycling parameters indicated in the following paragraph). This 
optimized protocol, using Pfu high fidelity DNA polymerase, was successfully used to 
amplify the PfTIM gene in large amounts. 
 
Table 2.3: Optimised PCR protocol used to amplify AT-rich PfTIM from P. falciparum cDNA.  
Reagents Volume 
P. falciparum cDNA (2 ng/µl) 1 µl 
HF Buffer (5 x concentration) 10 µl 
Forward Primer (10 pmol) 2.5 µl 
Reverse Primer (10 pmol) 2.5 µl 
dNTPs (10 mM) 1 µl 
Sterile DNA free H2O 32.5 µl 
Phusion Hot Start II Pfu Taq 0.5 µl 
Total 50 µl 
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Samples, prepared as in Table 2.3, were run on a rapid thermal cycler, starting with 2 min 
incubation at 98°C to activate the Phusion Hot Start II Taq (ThermoScientific). Cycling 
parameters then started with 20 sec at 98°C to separate DNA, followed by a custom two-step 
annealing process of 10 sec at 62°C, then 10 sec at 57°C, and finally DNA extension for 40 
sec at 60°C. This process was cycled through for 35 to 40 times before a final extension step, 
of 10 min at 60°C. The program ended with cooling to 4°C for a maximum time of 16 hours, 
or until the sample could be removed.  
This procedure produced blunt ended unphosphorylated DNA, ready for blunt end ligation, 
using the CloneJET™ PCR cloning kit described below (Section 2.2.11). 
2.2.11 CloneJET PCR cloning kit aka: (pJET1.2 vector) 
The blunt end cloning procedure, as detailed in the kit manual, was performed using DNA 
extracted from an agarose gel (Section 2.2.6) of the PCR product (Section 2.2.10) using the 
gel purification kit (Section 2.2.7). The gel-extracted DNA was quantified using a Nanodrop 
2000c spectrophotometer, which indicated 9.9 ng-1.µl-1 of PfTIM DNA had been extracted 
from gel of the PCR product. Using the manual guidelines, a 20 µl ligation reaction - to ligate 
the PfTIM gene into the blunt end pJET1.2 cloning vector - was setup (Table 2.4). 
 
Table 2.4: Blunt end ligation into CloneJET - pJET1.2 vector. 
Reagents Volume 
2x Buffer 10 µl 
PCR Product (37.5 ng) 3.8 µl 
pJET1.2 (50 ng/µl) 1 µl 
Nuclease free H20 4.2 µl 
T4 DNA Ligase 1 µl 
Total 20 µl 
 
Reagents were mixed by vortexing (3-4 sec) and then incubated (22°C, 5 min). Ligated 
plasmid mixture was used for transformations, with E. coli JM109 cells - see Section 2.2.3. 
This kit is a positive identification kit for high-efficiency cloning of PCR products and it 
includes the use of a lethal restriction enzyme gene, which is disrupted by the ligation of a 
DNA insert into the cloning site. This means that only cells with a DNA insert ligated into the 
plasmid cloning site are able to grow, thus allowing for positive selection screening. In 
addition to this, the kit included sequencing primers, for DNA sequencing. These were used 
to sequence the successful ligations to confirm the presence of the PfTIM gene (Appendix F). 
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2.3 Results and discussion 
The following sub-sections present the experimental work done to obtain expression ready 
forms of the hTIM and PfTIM genes. 
2.3.1 Obtaining the hTIM gene and sub-cloning  
The human TIM gene was purchased already-synthesised by Invitrogens’ Life Technologies 
division using their GeneArt® Gene Synthesis service. This included codon optimization for 
expression in E. coli cultures. The gene was supplied in the pMK-T vector (5 µg), with a 
plasmid map (Figure 2.1) and DNA sequencing results indicating the sent DNA sequence 
aligned with the codon-optimized sequence for hTIM gene. A translated amino acid 
sequence, for comparison with the known hTIM amino acid sequence, was included because 
the codon optimization process for E. coli meant the DNA coding sequence had being 
changed, due to silent mutations, and therefore would not be identical (in terms of DNA) to 
the known hTIM sequence, but the amino acid sequence it produced would be. These data 
and the supplied chromatogram are included in Appendix E.  
Figure 2.1: Map of the pMK-T plasmid, containing the hTIM and kanomycin-resistance genes, an 
origin of replication, for cloning in E. coli cell cultures. All relevant restriction sites are also shown. 
 
As shown in Figure 2.1 the gene has an NdeI site at its start and an XhoI site at its end. A 
double digestion reaction of pMK-T, using these restriction endonucleases, would therefore 
produce two bands on an agarose gel, ~2.3 Kbp in size (vector backbone) and the other ~750 
bp in size (hTIM gene). Using these restriction endonucleases would eloquently remove the 
target hTIM gene sequence, with sticky ends ready for sub-cloning into the pET28(b+) 
expression system, which also contains these restriction endonuclease sites.  
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The hTIM gene was cloned into the pET28(b+) expression vector for protein overexpression 
in E. coli BL21(DE3) cells. To achieve this, the supplied pMK-T plasmid was transformed 
into E. coli JM109 competent cells (Sections 2.2.2 and 2.2.3). A swipe of transformed 
colonies was selected from the plate and transferred into Luria broth, containing kanamycin, 
and incubated overnight (12-16 hours) at 37°C. After plasmid DNA extraction (Section 2.2.4) 
the sample was quantified using nanodrop, which indicated approximately 122 ng/µl of 
pMK-T plasmid DNA containing the hTIM gene had being obtained and was relatively pure, 
as indicated by the A260/A280 readings. 
Similarly, a culture of E. coli JM109 cells containing unmodified pET28(b+) plasmid, was 
grown in in Luria broth containing kanamycin for 12-16 hours at 37°C, and plasmid DNA 
extraction performed (Section 2.2.4), and the DNA concentration quantified indicating 
approximately 143 ng/µl of the pure pET28(b+) plasmid DNA had being obtained. 
A virtual DNA cloning, to evaluate the sticky end ligation of hTIM into pET28(b+) after both 
plasmids had undergone double digestion reactions using NdeI and XhoI restriction 
endonucleases, was computed using the freely-available pDraw32 application from 
(http://www.acaclone.com/). The result of this gave the following plasmid map (Figure 2.2).  
Figure 2.2: Plasmid map of the virtual cloning of hTIM into the pET28(b+) expression plasmid using 
NdeI and XhoI restriction endonucleases (designed using the open source program pDRAW32). 
 
Similarly the the virtual cloning procedure also indicated that a double digest reaction of 
empty pET28(b+) vector backbone, using NdeI and XhoI restriction endonucleases – 
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(plasmid map not shown), will produce only one visible band, of ~5.32 Kbp in size, on an 
agarose gel. 
After performing the virtual cloning and calculating the band sizes that should be observed 
from a successful double digestion procedure, the pMK-T and pET28(b+) plasmids were 
digested overnight using NdeI and XhoI. A 0.8% agarose gel (Section 2.2.6) of these samples 
was run to determine if the digested band sizes were correct (Appendix A). This gel was 
visualised under 365 nm light and bands corresponding to the calculated sizes for hTIM and 
pET28(b+) were excised from the gel, for DNA extraction (Section 2.2.7) see Appendix E4 
for this gel image. 
Extracted hTIM and pET28(b+) sticky end DNA was then ligated as per the DNA ligation 
procedure (Section 2.2.1). Ligated DNA was transformed into E. coli JM109 cells and 
screened on kanamycin plates (Section 2.2.3). Individual colonies were then picked and 
grown in LB overnight (12-16 hours). To screen for transformed colonies, a ‘dirty prep’ Lysis 
by boiling procedure (Appendix B) was used to screen ten colonies. Double digestion 
reactions were done and samples were electrophoresed for screening on a 0.8% agarose gel 
(Appendix E5). Clean plasmid DNA was then extracted (Section 2.2.4) from the two sample 
cultures identified from the ‘dirty prep’ procedure (Appendix E5). Extracted pure DNA from 
these transformed colonies was then screened using the double digest reaction (Section 2.2.5) 
to confirm if bands for hTIM were present at the expected size range, of ~750 bp, that would 
indicate a successful ligation of the correct DNA sequence into the pET28(b+) plasmid. This 
result is presented in Figure 2.3. 
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Figure 2.3: Agarose gel showing, Lane 1: GeneRuler DNA ladder and Lanes 2 and 3: Double 
digestion reactions (Section 2.2.5) on plasmid DNA extracted from select picked colonies that had 
been transformed using the pET28(b+) and hTIM DNA ligation mixture.  
 
Figure 2.3 confirms that hTIM was successfully ligated into the pET28(b+) expression 
system. Remaining extracted plasmid, used to produce Figure 2.3, was used to transform 
competent E. coli Bl21(DE3) expression-ready cells, (Sections 2.2.2 and 2.2.3). A swipe of 
transformed colonies was picked and grown in LB broth with kanamycin to make glycerol 
stocks (Section 2.2.8) that could be used later for recombinant protein expression of hTIM.  
2.3.2 Obtaining PfTIM from cDNA by PCR and sub-cloning 
Initially complementary DNA (cDNA) of Plasmodium falciparum 3D7 parasites blood-stage 
messenger RNA was obtained from the American Type Culture Collection (ATCC). To 
extract and amplify the PfTIM gene from this sample, a highly modified and optimised 
polymerase chain reaction (PCR) protocol had to be designed (Section 2.2.10) along with 
suitable PCR primers that introduced the restriction endonuclease sites of NdeI (forward) and 
EcoRI (reverse) on the primers, for easy DNA manipulation.  
After PCR amplification reactions (Sections 2.2.9 and 2.2.10) the PCR product was 
concentrated under a vacuum (Vacutec Centrivap cold trap and DNA concentrator). The dry 
PCR product DNA was then resuspended in MilliQ H2O and electrophoresed on a 0.8% 
agarose gel (Section 2.2.6). Some of this sample was photographed at 320 nm (Figure 2.4) 
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while the remainder was visualised under 365 nm light, excised from the agarose gel, and a 
DNA extraction performed (Section 2.2.7). Extracted DNA was then used as a template for a 
subsequent PCR reaction (Sections 2.2.9 and 2.2.10) which produced the necessary quantities 
of blunt end PfTIM DNA required for ligation into the blunt end pJet1.2 cloning vector. 
 
Figure 2.4: Agarose gel showing; Lane 1: GeneRuler DNA ladder, and Lane 2: The product of a PCR 
reaction detailed in Sections 2.2.9 and 2.2.10 using Plasmodium falciparum cDNA as template. 
 
As with hTIM, virtual cloning was done to assess the viability of the cloning procedure and 
to identify any potential problems. For PfTIM, however, the process was done twice: once for 
cloning into the pJet1.2 cloning vector and then again for cloning into pET28(b+) expression 
vector. Virtual cloning maps generated in this process are presented as Figure 2.5. 
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Figure 2.5: Virtual cloning using the pDRAW application of the PfTIM PCR product into, (a) the 
blunt end pJet1.2 PCR cloning vector, and (b) the virtual cloning into the pET28(b+) expression 
vector using NdeI and EcoRI restriction endonucleases to cut the PfTIM gene and pET28(b+) plasmid 
for sub-cloning and sticky end ligation reactions. 
 
Virtual cloning confirmed the viability of the cloning procedures being used and also 
indicated what band sizes to expect in agarose gels done on double digest reactions using 
NdeI and EcoRI restriction endonucleases. 
Cloning began with the ligation of the extracted PCR product into the blunt end pJet1.2 
cloning vector (Section 2.2.11). No phosphorylation process was required as this vector came 
pre-phosphorylated. After ligation (Section 2.2.1) the pJet1.2 and PfTIM ligation mixture was 
transformed into E. coli JM109 competent cells (Section 2.2.2) and grown on selective LB 
agar media containing ampicillin. Five colonies were picked from these plates and LB 
cultures grown with ampicillin (Section 2.2.3). Plasmid DNA was then extracted (Section 
2.2.4), followed by a double digestion reaction using NdeI and EcoRI (Section 2.2.5). The 
five samples were then electrophoresed on a 0.8% agarose gel to screen for successfully 
transformed colonies (Section 2.2.6). The result of this sub-cloning of the PCR product into 
pJet1.2 vector (Figure 2.5a) produced Figure 2.6, which indicates three of the five colonies 
selected appear to have the PfTIM gene insert. 
 
 
 
 
 
 
(a) (b) 
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Figure 2.6: Agarose gel of plasmid extracted from JM109 cells and digested using NdeI and EcoRI. 
Lanes 1 and 7 are GeneRuler DNA ladder. Bands in lanes 2, 5 and 6 correspond with the known sizes 
of pJet1.2 vector (3 kb) and PfTIM (756 bp), as indicated on the right of the Figure. Lanes 3 and 4 
have only 1 band that roughly corresponds to a plasmid that had only been cut once (~3.7 kb). 
 
As calculated in the virtual cloning process (Figure 2.5a), bands for PfTIM and the pJet1.2 
vector are clearly visible in their correct positions, of 756 bp for PfTIM and ~3 kbp, for 
pJet1.2 vector from the double digestion reaction using NdeI and EcoRI. After having 
obtained this result, additional plasmid DNA from the broth cultures of lanes 2 and 6 (Figure 
2.6) was extracted (Section 2.2.4). Samples of each (10 µl) were sent to Inqaba Biotech 
(South Africa) for DNA sequencing in both forward and reverse directions using the 
sequencing primers provided with the pJet1.2 cloning kit. The sequencing results from both 
samples were an exact match with the known PfTIM DNA sequence, indicating that no 
mutations had occurred during PCR or sub-cloning into pJet1.2 and the correct sequence had 
been obtained. The chromatogram and blast search using the DNA sequence returned from 
sequencing can be seen in Appendix F.  
After sequencing confirmed that the correct PfTIM gene sequence had been inserted into the 
pJet1.2 vector, it was digested using NdeI and EcoRI (Section 2.2.5). Similarly, a double 
digest reaction on empty pET28(b+) vector was also done using these restriction 
endonucleases. A 0.8% agarose gel (Section 2.2.6) was then prepared and electrophoresed for 
the sub-cloning and the digestion products visualised under UV light at 365 nm. Bands 
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corresponding to PfTIM and empty pET28(b+) vector were excised from the gel and the 
DNA extracted (Section 2.2.7). The image of this gel can be seen in Appendix D4. Extracted 
DNA was quantified and DNA ligation reactions set up and run (Section 2.2.1). The ligation 
mixture was then transformed into E. coli JM109 cells (Section 2.2.3) and cultured on 
selective LB agar plates containing kanamycin. Seven colonies were picked from the 
selective media and then grown in selective LB broth cultures (Section 2.2.3). Cells were 
harvested from the seven broth cultures and plasmid DNA extractions were performed 
(Section 2.2.4) on each sample, followed by double digest reactions using NdeI and EcoRI 
(Section 2.2.5) and then electrophoresed on a 0.8% agarose gel (Section 2.2.6). The image of 
this gel is shown in Figure 2.7 below.   
 
Figure 2.7: Agarose gel of, Lane1: GeneRuler DNA ladder, and Lanes 2-8: Double digest reactions 
using NdeI and EcoRI (Section 2.2.5) on plasmid DNA extracted from broth cultures of individually 
picked colonies that had being transformed with pET28(b+) plasmid ligated with PfTIM DNA. 
 
As shown in Figure 2.7 above, all picked colonies had successful ligations of the PfTIM gene 
into the pET28(b+) expression vector. The extracted plasmid sample that gave lane 2 (Figure 
2.7) was chosen to transform (Section 2.2.3) previously-prepared E. coli BL21(DE3) cells 
containing the pRARE2 plasmid. For this transformation, selective LB agar plates containing 
chloramphenicol and kanamycin were used (Section 2.2.3). A swipe of transformed colonies 
was picked from the selective media plates and grown for 12-16 hours in LB containing these 
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two antibiotics. This broth culture was then used to create glycerol stocks (Section 2.2.8). 
These E. coli BL21(DE3) expression ready cells contained the pRARE2 plasmid and the 
pET28(b+) expression vector with the PfTIM gene insert, as indicated by Figure 2.7, and 
were ready to be used for recombinant protein overexpression of PfTIM.  
2.4 Conclusions 
Thus the goal of this chapter, which was to obtain cell cultures of both hTIM and PfTIM that 
were ready for overexpression of these two recombinant enzymes, had been achieved. The 
glycerol stock aliquots were stored at -80°C so that when desired a 1.5 ml sample could be 
thawed, new broths grown, and the recombinant protein overexpression procedure initiated, 
as detailed in the next chapter. 
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3.	Recombinant	protein	expression,	
purification	and	characterisation.		
3.1 Introduction 
The aims of this chapter are to outline the experimental procedures and results done to obtain 
pure recombinant hTIM and PfTIM enzymes, to confirm enzyme activity, and characterise 
these two enzyme variants. 
Recombinant protein overexpression was performed using the prepared glycerol stocks which 
contained the pET28(b+) expression vector with the relevant genes ligated into the vectors 
expression site, using E. coli BL21(DE3) expression ready cultures. The PfTIM cultures also 
contained the pRARE2 plasmid due to the AT-rich nature of the PfTIM gene and its use of 
rare codons (Su et al., 1996; Baca and Hol, 2000). The pET28(b+) expression vector 
introduces a 6x histidine tag (His-Tag) to the N-terminal end of any expressed recombinant 
protein. This allowed for efficient and easy purification using Ni-affinity chromatography, 
which strongly binds these his-tagged proteins, resulting in a highly effective purification 
step. The recombinant proteins were then eluted from the Ni-Affinity column using 
increasing concentrations of imidazole in a ‘linear gradient’ achieved by the FPLC system, 
which gradually altered the ratio of (running:elution buffers) increasing the amount of elution 
buffer - which contains much higher concentrations of imidazole - from 0% to 100%. The 
imidazole then competes with the bound his-tagged recombinant protein displacing it and 
allowing it to elute out of the column. Further purification steps were also performed 
including, gel filtration - on Sephadex 200HR column - to remove the imidazole, and dialysis 
to eliminate NaCl used in the gel filtration buffer.  
An auto-induction medium was chosen because it has several advantages, such as creating a 
better-folded and more soluble target protein, which is typically several folds higher in 
concentration, compared to that produced by isopropyl-β-D-thiogalactoside (IPTG), 
induction methods (Studier, 2005). A typical induction system, such as that found in E. coli 
BL21(DE3) cells, uses the T7 RNA polymerase under the control of the inducible lacUV5 
promoter. Upon the introduction of any inducer (typically IPTG), T7 RNA polymerase is 
made and any DNA controlled by the T7 promoter is transcribed. T7 is so active that the 
amount of target RNA produced can be comparable to the total amount of RNA produced in a 
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cell (Studier, 2005). Target RNA, produced during this process, will typically contain a 
coding sequence with an appropriate translation initiation sequence upstream of the start 
codon. In pET28(b+) this sequence is of the T7 major capsid protein, which promotes gene 
translation and transcription. Consequently, the majority of protein synthesis is directed to the 
target gene, which usually becomes a large component of the total protein content in the cell, 
provided no further complications occur, such as gene toxicity in the E. coli cells (Studier, 
2005; Sørensen and Mortensen, 2005).  
One of the problems with the T7 expression system is that it is so active that even small basal 
levels of expression can result in substantial amounts of protein being expressed in cells, even 
in the absence of an inducer. This can cause toxicity problems and also result in lower yields. 
This problem can be circumvented by inserting the lac operator sequence downstream of the 
T7 start site, creating a T7lac promoter site (Sørensen and Mortensen, 2005). This allows for 
gene suppression, by interfering with the binding of the lac repressor to the lac operator site. 
This lac repressor prevents the establishment of an elongation complex by T7 RNA 
polymerase, resulting in substantial reduction in background mRNA expression (Sørensen 
and Mortensen, 2005). During induction, both the T7lac and lacUV5 sites are unblocked by 
the release of the lacI tetramer (Figure 3.1), allowing for maximal translation and expression 
levels to be obtained. The lacI tetramer release is triggered by the binding of IPTG to it or 
binding of a similar lac inducer to IPTG such as α-lactose used in auto-induction. The pET 
vectors utilise this lacI gene to control the repression of the lacUV promoter and the T7/lac 
hybrid promoter (Sørensen and Mortensen, 2005). This repression function of the lacI gene 
may also be further enhanced 10 fold, with the use of a mutant lacIq gene - which is 
overexpressed by the E. coli host. This whole system is represented graphically in Figure 3.1, 
obtained from Sørensen and Mortensen (2005). 
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Figure 3.1: The general overview of the pET expression system is shown on the left, and on the right 
the biochemical molecular interactions before and after induction are represented, Sørensen and 
Mortensen, (2005).  
 
The average half-life of mRNA in E. coli at 37°C can range from seconds to a maximum of 
20 min (Sørensen and Mortensen, 2005). This is worth noting because, while the expression 
system and conditions were the same for both hTIM and PfTIM, the AT-rich PfTIM gene 
which was not codon optimised for E. coli expression unlike the hTIM DNA sequence which 
was. As a result it is likely that destruction of the PfTIM mRNA would have been more rapid 
resulting in lower expression. 
 
Figure 3.2: The direction of the assay runs from right to left for the TIM reaction that will be 
monitored. On the far right is D-glyceraldehyde-3-phosphate (D-GAP) which is converted by TIM to 
dihydroxyacetone phosphate (DHAP) (centre). This is then converted to glycerol-3-phosphate (G3P) 
by α-glycerol-3-phosphate dehydrogenase (αG3PDH) with the concomitant oxidation of NADH, 
which is observed at 340 nm, to track the reaction. 
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The assay used for determining TIM activity is a coupled enzyme assay that monitors the 
oxidation of β-Nicotinamide Adenine Dinucleotide (NADH to NAD+) at 340 nm (Figure 3.2). 
This assay is relatively well studied and understood (Albertyn et al., 1992; De la Roche et al., 
2012; Warkentin and Fondi, 1973; Von Kalm et al., 1989). Adjustments of standard assay 
parameters of concentration, volume and mixing procedures were modified for use in 96 well 
plates. Results of some of the test experiments, performed in order to obtain good 
reproducibility, are included in Appendix G.  
Understanding the mechanisms of the TIM assay used in this project provides useful insight 
into assessing the results presented in this chapter. The two-stage TIM assay (depicted in 
Figure 3.2) works on the principal of the TIM product (DHAP) being immediately used by 
αG3PDH and producing a steady state reaction. The biomechanics of this process have being 
investigated (Knowles et al., 1972; Plaut and Knowles, 1972; Blacklow et al., 1988). The 
validity of such a system depends on the rapid removal of product from the first reaction by 
the second reaction, to ensure that product inhibition does not hinder the speed of the first 
reaction. Bergmeyer (1974) considered this mathematically and concluded that, to observe 
true activity with a 99% level of accuracy, the coupling enzyme would have to be 1000 times 
more concentrated. This observation by Bergmeyer (1974), while true, is ‘not so bleak’ as 
pointed out by Plaut and Knowles (1972), who note that coupled enzyme systems, such as the 
TIM and αG3PDH assay, go through a brief acceleration phase before reaching steady state 
kinetics. These produce consistent and accurate results from far lower coupling enzyme 
concentrations than suggested by Bergmeyer (1974) - provided that the product is removed at 
a sufficient rate, and that the ratio of substrate to product remains high, in favour of substrate 
to the first enzyme. Observed kinetic data are consistent, reliable, and accurately reflects the 
true kinetics parameters. This can be confirmed by assessing the linearity of the observed 
data after steady state kinetics is reached. As any shift in the substrate-to-product-saturation 
ratios would result in slowing the reaction rate and, subsequently, an observed decrease in 
linearity, indicating a deviation of the data from steady state kinetics (Putman et al.,1972; 
Plaut and Knowles, 1972). Understanding and checking for this provided an additional 
control and quality assessment when conducting TIM assays. 
Subsequently, good reproducibility was achieved using the micro-titre plate system and the 
final protocol described in Section 3.2.8 (Plaut and Knowles, 1972; Albertyn et al., 1992; De 
la Roche et al., 2012). 
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3.2 Materials and methods 
This section outlines protocols and reagents used in the experiments described in this chapter. 
A full list of reagents is also supplied (Appendix A) and a list of buffer preparation 
procedures of common buffers used, is provided (Appendix B). 
3.2.1 Recombinant protein expression using auto-induction 
The auto-induction protocol that was used is an adaptation of the protocol developed by 
Studier (2005). To start auto-induction, 100 ml aliquots of ZYP505/5052 (Appendix B) were 
distributed into autoclaved 500 ml Erlenmeyer flasks sealed with cotton wool. To this, 
suitable concentrations of sterile antibiotics were added: 30 µg/ml kanamycin (to retain 
pET28(b+) plasmid) and 34 µg/ml chloramphenicol (only in PfTIM samples, to retain 
pRARE2 plasmid). 
Prior to auto-induction, pre-cultures of the E. coli BL21(DE3) expression-ready cells, which 
included pET28(b+) plasmids containing the hTIM or PfTIM genes, were grown from frozen 
glycerol stocks (Chapter 2). For pre-cultures, 1 ml of relevant glycerol stock (hTIM or 
PfTIM) was grown in 100 ml LB broth with antibiotics (as mentioned) in 500 ml sterile 
Erlenmeyer flasks sealed with cotton wool (12-16 h, 30°C, 150 rpm). Pre-culturing ensured 
that cellular recovery from freeze thaw was complete, and that cells were ready for log phase 
growth when the auto-induction process was initiated.  
One ml of the pre-cultures were inoculated into the prepared ZYP505/5052 auto-induction 
media and grown (24-36 h, 20°C, 150 rpm). Cells were harvested by centrifugation (5000 x 
g, 10 min, 4°C).  
For the purpose of constructing a purification table, samples were taken every 2 h, from the 
auto-induction cultures, during the induction study. These samples were micro-centrifuged, 
(5000 x g, 45 sec) and frozen at -20°C, so that enzyme expression levels during auto-
induction could be analysed by SDS-PAGE. To assess the overall purification, samples were 
set aside at the following stages: pre lysis, post lysis, post 2700 x g centrifugation, post 
100000 x g centrifugation, post Ni-affinity chromatography, post gel filtration and post 
dialysis. 
3.2.2 Cell lysis and preparation for Ni-affinity chromatography 
Pelleted cells from auto-induction were washed with potassium phosphate (KHPO4) working 
buffer (3 washes, 100 ml, 100 mM, pH 7.4) and centrifuged after each wash step (5000 x g, 
10 min, 4°C).  
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Cells were re-suspended in working buffer (20 ml/g wet weight) with lysozyme (1 mg/ml) 
and an EDTA-free protease inhibitor cocktail tablet (Roche) was added to the mixture and 
incubated (37°C, 1 h, 120 rpm). The mixture was then frozen at -80°C overnight, for cell 
rupture. 
Samples were thawed on ice (also overnight) and centrifuged (2700 x g, 30 min, 4°C), after 
which the supernatant was collected and the sample was ultra-centrifuged (100000 x g, 90 
min, 4°C). Ni-affinity chromatography was then performed using a fast protein liquid 
chromatography (FPLC) system from GE Healthcare (Section 3.2.3).   
3.2.3 Ni-affinity chromatography using FPLC 
In preparation for Ni-affinity chromatography using the FLPC system, several FPLC buffers 
were prepared (Appendix B).  
Ni-affinity chromatography was run, using a 150 ml superloop injection system with a 5 ml 
His-trap FF column on a GE, Amersham FPLC system. Sample preparation for the superloop 
injection system involved mixing 1 part (4x loading buffer) to 3 parts supernatant from 
ultracentrifugation (Section 3.2.2). The volume of samples varied, due to different wet 
weights obtained during cell collection (Section 3.2.2).  
The superloop system and the column were connected to the FPLC system and the His-Trap 
FF column was equilibrated by washing successively with dddH2O (50 ml) and running 
buffer (Appendix B) until the UV absorbance of eluate remained at base level. The sample (in 
the superloop) was then injected onto the column by injecting 90-150 ml running buffer (i.e. 
the volume in the superloop) through the superloop injection system at a flow rate of 5 
ml/min. This was followed with a wash step of 50 ml running buffer, to wash out unbound 
protein from the column. An elution buffer gradient (0 - 100%) set to occur over 100 ml, was 
set up, starting with 100% running buffer and ending with 100% elution buffer (Appendix B). 
After the elution gradient finished an additional 25 ml of 100% elution buffer was passed 
through the column. Fractions (5.0 ml) were collected from the start of the elution buffer 
gradient. UV absorbance was monitored over the entire process so that fractions containing 
protein could be identified. From each fraction a 20 µl sample was set aside for SDS-PAGE. 
The 5 ml fractions corresponding to a spike in UV absorbance from the detector and 
containing the target protein were pooled. 
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3.2.4 Gel filtration chromatography using FPLC  
Active fractions from the Ni-affinity chromatography steps - 60 ml for (hTIM) and 45 ml for 
(PfTIM) were centrifuged (4000 x g; 5 min; 4 °C) in a spin column (Sartorius Stedim 
Vivaspin2, 10K MW columns) to a final volume (400 µl). To this, glycerol (200 µl) was 
added, and the sample mixed by inversion, before being subjected to further purification by 
gel filtration chromatography. A Sephadex G-200 HR gel column (1 m x 1.6 cm) was used on 
the FPLC system (GE Amersham) with an injection loop (5.0 ml) loading system. The 
column was equilibrated using 2 column volumes of FPLC gel filtration running buffer 
(Appendix B). The sample was then injected into a 5 ml injection loop on the FPLC system. 
The system then loaded the sample - in the loop - onto the column by emptying the loop with 
10 ml of running buffer. Afterwards the system equilibrated with 0.1 column volumes before 
eluting the sample with 1.5 column volumes of running buffer (Appendix B). During the 
elution phase 5 ml fractions were collected. Flow rate throughout was 1 ml/min always using 
FPLC gel running buffer (Appendix B).   
3.2.5 Dialysis 
Dialysis was performed (Snake-skin 10 kDa MWCO; Thermo Scientific, South Africa) with 
four buffer changes in 24 h using (KHPO4,100 mM; 2 l, 4°C) with vigorous stirring, using a 
magnetic stirrer. The volume of the samples, post–dialysis, were measured as hTIM (35 ml) 
and PfTIM (25 ml), and approximately 8-12 drops of glycerol were added. Samples mixed by 
inversion and 500 µl aliquots made in sterile tubes and frozen at -20°C.   
3.2.6 SDS-PAGE and staining/de-staining  
Sodium dodecyl sulphate – polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
on each stage of the purification, according to the manufacturer’s published procedures 
BioRad® (http://www.bio-rad.com/). SDS-PAGE buffers and gel preparations for a 12.5% 
resolving gel and a 4% stacking gel are included in Appendix B. 
Each gel was loaded with 10 µl of pre-stained PageRuler™ protein ladder 
(ThermoScientific). Wells not containing samples were loaded with 25 µl TS+TD solution 
(Appendix B). Gels were then electrophoresed (100 V, 75 min).  
A staining/de-staining protocol developed by Fairbanks et al. (1971) was used. In this 
protocol four solutions (Fairbanks A, B, C, D) are prepared (Appendix B). To stain/de-stain, 
gels are microwaved in Fairbanks A (100 ml, 2 min), mixed on a rocker (5 min), and then 
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rinsed with dddH2O. This process is repeated using Fairbanks B, C and D solutions until a 
clear de-stained gel is obtained in ~1 h, on which 25 ng or more of protein can be visualised.     
3.2.7 Protein determination (Bradfords Assay) 
Protein concentration was determined by Bradfords method (Bradford, 1976). An adaptation 
of this protocol, for use in 96-well micro-titre plates using pre-made Bradfords reagent 
(Sigma-Aldrich, 2012), was used. Active sample (5 µl) was mixed with Bradfords reagent 
(250 µl), left at room temperature (15 min) to allow complete colour development, followed 
by absorbance, read at 595 nm. A standard curve using bovine serum albumen (BSA) as 
protein standard in concentrations of 0.1 - 1.2 mg/ml, was constructed (Appendix G, Figure 
G1). From this, an equation to determine protein concentration from absorbance readings at 
595 nm was determined (Appendix G, Equation G1).  
It is noted that the protocol provided by Sigma-Aldrich, (2012) listed many incompatible 
reagents and the concentration levels at which they may start to interfere with the assay. 
Several reagents used during purification were listed, including imidazole, glycerol, EDTA, 
and Tris, among others. Of all of these, only imidazole was in a concentration range that may 
interfere with the Bradfords assay method but only in post-Ni-affinity samples. 
3.2.8 Triosephosphate isomerase assay 
This assay procedure (Figure 3.2) was adapted from published protocols (Bergmeyer, 1974; 
Knowles et al., 1972). All buffer, reagent and enzyme preparations are explained in 
Appendix B. A positive enzyme control was also conducted using commercial rabbit TIM 
(rTIM), (Appendix H, Figure H2).  
The assay was performed in a 96-well micro-titre plate, as follows: in a 1st well, NADH (10 
µl, 8 mM), αG3PDH (10 µl, 20 U/ml), DL-GAP (50 µl, 20 mM) were mixed with TEA buffer 
(230 µl, 300 mM, pH 7.6). In a 2nd well, a suitably diluted TIM sample was added (10 µl). 
Dilutions determined by optimization experiments (Appendix H) were for hTIM (1/2000) and 
PfTIM (1/300) from their purified stocks. The micro-titre plate was equilibrated at 25 °C in a 
BioTek Synergy MX spectrophotometer. The plate was then shaken (variably, for 30 sec) and 
change in absorbance at 340 nm of the 1st well measured (2 min, 15 sec intervals). This 
provided a baseline reading after equilibration and functioned as a negative enzyme control 
for each well. The micro-titre plate was then ejected from the spectrophotometer and the 
enzymatic reaction initiated by pipetting 290 µl from the 1st well and injected into the 2nd well 
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containing 10 µl of the relevant TIM (hTIM or PfTIM). The micro-titre plate was then shaken 
(variably, 30 sec) and change in absorbance measured (340 nm, 15 sec intervals, 10 min).    
 
Equation 3.1 
Units/ml = (∆A340 nm.min-1 sample) x (Vt = volume of assay) x (df = dilution factor) 
     εNADH x (Ve = volume of enzyme) 
 
εNADH = 6.22 µmol-1.ml-1.min-1  /aka/: 6220 Mol-1.l-1.cm-1   
 
 
One unit will convert 1.0 µmol of dihydroxyacetone phosphate to α-glycerophosphate per 
minute at 25°C, pH 7.6. 
The αG3PDH assays (Chapter 4; Section 4.2.1) also made use of Equation 3.1 because both 
the TIM and the αG3PDH assays monitor the depletion of NADH at 340 nm.  
3.3 Results and discussion 
3.3.1 Protein over-expression by auto-induction  
Transformed and ready-to-express cells from both hTIM and PfTIM (chapter 2) were over-
expressed using an auto-induction technique (Section 3.2.1).  
The processes described here for both hTIM and PfTIM were run concurrently, where 
possible, to minimise differences in their preparations and ensure accuracy and consistency.  
During auto-induction, 5 Erlenmeyer flasks were used for each sample (hTIM or PfTIM), 
only 4 of these were harvested for enzyme purifications while the 5th was used exclusively for 
the induction study over 36 hours. This eliminated the possibility of contamination being 
introduced when samples were taken every 2 hours for the induction study. For purification 
purposes the 4 hTIM Erlenmeyer flasks were harvested at 24 hours while the PfTIM ones 
were harvested at 36 hours. This was because it was known at this stage that the PfTIM-
expressing cells grew and expressed recombinant PfTIM slower than was the case for the 
hTIM expressing cells.   
3.3.1.1 SDS-PAGE of auto-induction 
The SDS-PAGE of the induction study tracks the growth and protein expression levels during 
auto-induction. The recombinant proteins, both of which are approximately 27 kDa (Ray et 
al., 1999; Orosz et al., 2006) in size, emerge amongst the other protein bands.  
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Figure 3.3: SDS-PAGE of the hTIM sample showing all protein expression during the 36 hour auto-
induction. Note: hTIM monomer is 27 kDa in size (Orosz et al., 2006). Lanes are labelled with the 
time they were harvested at and M represents lane loaded with PageRuler™ protein ladder 
(ThermoScientific).  
 
From the SDS-PAGE of the hTIM induction study (Figure 3.3) the dense bands that develop 
at the 27 kDa size range are consistent with the known size of hTIM, reported as a 54 kDa 
homodimer made up of two 27 kDa monomers (Orosz et al., 2006). 
 
Figure 3.4: SDS-PAGE of the PfTIM sample showing all protein expression over the 36 hour auto-
induction study. Note: PfTIM monomer is 27 kDa in size (Ray et al., 1999). Lanes are labelled with 
the time they were harvested at and M represents lane loaded with PageRuler™ protein ladder 
(ThermoScientific). 
 
The SDS-PAGE of the PfTIM induction study (Figure 3.4) also shows a strong band 
developing at the 27 kDa size range, in accordance with PfTIMs known size (Ray et al., 
1999). It is notable that this band is significantly weaker than that from hTIM (Figure 3.3), 
indicating a lower concentration of protein. The band also takes longer to appear, only 
noticeably showing up at approximately 18 hours for PfTIM (Figure 3.4) as opposed to a 
clear presence in the hTIM sample as early as 4 hours into auto-induction (Figure 3.3). Both 
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the hTIM and PfTIM SDS-PAGE gels were loaded with the exact same volume of sample per 
well and all preparation procedures were identical. 
Data relating to the hTIM samples (Figure 3.3) are interesting because it appears that the 
hTIM gene is being expressed before induction should begin. A low level of background 
expression is known to occur in plasmids. However, in this case, expression also appears to 
be relatively strong, despite the fact that notable early expression should not occur during the 
auto-induction process (Studier, 2005). Considerable amounts of recombinant enzyme seem 
to have been produced, and concentrations continued to increase throughout the induction 
study (Figure 3.3). This indicates that the early expression observed did not have any 
negative effect on host cell growth and high concentrations of recombinant enzyme were well 
tolerated, without any apparent toxicity and recombinant hTIM retained its activity. It is also 
notable that hTIM-expressing cells were grown in the presence of kanamycin only (to retain 
the pET28(b+) expression vector), while PfTIM samples had both kanamycin and 
chloramphenicol (to retain pRARE2 plasmid). This helps explain the more rapid growth and 
earlier expression seen for hTIM-expressing cultures, as compared with PfTIM-expressing 
cultures. The hTIM gene sequence was also ‘codon optimised’ for expression in E. coli, 
while the PfTIM gene was not. The PfTIM gene sequence is also highly AT-rich, meaning 
that translated PfTIM mRNA would likely suffer more rapid degradation in the host E. coli 
BL21(DE3) cells. This is because E. coli is known to not tolerate AT-rich genes and their 
transcribed mRNA very well, with the E. coli identifying the foreign mRNA by its ‘codon 
bias’ and degrading it rapidly (Sørensen and Mortensen, 2005).  
The strong early expression seen in hTIM samples (Figure 3.3), prior to full induction 
(Studier, 2005), is an indication that hTIM mRNA is probably well tolerated and able to exist 
for a long period of time in the E. coli BL21(DE3) cells. By codon optimizing the hTIM 
gene, its mRNA is able to appear as a native mRNA species to the host cells and avoid 
destruction by the host cells (Sørensen and Mortensen, 2005). In auto-induction, typically a 
low background level of mRNA is produced during cell growth by an expression plasmid (in 
this case, pET28(b+)). This background mRNA does not usually result in significant levels of 
recombinant enzyme expression, primarily due to natural mRNA degradation by the host cell 
and especially so if the sequence is recognised as foreign. All mRNA is not created equal, 
however, and depending on sequence, the life span of an mRNA stand can vary from seconds 
to up to 20 minutes. Regulation of mRNA longevity and DNA translation to mRNA are two 
main methods used in cellular biochemistry for controlling protein expression (Sørensen and 
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Mortensen, 2005). The early recombinant hTIM expression (Figure 3.3) indicates that the low 
level background hTIM mRNA produced was retained sufficiently long enough to result in 
noticeable and significant levels of recombinant hTIM production, indicating that hTIM 
mRNA is long-lived. For the ‘unoptimised’ PfTIM, on the other hand, being AT-rich, its 
mRNA was likely identified by the host E. coli BL21(DE3) cells as foreign and more rapidly 
degraded, meaning the PfTIM mRNA, was short-lived (Sørensen and Mortensen, 2005). This 
is indicated by the fact that no bands corresponding to recombinant PfTIM are present in 
Figure 3.4 prior to induction and a lower overall concentration of recombinant PfTIM is 
achieved. This was why it was decided to only harvest recombinant PfTIM after 36 hours, 
while hTIM was harvested at 24 hours, as per standard auto-induction protocol.  
Once full induction occurs in the auto-induction process, massive levels of PfTIM mRNA are 
produced and this effectively minimises any mRNA destruction effects by host cells. This is 
why relatively high levels of recombinant PfTIM could to be achieved. This massive induced 
mRNA production is part of how expression plasmids, such as pET28(b+), function and are 
able to achieve high expression levels of any gene used with them. The effectiveness of the 
expression plasmid to produce massive levels of mRNA does not entirely mitigate the effects 
of host cell mRNA destruction and, as a result different levels of recombinant enzyme, 
expression is often achieved, as was the case here (Figures 3.1 and 3.2). Another possible 
negative effect of PfTIM not being ‘codon optimised’, is that it can result in pauses during 
protein translation and elongation, when a codon triplet sequence - that requires a rare tRNA - 
is encountered. This possible problem was anticipated, and compensated for by the inclusion 
of the pRARE2 plasmid, which produces these rare tRNA’s. For this reason it is unlikely that 
rare tRNA codon use by the PfTIM gene is responsible for the lower level of PfTIM 
expression compared to that of hTIM (Figures 3.3 and 3.4).  
In conclusion, it is most likely that the more rapid PfTIM mRNA destruction by the host cells 
is due to the foreign, AT-rich nature, of this gene sequence (Su et al., 1996; Baca and Hol, 
2000; Sørensen and Mortensen, 2005). Additional environmental strain, on the PfTIM 
cultures, due to the presence of a second antibiotic (chloramphenicol), which was required to 
maintain the pRARE2 plasmid – can also partially explain the lower recombinant enzyme 
expression observed in PfTIM expressing cultures (Figure 3.4), under otherwise identical, 
auto-induction expression parameters to hTIM expressing cultures (Figure 3.3), (Sørensen 
and Mortensen, 2005).      
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3.3.2 Purification 
3.3.2.1 Ni-affinity chromatography using His-Trap FF columns 
Ni-affinity chromatography was performed (Section 3.2.3). The chromatogram profiles for 
both hTIM and PfTIM are illustrated in Figures 3.5 and 3.6, respectively. 
Figure 3.5: Ni-affinity chromatogram of the hTIM sample, showing mAU readings in blue (primary 
y-axis) and the concentration of the elution buffer in red (secondary y-axis) versus elution volume. 
Fraction collection (5.0 ml) began at the start of gradient elution (140 ml), marked with a green arrow. 
 
Figure 3.6: Ni-affinity chromatogram of the PfTIM sample, showing mAU readings in blue (primary 
y-axis) and the concentration of the elution buffer in red (secondary y-axis) versus elution volume. 
Fraction collection (5.0 ml) began at the start of gradient elution (140 ml), marked with a green arrow. 
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As seen in Figures 3.5 and 3.6, it is clear from the mass Absorbance Unit (mAU) readings 
that substantially more hTIM (Figure 3.5) was obtained than PfTIM (Figure 3.6). For hTIM 
the protein starts eluting when the elution buffer concentration reached ~20% and finished 
eluting at ~70% concentration. PfTIM elution began at a slightly higher elution buffer 
concentration, of ~30%, and completed at ~55%. The different durations seen between the 
two elutions, and the differences in elution buffer starting percentage, can be attributed to the 
apparent large differences in concentration, indicated by the mAU response: 1403 mAU at 
the apex of the elution peak for hTIM, and only 369 mAU at the apex of the PfTIM peak. 
Although this implies a 3.8 fold higher protein concentration for hTIM than PfTIM, there are 
other factors, such as residue concentration and positioning, which influence this response. 
This is because UV absorbance is different for different amino acid residues and other 
organic compounds. Residues such as phenylalanine, tyrosine, tryptophan and histidine are 
therefore known to produce stronger UV absorbance readings (due to their imidazole and/or 
benzene rings) than other amino acid residues (Voet and Voet, 2004). Imidazole is also part 
of the elution buffer, further interfering with UV protein estimations. Nevertheless, the UV 
response gives a fairly accurate indication of protein concentration. In this case, two different 
variants of the same enzyme (TIM) are being compared and they therefore share a similar 
size and amino acid composition, meaning that UV protein estimations should be 
comparable. Bradford’s protein assay method was used to determine protein concentrations 
quantitatively.      
SDS-PAGE analysis for collected fractions from Ni-affinity chromatography for hTIM 
(Figure 3.7) and PfTIM (Figure 3.8) are represented.  
 
Figure 3.7: SDS-PAGE of 5.0 ml fractions (labelled 1-20) collected from the hTIM Ni-affinity 
chromatography purification. 
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The SDS-PAGE gels from the hTIM Ni-affinity chromatography (Figure 3.7) indicate strong 
protein bands present at ~27 kDa in size, as would be expected for hTIM (Orosz et al., 2006). 
There also appears to be noticeable bands of contaminating proteins at ~70 kDa, visible in 
fractions 3-6, and from ~55-70 kDa in fraction 16. Fractions 4-15 (Figure 3.7) were pooled, 
concentrated in a spin column and subjected to gel filtration.   
 
Figure 3.8: SDS-PAGE of 5.0 ml fractions (labelled 1-20) collected from the PfTIM Ni-affinity 
chromatography purification.  
 
For PfTIM (Figure 3.8), bands at 27 kDa appear fainter than for hTIM (Figure 3.7), 
indicating that a lower concentration was obtained. Contaminating proteins appear to have 
eluted in fractions 3-6 (Figure 3.8). These contaminating bands in the SDS-PAGE analysis 
for both hTIM and PfTIM can be explained. It is known that several E. coli proteins have a 
high affinity to divalent nickel or cobalt ions, due to the presence of clustered histidine 
residues and/or biological metal binding sites. These E. coli proteins are known to only elute 
at relatively high imidazole concentrations during Ni-affinity chromatography (Robichon et 
al., 2011). Fractions 6-14 (Figure 3.8) were collected and pooled from PfTIM Ni-affinity 
chromatography, concentrated and subjected to gel filtration. 
3.3.2.2 Gel filtration chromatography on a Sephadex G-200 HR column  
To further improve purification and to eliminate the imidazole introduced from Ni-affinity 
chromatography, samples were subjected to gel filtration chromatography using a Sephadex 
G-200 HR column (Section 3.2.4).  
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Figure 3.9: Gel filtration showing hTIM purification in blue and PfTIM purification in red. (a) The 
SDS-PAGE of hTIM 5.0 ml fractions (18-30) of which (20-27) were collected for dialysis. (b) SDS-
PAGE of PfTIM fractions (18-30) of which (21-26) were collected for dialysis. 
 
When compared to the Ni-affinity chromatography results, the gel filtration produced a very 
similar set of results, in terms of relative mAU readings obtained. Gel filtration was 
successful in eliminating some of the larger contaminating proteins, seen before (Figures 3.7 
and 3.8), for both the hTIM and PfTIM samples, respectively. Close inspection of the SDS-
PAGE gels (Figure 3.9 a; b) reveals several smaller bands that co-eluted with the target 
protein during gel filtration. These amounted to an estimated < 1 % total protein and were 
only visible using enhanced SDS-PAGE de-staining procedures that are capable of 
visualizing as little as 25 ng of protein. It was thought that this low level of contamination 
would not cause any subsequent problems in terms of enzyme analysis and activity. 
3.3.3 Characterisation  
A final dialysis step, to remove excess salt, was performed (Section 3.2.5). Each step of the 
protein expression and purification procedures for hTIM and PfTIM was then subjected to a 
Bradford protein determination assay (Section 3.2.7), enzymatic activity assays (Section 
3.2.8) and SDS-PAGE analysis (Figures 3.10 and 3.11), which meant that enzyme 
concentration, activity, and the quality of the purification were assessed. 
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3.3.3.1 SDS-PAGE  
SDS-PAGE analysis of each purification step for the hTIM and PfTIM purifications. 
 
Figure 3.10: SDS-PAGE analysis of the purification steps for hTIM. (M) protein MW-marker, (1) 
extracellular fraction from auto-induction, (2) pelleted washed cells 3 x at 10000 x g centrifugations, 
(3) post lysis using lysozyme, (4) post 2700 x g 30 min centrifugation, (5) post ultra-centrifugation 
100000 x g for 90 min, (6) post Ni-affinity chromatography pooled fraction, (7) post gel filtration 
pooled fraction, (8) post dialysis. NB: This fraction was stored for use in all subsequent 
experimentation.  
 
As shown in Figure 3.10 the purification process proved to be successful overall, with a 
single dense band at 27 kDa indicating the presence of the hTIM in large quantities. It is clear 
from Figure 3.10 that the most effective step was the Ni-affinity chromatography, where most 
contaminating bands were eliminated. Gel filtration was also successful in eliminating some 
heavier proteins, which appear faintly at ~70 kDa (Figure 3.10, lane 6) and were also visible 
in (Figure 3.7, lane 16). It is apparent that by carefully selecting which fractions are pooled, 
greater purification is achieved (Figures 3.7 and 3.8). The gel filtration did not however 
separate some lower-weight contaminating proteins, which can be seen as faint bands at ~12-
20 kDa in the post-gel-filtration products. Final confirmation about the success of the 
purification however, will only be proven once enzyme activity has been demonstrated. 
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Figure 3.11: SDS-PAGE analysis of the purification steps for PfTIM. (M) protein MW-marker, (1) 
extracellular fraction from auto-induction, (2) pelleted washed cells 3 x at 10000 x g centrifugations, 
(3) post lysis using lysozyme, (4) post 2700 x g 30 min centrifugation, (5) post ultra-centrifugation 
100000 x g for 90 min, (6) post Ni-affinity chromatography pooled fraction, (7) post gel filtration 
pooled fraction, (8) post dialysis. NB: This fraction was stored for use in all subsequent 
experimentation. 
 
The PfTIM purification results (Figure 3.11) appear similar to that of the hTIM purification 
(Figure 3.10), however close inspection indicates the presence of a relatively thick band at 27 
kDa, (target TIM size), after lysis with lysozyme, (Figure 3.11, lane 3), which becomes 
noticeably fainter after 2700 x g centrifugation (Figure 3.11, lane 4). It is interesting to note 
that at this point in the hTIM purification (Figure 3.10, lane 4) there is no noticeable decrease 
in target protein concentration and since the overall concentration hTIM is generally 
significantly higher throughout the purification process (Figure 3.10), this may indicate that 
PfTIM is more likely to aggregate under the current purification conditions (buffer type, ionic 
strength and pH level). Interestingly, this is an indicator of differences in surface structure 
and charge at the used pH levels but, at this stage, all that can be deduced is that hTIM is 
more soluble under the given conditions than PfTIM is. The 3D protein structures of these 
two TIM variants are already known to exhibit several key differences in amino acid 
sequence, protein surface structure, and residue exposure (Figure 1.7; pg. 16). These 
differences, interestingly, appear to have already resulted in differences during the 
purification of these two isozymes. Nevertheless, the two purifications produced similar 
results, with relatively excellent levels of purification being achieved after the Ni-affinity 
chromatography step. 
During these purification steps it was also noted that hTIM samples appeared lighter (a 
whitish cream) in colour when compared to PfTIM samples that were greyish yellow in 
colour. Another observation was that hTIM samples compacted better at 2700 x g 
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centrifugation (forming a denser pellet) than PfTIM samples. It is not known what caused 
this, but it could be theorised that the additional proteins (for chloramphenicol resistance) 
and/or rare tRNA production, created by the pRARE2 plasmid, somehow caused the changes 
that resulted in these observations. Alternatively, the higher concentrations of hTIM protein 
produced in hTIM cultures could equally account for the observed differences and, logically, 
a combination of these factors should also be considered. 
3.3.3.2 Protein concentration (Bradfords assay) and enzyme activity assay  
Bradfords assays (Section 3.2.7) and TIM enzyme activity assays (Section 3.2.8) were 
performed at each step of protein purification, for both hTIM and PfTIM samples 
(Bergmeyer, 1974; Bradford, 1976). Activity assay graphs are included in Appendix I.  
Figure 3.12: Protein concentrations for PfTIM (red) and hTIM (blue) as determined by Bradfords 
assay for each purification step: (1) extracellular fraction from auto-induction, (2) pelleted washed 
cells 3 x at 10000 x g centrifugations, (3) post lysis using lysozyme, (4) post 2700 x g 30 min 
centrifugation, (5) post ultra-centrifugation: 100000 x g for 90 min, (6) post Ni-affinity 
chromatography pooled fraction, (7) post gel filtration pooled fraction, (8) post dialysis. 
 
It is noted that approximately 3.9 fold more hTIM than PfTIM was obtained, which correlates 
with the estimated values, based on UV mAU readings taken during purification using gel 
filtration (Figure 3.9). Calculated protein concentrations (Bradford, 1976) are indicated for all 
purification steps in Figure 3.12. Step 1 (extracellular fraction) is not technically part of the 
purification but was included to show that no significant amount of protein was present in 
this fraction, which was discarded. Concentration values determined for purification steps 2 
(whole cells) and 3 (un-centrifuged lysed cells) are included (Figure 3.12) but are considered 
inaccurate, due to cellular debris interference with the Bradfords assay method (Bradford, 
0.06
0.78
0.78
1.31
1.51
0.32 0.28 0.38
0.06
1.29
1.04
2.29
2.32
0.09
1.43 1.49
0
0.5
1
1.5
2
2.5
3
1 2 3 4 5 6 7 8
C
o
n
ce
n
tr
a
ti
o
n
 in
 m
g
/m
l
Purification step
pfTIM
hTIM
67 
 
1976). These steps are not however included as part of the purification tables, because any 
subsequent calculated values determined using this method would be invalid and incorrect. 
Purification step 6 for hTIM (Figure 3.12) contained a noticeable precipitate, and very low 
protein concentration (0.09 mg/ml) was recorded. This was caused by the high concentrations 
of imidazole and protein present in the hTIM sample. This resulted in protein aggregation 
that could not be alleviated by sonication. The step 6 PfTIM sample (Figure 3.12) had a 
significantly lower protein concentration and did not have any precipitate.  
Separate samples were used for Bradfords assays and activity assays to eliminate any effects 
on activity that may have been caused by the freeze thaw process. Graphs to determine TIM 
activity and an example of Equation 3.1 are included in Appendix I.   
The purification tables for hTIM and PfTIM are represented as Tables 3.1 and 3.2, 
respectively. Note: Fold Purification = specific activity / specific activity 2700 x g 
centrifugation; Yield = total activity of sample / total activity 2700 x g centrifugation.   
 
Table 3.1: Protein purification table of hTIM 
Fraction Volume 
in ml 
Protein 
(mg.ml-1) 
Total 
Protein 
(mg) 
Activity 
(µmol.m
l-1.min-1) 
Total 
activity 
(U) 
Specific 
Activity 
(U.mg-1) 
Fold 
Purificat-
ion 
Yield  
(T.Act/T.
Act start 
(%) 
Crude 2700 x g 
centrifugation 
71.5 2.29 163.7 1554.5 
 
111147 
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1.0 100 
Ultra (100000 x 
g) centrifugation 
70.5 2.32 163.5 1531.8 
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1.0 97 
Ni-affinity 
chromatography 
55 
ppt’d 
NA  
ppt’d 
NA 
ppt’d 
NA 
ppt’d 
NA 
ppt’d 
NA 
ppt’d 
NA    
ppt’d 
NA   
ppt’d 
Gel Filtration 37 1.43 52.9 1436.8 53162 1005 1.5 48 
Dialysis 35 1.49 52.1 1799.0 62966 1207 1.8 57 
 
Important variables used to draw up purification tables are; protein concentration, enzyme 
activity and volume of sample, which are then used to calculate other values. Each assay used 
(i.e. Bradfords and enzymatic TIM assays) has an inherent margin of error, as do volume 
measurements. Error (standard deviation) was determined for each experiment and varied 
between purification steps. The determined margin of error range was around +/- 5% for both 
protein concentration and activity assays, and volume measurements were accurate to about 
0.5 ml. The margin of error is compounded for calculations in which these three variables are 
used, meaning that a margin of error of +/- 10-15% is more accurate for values determined on 
the purification tables. Purification tables used single averaged values for practical reasons 
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when doing calculations and therefore do not show this margin of error. This should however 
be considered when inspecting purification tables. Samples taken at each purification step 
differed in concentration and therefore required different dilutions to obtain suitable assay 
ranges. Because different dilutions had to be performed, this also introduced an additional 
step, where error could be introduced. After completing the assays, the determined values 
were multiplied by their relative dilution factors. This has the disadvantage of also further 
multiplying any additional error that may have been introduced. Milligram levels of enzyme 
were obtained during both enzyme purifications (Figure 3.12). For this reason, high dilutions 
were needed (for example, 1/1000 and 1/2000 dilutions were used for hTIM enzymatic assays 
for gel filtration and dialysis, respectively).  
In Table 3.1, the final calculated yield for hTIM was 57% (post dialysis) which was higher 
than the calculated yield of the previous step (gel filtration) at 48%. This appears to be 
incorrect, but this discrepancy can be accounted for if a 10% margin error for each step is 
assumed. Samples were all run in triplicate but it may have been better to run them in 
sextuplicate or even nonuplicate, so as to minimise the margin of error as much as possible.  
The standard deviation margins of error for Bradfords assays are included as error bars 
(Figure 3.12). On inspecting these error bars across purification steps one can see that, where 
protein concentration seems to have changed in an unexpected manner on the purification 
tables, the calculated margin of error in the Bradfords assays (Figure 3.12) can account for 
the discrepancy. Keeping this in mind, as well as the changes in volume levels during 
purification, these aspects effectively account for all the discrepancies seen in the purification 
tables as each aspect has its own relatively small margin of error. 
 
Table 3.2: Protein purification table of PfTIM 
Fraction Volume 
in ml 
Protein 
(mg.ml-1) 
Total 
Protein 
(mg) 
Activity 
(µmol.
ml-1 
.min-1) 
Total 
activity 
(U) 
Specific 
Activity 
(U.mg-1) 
Fold 
Purificat-
ion 
Yield 
(T.Act/T.
Act start 
(%) 
Crude 2700 x g 
centrifugation 
71 1.31 93.0 268.2 19040 205 1.0 100 
 
Ultra (100000 x 
g) centrifugation 
70 1.51 105.7 307.7 21540 204 1.0 113 
 
Ni-affinity 
chromatography 
42 0.32 13.44 434.1 18232 1357 6.6 96 
 
Gel Filtration 28 0.28 7.84 388.3 10871 1387 6.8 57 
Dialysis 25 0.38 9.5 178.3 4458 469 2.3 23 
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Likewise, the results (in Table 3.2) for PfTIM indicate that there is an increase in yield of 
13% after ultracentrifugation. This is clearly not possible, but lies well within a 10% margin 
of error of each sample as is therefore deemed insignificant.     
Analysis of the purification tables (Tables 3.1 and 3.2) indicates that a substantial amount of 
activity loss (more than 50%) occurred during dialysis for PfTIM (Table 3.2). This level of 
loss was not seen for hTIM (Table 3.1) and is significantly greater than the 10% margin of 
error considered for these samples. This indicates that PfTIM was not stable during dialysis 
under the conditions used (4°C, pH 7.4, 100 mM KHPO4), while hTIM was. This instability 
was later shown to be due to a low pH tolerance of PfTIM for levels above pH 6.5. The lower 
protein concentration of PfTIM (~0.38 mg/ml) may also partially account for this instability, 
because proteins are generally more stable at higher protein concentrations (i.e. >1 mg/ml), 
(Ugwu and Apte, 2004; Link, 2008). Further details of this are revealed in Chapter 4, where 
each TIM variant is characterized for kinetics, pH and temperature optima, and stability. 
In summarizing these results, it is clear that high concentrations of hTIM (1.4 +/- 0.1 mg/ml) 
and excellent retention of enzyme activity was achieved, with a fold purification of ~1.8 and 
a yield of around 50% +/- 10%. The high levels of hTIM obtained is the reason why a 
relatively low-fold purification level was achieved, because fold purification is relative to 
starting protein concentration and activity, which was already very high for hTIM, indicating 
that relatively excellent expression occurred for hTIM during auto-induction. On the other 
hand, PfTIM samples had a fold purification level of ~6.8 and a yield of 57% +/- 10% after 
gel filtration. This then dropped to ~2.3 and 23% +/- 10% respectively after dialysis 
indicating that this purification step was unsuccessful and generally destructive, effectively 
reversing gains made during previous purification steps.  
3.4 Conclusions 
In conclusion, however, it can be said that both purifications were a success: active hTIM and 
PfTIM enzymes were obtained in high concentrations that required large dilutions for 
enzymatic assays. In fact more than enough enzyme was obtained from a single purification 
to conduct all the subsequent enzymatic assay experiments a thousand times over. That said 
PfTIM purification could have been improved if a different dialysis buffer - with a lower pH - 
was used for PfTIM dialysis, as this would have suited its lower pH optimal stability of 
PfTIM. This however, was only determined after these purifications and more than enough 
active enzyme had already been obtained at this stage.        
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4.	Characterisation	of	purified	enzymes	
4.1 Introduction 
One of the key aspects of understanding enzymatic interactions and reactions is to understand 
the conditions that the enzyme favours. This can be achieved by performing experiments that 
assess activity under variable pH, temperature and time conditions whilst maintaining other 
conditions in a steady state, using suitable buffers to maintain pH and ionic concentrations in 
a cell-like environment.  
Glycolysis metabolism in P. falciparum is a critical energetic process to the survival of the 
parasite and triosephosphate isomerase is a key enzyme in this process (Parthasarathy et al., 
2002). The glycolysis pathway of the parasite essentially uses the same core enzymes found 
in almost all eukaryotes. The biochemical function of this pathway, as well as that of other 
essential biochemical pathways in Plasmodium species, however differs from the standard 
biochemical model. Something not commonly known about these biochemical pathways is 
that they have been repeatedly remodelled over the course of eukaryote evolution, to adapt to 
different environments (Vaidya and Mather, 2009; Ginger et al., 2010). Remodelling, 
involving sub-compartmentalisation of parts of the ubiquitous intermediary metabolic 
pathways has been shown to have occurred extensively in many Protists, while being largely 
conserved in other groups, such as plants, animals and yeasts. The metabolic remodelling, or 
‘rewiring’, seen in Protists can greatly influence the regulatory mechanisms that control 
carbon flux through the core metabolic processes (Ginger et al., 2010). This metabolic 
compartmentalisation occurs through the acquisition of new organelles, photosynthetic 
plastids, or non-photosynthetic plastid-like relics such as apicoplasts, as seen in malarial 
parasites (Figure 4.1), (Vaidya and Mather, 2009; Ginger et al., 2010; Olszewski and Llinás 
2010). Through apicomplexan complex acquisitions, organisms are able to reorganise the 
functional nature of their metabolism on a large scale, allowing metabolic adaptations, which 
better suit new environments (Ginger et al., 2010; Olszewski and Llinás 2010). In 
Plasmodium the glycolysis pathway is surrounded by several unexpected modes of 
compartmentalisation, which offer new insights and possible opportunities for drug 
developments (Lian et al., 2009; Ginger et al., 2010; Olszewski and Llinás, 2010).  
Plasmodium species follow a very similar life cycle to that of Trypanosoma species, such as 
T. brucei and T. cruzi, which also depend heavily on glycolysis for energy production and 
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share a high genetic similarity with Plasmodium species (Michels, 1988; Mande et al., 1994; 
Gómez-Puyou, 1995; Parthasarathy et al., 2002). It has been suggested that the development 
of any selective inhibitors for one of these parasite species will likely work in a similar 
manner as for others, due to genetic and life cycle similarities. Thus, the targeting of key 
metabolic pathway enzymes has become a cornerstone for the development of new 
antimetabolite drugs, to target these parasites (Singh et al., 2001; Parthasarathy et al., 2002; 
Olivares-Illana et al., 2007; Ginger et al., 2010; Olszewski and Llinás 2010). Extensive work 
on tracking the carbon flux as it moves through the P. falciparum parasites biochemical 
pathways has allowed for the construction of an overall view of the parasite’s unique 
metabolic processes. The development of such new metabolic pathways is more modular and 
streamlined than the metabolic pathways of free-living Protozoa (Olszewski and Llinás 
2010). This new metabolic network map has recently being described, summarizing decades 
of work done to elucidate these processes, as illustrated in Figure 4.1 (Olszewski and Llinás 
2010).  
 
Figure 4.1: The metabolic network in Plasmodium falciparum in which the carbon flow and 
metabolism is tracked with arrows, indicating the proposed net flow of carbon during the blood-stage 
metabolism of the parasite. Text in circles represents major biomass components. Image taken directly 
from (Olszewski and Llinás, 2010). 
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The whole process of energy production in P. falciparum is unique and known to be crucial 
for survival. As mentioned earlier, (Section 1.3: pg. 3-6), it has long been known that the 
parasite does not have an active tricarboxylic acid (TCA) cycle (Velanker, et al., 1997; 
Sherman, 1979; Miller et al., 2002; Parthasarathy et al., 2002; Ravindra and Balaram, 2005; 
Tuteja, 2007; Shekinah and Rajadurai, 2008). This, however, has been shown to be not 
entirely true and the situation is more complicated than was originally thought. Recent DNA 
evidence shows that the parasite does actually have all the necessary genes for a functioning 
TCA cycle. However, metabolic observation experiments have shown that something 
different is occurring in the P. falciparum TCA metabolic pathway. The early researchers 
showed, via electron-micrographs, that malarial mitochondria have minimal cristae and, 
therefore, are unable to function in a conventional sense (Trager et al., 1966). The red blood 
cells of the host also do not possess mitochondria, eliminating the possibility of metabolic 
hijacking. This, along with very low observed levels of oxygen consumption, all confirms 
that the TCA cycle is not functional in a typical sense (Trager et al., 1966; Olszewski and 
Llinás 2010) and implies that its absence, as stated by many researchers (Velanker et al., 
1997; Sherman, 1979; Miller et al., 2002; Parthasarathy et al., 2002; Ravindra and Balaram, 
2005; Tuteja, 2007; Shekinah and Rajadurai, 2008).  
More recent research into Plasmodium spp metabolism (Olszewski et al., 2010), has shown 
that Plasmodium spp have a ‘highly streamlined carbon metabolic network’ (Figure 4.1) in 
which enzymes of the TCA cycle are present and do indeed play an important and novel 
‘alternative’ metabolic role (Figure 4.2). The blood-stage parasite still relies almost entirely 
on glucose fermentation, via glycolysis, for energy production and the parasite only 
consumes very little oxygen, required for the TCA (Olszewski et al., 2010). This is because 
the mitochondria of P. falciparum have undergone significant metabolic remodelling and a 
downscaling of functionality (Trager et al., 1966). In fact P. falciparum was shown to have 
the smallest mitochondrial DNA sequence to date, when it was sequenced in 2009, encoding 
just three proteins, it has drastically reduced metabolic functionality compared to other 
eukaryotes (Vaidya and Mather, 2009). In spite of this Plasmodium mitochondrial enzymes 
are still considered attractive targets for antimalarial drug design (Vaidya and Mather, 2009). 
This reduced functioning is emphasised by the observable reduction in cristae, which are 
normally critical for mitochondrial functioning (Trager et al., 1966; Vaidya and Mather, 
2009; Olszewski et al., 2010). P. falciparum mitochondria are thought to have originated 
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when dinoflagellates and apicomplexan parasites diverged from ciliates (Vaidya and Mather, 
2009). 
Figure 4.2: Schematic of the modified, (in red), TCA (half-cycle) of Plasmodium falciparum, with 
arrows indicating the direction of net metabolic flux. This indicates the reversal of several TCA cycle 
steps, to allow for the creation of Malate as a net waste product. Asterisk (*): the enzyme responsible 
for the citrate cleavage step and its localization are unclear; double asterisk (**): there are two 
predicted enzymes capable of catalysing this reaction: (1) cytosolic malate dehydrogenase 
(PFF0895w), and (2) putative mitochondrial malate quinone oxidoreductase (MAL6P1.258). Image 
taken directly from (Olszewski et al., 2010). 
 
Such metabolic rewiring and remodelling, via compartmentalisation and other changes, has 
also being discussed in evolutionary terms (Ginger et al., 2010; Olszewski and Llinás, 2010). 
The parasite encodes orthologues of all the TCA cycle enzymes and they are also all 
transcribed during the parasites blood-stage of infection. Still other known mitochondrial 
TCA cycle-associated biochemical processes, such as de novo amino acid biosynthesis, have 
being disposed of and are entirely absent from the parasite, having been replaced by a new 
metabolic model (Olszewski et al., 2010). It has also been shown that the critical metabolic 
function of the electron transport chain in blood-stage malaria mitochondria is not to 
regenerate chemical energy (its typical function) but instead to regenerate ubiquinone, to 
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supply the pyrimidine biosynthesis process (Painter et al., 2007). Furthermore, radioactive 
labelling with C13 has shown that the TCA enzymes do not all perform as expected in blood-
stage malaria, with several of the biochemical reactions optimised to run in reverse to the 
typical cycle, counter clockwise to the TCA cycle. This means the development of a new 
metabolic process for P. falciparum (Figure 4.2), which is different from any previously–
described process (Olszewski et al., 2010). This novel process, (Figure 4.2), is seen to link up 
with the other altered metabolic processes, (Figure 4.1), of blood-stage P. falciparum, note 
the link point is labelled ‘TCA metabolism’ in Figure 4.1.  
The branched TCA cycle, depicted in Figure 4.2, is considered as an evolutionary trade off 
which has resulted in a loss of metabolic flexibility, but allows for enhanced growth in a 
specific environment. This trade off relies heavily on an abundant source of glucose, which is 
readily supplied through the host’s blood stream (Olszewski et al., 2010; Olszewski and 
Llinás, 2010). This allows for a modified mitochondrial metabolism, which uses C5 carbon 
skeletons - provided from plasma glutamine - to biochemically produce ubiquinone, succinyl-
CoA, and C2 acetyl units. This has also been shown to link up with regulatory mechanisms 
that sense changes in the nutrient environment, for organisms that follow a diverse life style 
with changing nutrient availability (Olszewski et al., 2010). There is also evidence that 
infected erythrocytes incorporate small extracellular macro-molecules for digestion too - 
something that does not normally occur in mature erythrocytes which are incapable of 
endocytosis (Burns and Pollack, 2008). It was demonstrated that P. falciparum parasitized 
erythrocytes incubated with ferritin internalised the macro-molecules, with the parasitized 
cells being shown to bind and incorporate ferritin and apoferritin while normal erythrocytes 
did not (Burns and Pollack, 2008).  
The complexity and evolutionary history and specialization, described above, allows for 
targeted drug developments, to target the metabolic enzymes of Plasmodium spp. This is 
possible because of significant genetic changes in key, fundamentally important, biochemical 
pathway enzymes, such as TIM. The fundamental biochemical importance of these processes 
and the genetic loss of metabolic flexibility - associated with such evolutionary 
specializations - have created an inflexible, but optimised metabolism for the parasite (Ginger 
et al., 2010; Olszewski and Llinás, 2010). It is this optimisation that allows for the extremely 
rapid growth and proliferation of the parasite during the blood stages of its life cycle. Indeed 
it is the rapidity of the process, which strains the host to such an extent, it is able to cause the 
heavy fever and anaemia that is ultimately the cause of the fatalities associated with malaria 
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(Miller et al., 2002; Trampuz et al., 2003; Tuteja, 2007). Targeting these modified metabolic 
pathways in the parasite is however complicated by evolutionary changes, most notably the 
compartmentalisations that have evolved in many Protists - including Plasmodium spp - as 
they adapted to their complex life cycles (Ginger et al., 2010). One of the advantages that the 
nanotechnology approach has - is that nanoparticles, as drug delivery mechanisms - are 
highly mobile and known to freely travel between the various intracellular 
compartmentalisations, including the mitochondria, glycosomes, and even the nucleus (Jong 
and Borm, 2008). Nanoparticle-based drugs would therefore theoretically be able to target 
any metabolic enzyme, because they can move freely throughout the complex, 
compartmentalised, metabolic network, of malaria and other Protist parasites, something that 
conventional drugs cannot do (Jong and Borm, 2008; Ginger et al., 2010). This, and the 
ability of nanoparticle base drugs to persist in the blood stream (Charoenphol et al., 2010; 
Huang et al., 2010; Charoenphol et al., 2011) - increases the likelihood of nanodrug 
developments being able to target key parasite enzymes, such as TIM, in new and novel 
ways, giving scientists new tools to create advanced, selective and powerful antimetabolite 
drugs, that would also be difficult for the parasite to develop drug resistance to (Jong and 
Borm, 2008). This would have a strong and lasting impact on combating malaria (Jong and 
Borm, 2008; Ginger et al., 2010; Tuteja, 2007; Vaidya and Mather, 2009). 
Due to this compartmentalisation of metabolic enzymes and evolutionary re-ordering it is 
important to carefully characterise enzyme parameters, as these data might elucidate further 
understanding that aids in selective drug development aimed at targeting the P. falciparum 
variant TIM. In biochemical terms, the pH of different sub-cellular compartments and cell 
environments can vary noticeably. For P. falciparum, the life cycle of the parasite requires it 
to adapt to several different environments and conditions. The parasite conducts a highly 
catabolic biochemical digestive process in its sub-cellular compartments, even creating its 
own sub-cellular compartment within host red blood cells. Using digestive proteases 
extensively for its catabolism of host haemoglobin requires that it creates 
compartmentalisations for catabolic digestive metabolism (Figure 4.1), (Trager, 1966; 
Sherman, 1979; Entzeroth et al., 1998; Wilkesman et al., 2009; Olszewski and Llinás, 2010). 
4.2 Materials and methods 
To assess differences between the two purified TIM enzymes, parameters of pH, temperature 
and stability over time were tested. To establish a suitable test range for each parameter under 
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examination, preliminary tests were conducted by incubating the purified TIM enzymes (pH 
7.0, temperature 30°C) for (3 h, 6 h and 18 h) to assess stability. Results were compared with 
published data of hTIM, PfTIM and other studied TIMs (Mier and Cotton, 1970; Knowles et 
al., 1972; Plaut and Knowles, 1972; Putman et al., 1972; Sigma-Aldrich, 2012,). More tests, 
to analyse differences between freshly thawed and refrozen/rethawed TIMs, were also done, 
as to ascertain the effects of freeze-thaw cycles and to ensure that all aliquots used in 
characterisation tests had being subjected to the same number of freeze-thaw cycles.  
4.2.1 α-Glycerol phosphate dehydrogenase assay (EC 1.1.1.8) 
Alpha-glycerol phosphate dehydrogenase (αG3PDH) converts dihydroxyacetone phosphate 
(DHAP) into glycerol-3-phosphate (G3P), with the concomitant oxidation of NADH to 
NAD+ (Figure 3.2; pg. 50). This oxidation process is used to monitor the reaction progress for 
both αG3PDH reactions and coupled triosephosphate isomerase reactions (Section 3.2.8; pg. 
55).  
The second step of the coupled assay (Figure 3.2; pg. 50) using only αG3PDH and DHAP as 
substrate was tested separately so as to independently determine the effects of the AgNPs on 
the coupling enzyme αG3PDH of the coupled TIM assay (Figure 3.2; pg. 50). The protocol 
used was adopted from the Sigma-Aldrich website and ultimately developed from published 
protocols (Beisenherz et al., 1955; Bergmeyer, 1974). For reagent and buffer preparations, 
see Appendix B. 
The αG3PDH assay, adapted from a Sigma-Aldrich assay (bulletin #: SPDHAP02), was 
performed in 96-well micro-titre plates as follows: DHAP (10µl, 76 mM) and NADH (10 µl, 
8 mM) was mixed with TEA buffer (280 µl, 300 mM, pH 7.4) in a well (1st). In a separate 
(2nd) well, αG3PDH (10 µl, 1 U/ml) was added. The micro-titre plate was then equilibrated in 
a BioTek Synergy MX spectrophotometer (25°C, 5 min). Change in absorbance at 340 nm of 
the (1st) well was measured for 2 min, at 15 sec intervals, after shaking (variably for 30 sec). 
This provided a baseline reading after equilibration as well as functioning as a negative 
enzyme control for each sample. The micro-titre plate was then ejected from the BioTek 
Synergy MX spectrophotometer and the enzymatic reaction initiated by pipetting 290 µl from 
the 1st well and injecting it into the 2nd well containing the 10 µl of αG3PDH. The micro-titre 
plate was then shaken (variably, for 30 sec) and the change in absorbance recorded (340 nm, 
15 sec intervals, 10 min).  
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The progress of the reaction was monitored by the depletion of NADH, which is explained 
mathematically in Equation 3.1 (pg. 56) (Sigma-Aldrich, bulletin #: SPDHAP02). Further 
details about the optimisation of this assay are presented (Appendix B). 
4.2.2 pH  
For the pH study a buffer cocktail was prepared using zwitterionic ‘Goods’ buffers. These 
buffers exhibit highly similar characteristics and are homologous to each other, making them 
excellent for pH studies (Link, 2008). The buffer cocktail covered the pH range from pH 3.5 
to 9.0 in 0.5 pH-level increments over 12 individually-prepared buffers. For details on buffer 
preparation, see Appendix B.  
The pH study was conducted at 25°C using a BioRad® heat block, with readings taken at 0, 
15, 45, 75, 105, 135 and 180 minutes, to evaluate stability at different pH levels. For this 
study, serial dilutions, to obtain hTIM and PfTIM in suitable assay concentrations, were set 
up in a 2 ml tube, using the pH buffer being tested.  
Once both TIM enzymes were diluted to effective assay concentrations in a 2 ml tube and 
mixed at a test pH level, an immediate (T0) sample was taken for assay in triplicate. All other 
necessary reagents for these assays were prepared in advance, so that assays could be 
recorded immediately. The remaining TIM sample (in 2 ml tubes at test pH levels) were 
incubated on a BioRad® heat block, (25°C) until the next set of samples were taken for assay. 
Pipetting out of micro-titre plates was done during the interim between assays. This ensured 
that the reagents in the plates were not left standing for more than 5-10 min. For assay details 
see Section 4.2.4. 
4.2.3 Temperature optimum study 
The temperature study was conducted at 20°C, 25°C, 30°C, 35°C, 45°C, 55°C and 65°C, at 
optimum pH 5.25 (0.1 M potassium acetate buffer) for PfTIM and pH 6.75, (0.1 M potassium 
phosphate buffer) for hTIM. The assay procedure is detailed in (Section 4.2.4). BioRad® heat 
blocks (2.0 ml) were used pre-heated to the desired temperatures. To obtain a temperature of 
20°C, (i.e. below room temperature), the heat block was placed in a 4°C walk in fridge and 
set to maintain its temperature at 20°C. Buffer aliquots in 2 ml tubes were prepared in 
advance and pre-incubated at the set temperatures for approximately 20 min before the TIM 
enzyme dilutions were made. This ensured that at T0 and T15 recording times the TIM 
enzymes had being subjected to the desired temperatures indicated for the full duration 
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intended, eliminating any heating ‘lag’ that may have occurred in the 2 ml volume in the 
tubes.  
4.2.4 Assay protocol for pH and temperature stability studies 
This assay was the same as the TIM assay (Section 3.2.8; pg. 55). However, some procedural 
differences had to be incorporated (see Appendix J), for pH and temperature tests to run 
systematically. Using these values, a relative % activity level was determined for each pH 
and temperature so that the optimums could be determined. These tests were run concurrently 
on the same day using the same dilutions and same perishable reagents, such as NADH 
preparations that were always prepared fresh. The pH and temperature study samples were 
only directly compared with negative control samples that were setup in an identical manner 
as test samples and run concurrently with these studies. This ensured that the relative 
percentage activity levels calculated for the studies were valid, comparable and as accurate as 
possible. The relative percentage activity levels could then be used to objectively compare the 
different TIM samples to observe the relative effects.    
4.2.5 Kinetics study 
The kinetic properties, namely the Michaelis-Menten constant (Km) and the maximal enzyme 
velocity (Vmax), were determined by varying the assay at the following substrate 
concentrations: 0.25, 0.5, 0.75, 1.25, 2.5, 5.0, 7.5 and 10.0 mM of DL-GA3P. Kinetic 
parameters were calculated using three methods, namely the Lineweaver-Burk and Hanes-
Woolf plots and a non-linear regression - considered the most accurate (Greco and Hakala, 
1979). All these plots employ variations of the Michaelis-Menten equation indicated below 
(Equation 4.1). 
Equation 4.1: Michaelis-Menten equation  
v = Vmax.[S]/(Km+[S]) 
 
 
Kinetics assays are different to the standard TIM assays done in (Section 3.2.8; pg. 55), 
because kinetics assays use varying substrate concentrations, so the following adjustments 
had to be made. In the 1st well the following is added: NADH (10 µl, 8 mM), αG3PDH (10 
µl, 40 U/ml), DL-GA3P (50 µl, varying concentrations) and TEA buffer (230 µl, pH 7.6). In 
the 2nd well, TIM (10 µl) is added in a suitably diluted concentration described previously 
(Section 3.2.8). The micro-titre plate is then pre-incubated (5 min, 25°C) and change in 
absorbance (340 nm, 2 min) monitored.  
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After the 5 min pre-incubation, to equilibrate, the plate was placed in a BioTek Synergy MX 
micro-titre plate (25°C) and shaken for 45 sec. The kinetic readings of the 1st well were 
recorded (21 sec intervals, 2 min, 340 nm) - note recording intervals also had to change due 
to the fully used micro-titre plate. 290 µl from the 1st well was pipetted into the 2nd well 
containing the 10 µl of TIM (PfTIM or hTIM). The tray was then pulled back into the system 
and shaken variably for 17 sec and kinetics recorded (340 nm, 21 sec intervals for 10 min).  
The linearity of NADH was also tested which constituted another form of a control 
(Appendix H, Figure H3). Additional details and calculations are given in Appendix J. 
4.3 Results and discussion 
4.3.1 pH     
The pH study readings from 45 min incubations were taken, to determine pH optima, as these 
samples showed the greatest level of contrast. The following graphs (Figure 4.3) show the 
relative percentage activity of hTIM and PfTIM versus pH. Converting enzymatic activity 
levels to relative percentage activity allows for side-by-side comparison of hTIM and PfTIM.  
 
Figure 4.3: Comparative pH study data for the T45 min incubation period at varying pH levels for 
both PfTIM (red) and hTIM (blue). All pH tests done in triplicate and error bars calculated using 
standard deviation. See Appendix K for, in assay, activity levels at each pH and time frame. 
 
These data (Figure 4.3) indicate a clear preference of PfTIM (red) for lower pH levels, with a 
pH optimum between pH 5.0 and 5.5. The PfTIM also appears to have a wider range of an 
acceptable >50% level of activity, represented by a greater area under the curve. For hTIM, 
(blue) the pH optimum is between pH 6.5 and 7.0, with a sharp decline between pH 7.0 and 
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7.5. This corresponds with the homeostatic controlled environment that hTIM can operate in, 
while PfTIM may often exist in a less stringently controlled environment throughout its life 
cycle (Olszewski and Llinás, 2010). These pH optima levels for hTIM correspond well with 
the literature regarding TIMs of yeast, rabbit (Sigma-Aldrich 2012) and others (Plaut and 
Knowles, 1972; Gracy, 1975; Orosz et al., 2006) while the pH optimum for PfTIM seems to 
diverge from most known TIM pH optimum levels. 
Both enzymes still had almost 50% relative activity remaining at pH 9.0 and could therefore 
have been tested at even higher pH levels. Other information in the literature however 
indicates that this point (pH 9.0) is typically a drop-off point for TIM, where activity rapidly 
declines to zero (Veech et al., 1969; Plaut and Knowles, 1972). Graphs for all pH tests with 
recorded activity levels, instead of relative % activity, are included in Appendix K. 
After careful inspection the pH optimum for PfTIM was selected as pH 5.25 and that for 
hTIM was pH 6.75. The next series of experiments, to find temperature optimums, made use 
of buffers configured for these pH values.  
4.3.2 Temperature study 
As was the case for the pH study, the temperature study readings from 45 min tests had the 
greatest contrast and were used to determine temperature optima. These data were used to 
determine relative percentage activity for each temperature (Figure 4.4). A full breakdown of 
all temperature tests and their recorded activity levels is available in Appendix L. 
Figure 4.4: Temperature study data indicating relative percentage activity of PfTIM (red) and hTIM 
(blue) over temperatures from 20°C to 65°C. For activity graphs of all test times, see Appendix L. 
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As was seen for the pH studies, these temperature data (Figure 4.4) indicate clear differences 
in the thermal stability of PfTIM and hTIM. For PfTIM, a temperature optimum at a 
relatively low 25°C, a rapid drop off in activity from 35°C to 45°C and complete enzyme 
inactivation at 55°C and above. This is interesting as one might speculate that the 
temperatures experienced by the P. falciparum parasite, within the mosquito environment, 
could vary greatly due to the relatively large surface area to volume ratio of the tiny insect, 
possibly requiring this low optimum at cooler times such as night time. Malaria mosquitoes 
and the parasite P. falciparum are only known to occur in warmer climates, mostly within the 
tropics where the mosquitoes come out in the evenings when it’s somewhat cooler, around 
20-30°C. Within the human host the parasite experiences a well regulated homeostatic 
temperature of 37°C (Kaiser et al., 2003).  
The hTIM seems to be more stable in higher temperature environments: incubation, even at 
temperatures of (55°C; 45 min), still had over 40% relative activity remaining (Figure 4.4). 
This ability to handle higher temperatures emphasises that hTIM is adapted to be stable 
within the human body at 37°C for significantly longer periods of time than tested, as would 
be expected. PfTIM, on the other hand, appears to be operating at its upper thermal limit at 
37°C within the human body. This implies that it is not fully optimised to operate at human 
body temperatures and tends to prefer a room temperature environment of around 25°C. The 
evolutionary requirement of the parasite’s PfTIM - to be able to conduct energy production 
via glycolysis within the human host - can however be said to be satisfied by these 
temperature data. These data indicate that PfTIM is not well adapted to temperatures greater 
than human body temperature, with rapid activity loss occurring over 40°C. Considering 
these data, in conjunction with the complex life cycle of the parasite - which requires it to be 
able to function and survive in a small mosquito at low temperatures at night and in a warm 
host at a constant 37°C - these data support the notion that the parasite enzyme (PfTIM) is 
adapted for flexibility and has not become optimised to any specific environment. This is in 
accordance with literature, which indicates that adaptations of life to suit a new-niche 
environment that is different to the standard one do not become fully optimised in such an 
environment (Miller et al., 2002; Painter et al., 2007; Tuteja, 2007; Ginger et al., 2010; 
Olszewski and Llinás, 2010). 
Stability at optimum pH and temperature was also tested for up to 3 hours and, under optimal 
conditions, there was no observed loss in activity between incubated samples and freshly 
thawed samples. These data are shown in Appendixes K and L. 
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4.3.3 Kinetics study 
A kinetics study was prepared and performed as described (Section 4.2.5). To evaluate results 
Hanes-Woolf and Lineweaver-Burk plots were drawn and a non-linear regression performed, 
to determine the most accurate possible Km and Vmax values, using the Michaelis-Menten 
equation (Equation 4.1) and the solver in MS Excel, to find the minimum sum of the 
difference of squares between recorded data and Michaelis-Menten-modelled data by 
iteratively altering the values of Km and Vmax and checking against the sum of the difference 
of squares for the lowest value. This method, while computationally intense, is known to be 
considerably more accurate, for determining Km and Vmax values, than the Hanes-Woolf and 
Lineweaver-Burk plots (Greco and Hakala, 1979). Further details are included in Appendix 
M. 
For hTIM, Lineweaver-Burk and Hanes-Woolf linear plots are shown (Figure 4.5) and a 
Michaelis-Menten curve, including the non-linear regression ‘best fit’ curve, is shown in 
Figure 4.6. The equations used to determine Km and Vmax values from these plots and the 
mathematical methodology for the non-linear regression, with examples, are included in 
Appendix M (Equations M1, M2 and M3). 
 
Figure 4.5: The Lineweaver-Burk plot (a), and Hanes-Woolf plot (b) for enzyme kinetics experiments 
done on hTIM samples (n=3) with error bars calculated using standard deviation. The linear equations 
of these plots were used to determine Km and Vmax values with the aid of Equations M1 and M2, see 
Appendix M for calculations.  
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Figure 4.6: Michaelis-Menten curve showing the hTIM kinetic data points with error bars calculated 
using standard deviation, and the curve calculated from the Km and Vmax values, determined by non-
linear regression computation and plotted using the using the Michaelis-Menten equation (see 
Equation 4.1). 
 
As can be seen for hTIM (Figure 4.6) the non-linear regression line fits actual data on the 
Michaelis-Menten curve exceptionally well. Good correlation between the non-linear 
regression method results and the Hanes-Woolf data indicates strong and robust kinetics 
experiment data were obtained for hTIM samples.  
Similarly Km and Vmax values were also calculated for PfTIM, Lineweaver-Burk and Hanes-
Woolf plots are shown in Figure 4.7 and the Michaelis-Menten plot with non-linear 
regression ‘best fit’ curve shown in Figure 4.8. 
Figure 4.7: The Lineweaver-Burk plot (a), and Hanes-Woolf plot (b) for enzyme kinetics experiments 
done on PfTIM samples (n=3) with error bars calculated using standard deviation. The linear 
equations of these plots were used to determine Km and Vmax values with the aid of Equations M1 and 
M2, see Appendix M for calculations. 
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Figure 4.8: Michaelis-Menten curve showing the PfTIM kinetic data points with error bars calculated 
using standard deviation (n=3), and the curve calculated from the Km and Vmax values determined by 
non-linear regression and plotted using the using the Michaelis-Menten equation (see Equation 4.1). 
 
The equations used to determine the kinetics values were identical for both the hTIM (Figures 
4.5 and 4.6) and the PfTIM (Figures 4.7 and 4.8) samples. Results of these calculations and 
additional details including the calculations used to determine the Kcat and Kcat/Km values 
(presented in Table 4.1) are provided with examples in Appendix M - see Equations M 1, 2, 3 
and 4. 
 
 
Table 4.1: Kinetic parameters calculated from the three graphical plots, Lineweaver-Burk, Hanes-
Woolf and Non-linear regression using Michaelis-Menten (Figures 5.9 to 5.12). Analysis of human 
and Plasmodium falciparum TIM enzymes, units under each parameter. 
Plot Type 
and Sample Homo sapiens TIM Plasmodium falciparum TIM 
Variables Km (mM) 
Vmax 
(µmol.ml-1min-
1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
Km 
(mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
Line-weaver 
Burk 2.62  0.7762 2.81 x 104 1.07 x 107 2.49 0.6461 1.38 x 104 5.54 x 106 
Hanes-
Woolf 2.41 0.7297 2.64 x 104 1.10 x 107 3.68 0.8203 1.75 x 104 4.76 x 106 
Non-linear 
Regression 2.27 0.7148 2.59 x 104 1.14 x 107 4.34 0.8671 1.85 x 104 4.26 x 106 
 
Values from the linear plots, Lineweaver-Burk and Hanes-Woolf plots correlate well for 
hTIM data (Figure 4.5a and b). Correlation between the different mathematical linearization 
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methods, which skew the results in different ways, indicates that accurate data was obtained 
for the hTIM assays (Greco and Hakala, 1979).  
Of the linear plots, the Hanes-Woolf plot is considered the most accurate; however, the 
Lineweaver-Burk is useful for distinguishing different types of inhibition and is included for 
this reason. The Hanes-Woolf plot is also used as a comparison for values obtained from the 
non-linear regression method, which is not a linear plot but considered to be the most 
accurate of all methods for determining kinetics, due to is ability to exhaustively find the 
‘best fit’ Michaelis-Menten curve. It also serves to act as a control to assess if calculations 
were done correctly as well as offering an alternative method (Greco and Hakala, 1979). 
From Table 4.1 it can be seen that the Km values obtained from the different methods for 
PfTIM show significant variation, which is notably higher for hTIM data. This indicates that 
the PfTIM data are not as consistent or as accurate as the hTIM data. This is also indicated by 
observing that the error bars for PfTIM samples are noticeably larger (Figures 4.7 and 4.8). 
The Vmax values for PfTIM samples are more consistent, especially for values determined by 
Hanes-Woolf and non-linear regression. Lineweaver-Burk values should be excluded from 
consideration because, as stated, this plot was primarily included for its ability to aid in 
identifying different types of inhibition, and not for its accuracy.  
The non-linear regression data were used to extrapolate the Michaelis-Menten curve to very 
high (80 mM) substrate concentrations that would be practically impossible to test. This was 
done so that the two TIM enzymes could be compared ‘side-by-side’ on a Michaelis-Menten 
plot that had suitably high substrate concentrations, to approach Vmax (Figure 4.9). These data 
indicate that the kinetics of the two enzymes hTIM and PfTIM have noticeably different 
profiles, with noticeably different Km and Vmax values. The kinetics experiments were 
sensitive, effective and capable of producing the quality of data necessary for identifying 
differences in the kinetics of these two TIM variants under identical running conditions.  
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Figure 4.9: Michaelis-Menten curves showing the extrapolated data for both PfTIM (red) and hTIM 
(blue) using non-linear regression determined values and the Michaelis-Menten (Equation 4.1) to 
determine the shape curves. 
 
 
The extrapolation indicates that substrate concentrations of around 60 mM to 80 mM may 
have being required to show over 90% of the full Michaelis-Menten curve, while to show 
100% of the curve is literally impossible. Given the constraints associated with purifying the 
substrate DL-GA3P – which is a structural isomer of DHAP – it can be concluded that these 
kinetic tests were well optimised because achieving a maximum substrate concentration of 
anything over 15 mM would be experimentally difficult and not necessary. For inhibition 
experiments with AgNPs (Chapter 5) all kinetics had to be repeated because the negative 
controls (with no nanoparticles) still had to have the nanoparticle stabilizing mixture (PVP 
and EtOH) included in the negative controls. For this reason the kinetics data shown here 
cannot be compared with the inhibition kinetics data of Chapter 5. The experiments were also 
conducted on different days using different preparations of buffer, NADH, substrate and 
enzyme dilutions. For maximum accuracy these were always prepared on the day of any 
particular comparative experiment and the experiments run concurrently, to ensure identical 
running conditions. 
4.4 Conclusions 
This chapter has outlined the methodologies and experiments used to characterise the two 
TIM enzymes (hTIM and PfTIM) being investigated. Subsequently, it has been revealed that 
hTIM has a pH stability optimum ranging from pH 6.5 to pH 7.0, a thermal stability optimum 
of approximately 30°C, and enzymatic kinetic parameters of Km 2.27 mM and Vmax 0.7148 
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µMol.ml-1.min-1 and Kcat 2.59 x 104 min-1, as determined by a non-linear regression method. 
Similarly it was shown that PfTIM has a pH stability optimum ranging between pH 5.0 and 
pH 5.5, a thermal stability optimum of approximately 25°C, and enzymatic kinetic 
parameters of Km 4.34 mM and Vmax 0.8671 µMol.ml-1.min-1 and Kcat 1.85 x 104 min-1. Due to 
enzyme inactivation, however, it is not known what portion of the measured TIM enzyme 
concentration (in mg) was active or inactive, although these data indicate that, after 
purification, more PfTIM was inactive than was the case for hTIM. In conclusion, the 
characterisation experiments were successful, spotting a rapid thermal drop-off in activity of 
PfTIM (above 45°C), as well as a clear inclination for PfTIM to favour significantly lower 
pH values (pH 5.0-5.5). When this is considered in conjunction with our knowledge of the P. 
falciparum metabolic processes using subcellular compartmentalisation (Figure 4.1) along 
with the catabolic nature of the parasite’s life cycle with regard to consuming red blood cell 
haemoglobin (Miller et al., 2002; Trampuz et al., 2003), it is not really surprising that a low 
pH environment is favoured, as such an environment is generally useful for digestive 
processes (Painter et al., 2007; Ginger et al., 2010; Olszewski and Llinás, 2010; Vaidya and 
Mather, 2009). 
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5.	Nanoparticle	synthesis,	
characterisation	and	TIM	interactions	
5.1 Introduction 
Nanoparticle technology has advanced rapidly in recent years and the possibility of using 
nanoparticles as functionalized, nanotechnology-derived, integrated drug development 
systems is now a reality. This approach involves customising the functional and chemical 
properties of nanoparticles using modern nanotechnology techniques. The nanoscale systems 
that can be ultimately obtained through such customizations are seemingly limitless and have 
the ability to satisfy the highly specific and difficult set of biochemical properties demanded 
for use as modern nanodrugs. The recent release of such nanodrug systems (Hrkach et al., 
2012; Sheridan, 2012) demonstrates the importance and versatility of this methodology. 
Success is dependent on the ability of the nanodrug ‘nanoparticle system’ to achieve the 
desired biochemical properties of decreased host toxicity and increased specificity to target 
cell lines or locations. Advanced targeting methods, using nanoparticle functionalization, is a 
key aspect of this and is what allows for lower overall dosage levels to be achieved, by 
employing highly specific targeting, to localise the nanodrug to target areas. This limits body-
wide drug damage while also preventing or limiting side effects associated with high drug 
dosage (Guzmán et al., 2008; Rana et al., 2010). Another important aspect of nanoparticle 
systems as drug delivery ‘vessels’ is that the key nanoparticle is able to persist in the body 
longer than is the case for conventional drugs, typically resulting in decreased catabolic 
destruction of active compounds (Kholoud et al., 2010; Rana et al., 2010). This is due to the 
alien nature of nanoparticle systems, which makes it difficult for host biochemical processes 
to handle and process. Long-term effects of using nanoparticle systems are however still 
widely unknown and a complete understanding of all possible nanoparticle system 
interactions are difficult to establish and are not currently fully understood.  
Extensive research in this field is still required and already well underway, with some recent 
studies showing promise (Rana et al., 2010; Sheridan, 2012). Several nanoparticle-based 
drugs have been developed and some are already being used to treat various cancers. Still 
more are currently in drug trials, with promising results (Sheridan, 2012). With an increasing 
number of NP-development and customisation techniques being discovered, nanosystems 
represent a new approach in drug development with ever-increasing advanced capabilities.   
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5.2 Materials and methods 
Subsections here outline the protocols used to develop, characterise and interact silver 
nanoparticles with the two TIM enzymes being studied. 
5.2.1 Silver nanoparticle preparation and characterisation 
To obtain silver nanoparticles, a 0.1 M solution of AgNO3 was prepared and 0.2 ml of this 
solution was then added to 9.8 ml of absolute (95%) ethanol (EtOH) with 0.1 g of 
polyvinylpyrrolidone (PVP). The solution was then mixed and placed into a 25 ml 
Erlenmeyer flask, covered with cotton wool, and microwaved (800 W, 5 sec) in a Sharp 800 
W microwave. After removal from the microwave, the solution had a pale yellow tint, 
indicating the formation of silver (Ag) nanoparticles (Pal et al., 2009). Samples were left 
overnight at room temperature to allow for AgNP seed growth. This process was monitored 
by performing wavelength scans (300-700 nm) in a Synergy MX spectrophotometer. 
Microwave heating rapidly creates high temperature zones or ‘micro-pockets’ throughout the 
solution, which aids in small- and  nano- particle creation (Liu et al., 2005) while PVP works 
as a stabilizing agent, functionalising the nanoparticles and ensuring that they are mono-
dispersed and remain highly soluble.  
Nanoparticles were also assessed by Transmission Electron Microscopy (TEM), using a Zeiss 
Libra 120 TEM, with imaging done at different times to assess particle growth, size, shape, 
distribution, stability, and whether aggregation was occurring over time. All NP samples 
were stored wrapped in tinfoil, to limit light exposure for at least 1 day, so that seed growth 
could occur prior to TEM imaging. 
5.2.2 Evaluation of the effect of AgNPs on αG3PDH 
To test AgNP effects on the αG3PDH coupling enzyme, the following assay experiment was 
conducted using dihydroxyacetone phosphate (DHAP) as substrate. This represents the 
second part of the coupled TIM assay (Chapter 3, Section 3.2.8; pg. 55).  
An assay series, using final AgNP concentrations of 0, 20, 40, 60, 80, 100, and 150 µM, was 
performed in triplicate. AgNP negative controls, using only PVP and EtOH in equivalent 
dilutions to that of the 150 µM AgNP sample, were also performed, as well as a full negative 
control using the standard assay protocol. The full negative control was then used as the 
reference sample to calculate relative percentage activity. These data were then used to 
determine the effect of AgNPs on αG3PDH, covering an effective inhibition range from 0-
100%.  
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The assay for this experiment was performed in a slightly different manner to that previously 
described, because in this case the assay is designed to replicate the TIM assay, where the 
AgNPs are part of the 5 min pre-incubation. To replicate this, the reaction was initiated by the 
addition of substrate (DHAP) instead of enzyme (αG3PDH).  
Using a 96-well-plate: In a 1st set of wells the following solutions were added: NADH (8 
mM, 10 µl), αG3PDH (1 U/ml, 10 µl), TEA buffer (280 µl, pH 7.4), with relevant AgNP 
concentrations to obtain final AgNP ‘assay concentration levels’ of 0, 20, 40, 60, 80, 100, or 
150 µM. In the 2nd set of wells; DHAP (76 mM, 10 µl) was added. Pre-incubation was 
performed (25°C, 5 min) and then the pre-assay change in absorbance was monitored (2 min, 
340 nm, 15 sec intervals). After which 290 µl from the 1st wells was pipetted into the 2nd 
wells – initiating the assay – and the decrease in absorbance for the assay was monitored (10 
min, 340 nm, 15 sec intervals), (Beisenherz et al., 1955; Bergmeyer, 1974). 
5.2.3 TIM and AgNP incubations under optimum conditions  
Using optimum pH and temperature parameters for the two enzymes hTIM and PfTIM 
(Chapter 4, Section 4.4; pg. 86), the AgNPs interaction assays were performed in the 
presence of varying concentrations of AgNPs. The activity was monitored immediately (at 0 
min) and again after 45 min.  
The standard TIM assay protocol (Section 3.2.8; pg. 55) was used (Beisenherz et al., 1955; 
Knowles et al., 1972; Bergmeyer, 1974). AgNPs were diluted with buffer, after calculating 
the correct dilution ratios to obtain the desired AgNP concentrations, of 0 µM (-ve control), 
and 0.015, 0.03, 0.06, 0.12, 0.25, 0.5, 0.75, 1.0, 1.5 and 2.0 µM in the 2 ml incubation tube 
(Appendix N). As per the standard TIM assay, 10 µl of this solution was added to micro-titre 
plate for assay. This ‘in assay’ dilution of nanoparticles also further limits the nanoparticle 
effects on αG3PDH during assays.  
5.2.4 TIM kinetics in the presence of AgNPs 
To evaluate the inhibitory effects of AgNPs, a full set of kinetic experiments, using varying 
substrate concentrations, was performed with and without AgNPs. This allowed for a direct 
comparison to gauge the effects of AgNPs on TIM kinetics. This also helped to identify the 
mode of enzyme inhibition/activation occurring. Experiments were set up in a similar manner 
as that of previous kinetics experiments, (Section 4.2.5; pg. 78), but additional substrate 
concentrations were used.  
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In these kinetics experiments, substrate concentrations of 0.25, 0.75, 1.25, 2.5, 5, 7.5, 10 and 
15 mM of DL-GA3P were prepared. For the inhibition kinetics study 0.06 µM AgNPs was 
chosen as this concentration was determined to be a concentration level where both hTIM and 
PfTIM showed a noticeable level of inhibition (Figures 5.5 to 5.8), yet still maintained 
enough activity to produce reliable results. Assays were performed concurrently against 
negative controls, which contained PVP and ethanol at the exact same concentration level as 
that of the 0.06 µM AgNP samples. For calculations, see Appendices M and N. 
In a 1st well the following was added: αG3PDH (10 µl, 40 U/ml), NADH (8 mM, 10 µl), DL-
GA3P (50 µl, varying concentrations listed) and TEA buffer (230 µl, pH 7.6). In a 2nd well 10 
µl of the respective diluted TIM (hTIM and PfTIM) was added. Diluted TIM samples were 
incubated (45 min, 25°C) with AgNPs (0.06 µM) or PVP + EtOH (0.06 µM equivalent 
dilution) - negative controls. Kinetics data were then recorded (10 min, 20 sec intervals at 
340 nm) – samples all run in triplicate.  
5.2.5 Sample preparation for TEM 
TEM samples were prepared at least one day in advance so that the NP samples could mature 
after sysnthesis so they could completely form before running TEM. Sample preparation 
involved depositing one drop of sample onto a copper TEM grid and allowing it to settle for 
30 seconds. The drop was then reabsorbed by touching the corner of the grid sample with 
filter paper. The grid sample was then set aside to dry out completely – (at least 4 hours).  
AgNPs were visualised using Transmission Electron Microscopy (TEM) on a Zeiss Libra 120 
at operating at 120 KeV. 
5.3 Results and discussion 
5.3.1 AgNP preparation and characterisations 
The sysntesised AgNPs were visualised by TEM (Zeiss) and characterised in terms of size 
and conformation see Figures 5.1 to 5.3. 
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Figure 5.1: Four progressively zoomed-in (a to d), TEM images of AgNPs. Note: AgNPs appear to be 
mostly spherical in shape and of varying size. (Scale bars are in nm and differ for each image). 
 
After removal from the microwave, a faint yellow colour was observed indicating the 
presence of AgNPs. After aging the samples, this colour darkened to a yellow-orange and 
spectral scans indicated a stronger peak at 400-408 nm, indicating more NPs (Appendix O).  
A size distribution graph of AgNPs was made using the Zeiss Libra TEM software to 
measure NP size (Figure 5.2a) from TEM images of a 1-day-old AgNP sample. An additional 
spectral wave-scan (300-700 nm) was done by sampling different preparations of AgNPs 
after various storage times. This was to assess for NP aggregation, which is known to cause a 
detectable shift in peak absorbance on spectral scans (Figure 5.2b). 
 
 
 
(a) 
(c) (d) 
(b) 
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Figure 5.2: (a). Calculated size distribution graph of freshly prepared AgNPs where a majority of 
NPs were less than 10 nm in size. (b). Spectral wave scans of AgNP samples taken at different times, 
as indicated on the graphs.  
 
Results illustrated in Figure 5.2a show that freshly prepared AgNPs have a slightly different 
size distribution profile (majority 2-8 nm) compared to those of the 1-week old samples 
stored at room temperature (majority 4-10 nm; Figure 5.3). This is consistent with a seeded 
growth process of AgNPs, where maturation results in the smallest NPs aggregating slowly 
over time, due to a larger surface area to volume ratio (Pal et al., 2009). Maturation of AgNP 
seeds is important, to ensure that all of the AgNO3 in solution is depleted. AgNO3 is 
eliminated when Ag+ ions link with the AgNP seeds, causing them to increase in size. The 
smallest AgNPs are the most mobile and interactive and pick up the most Ag+ ions. This 
ensures relatively consistent AgNP seed growth.  
Absorbance peaks (400-408 nm) are consistent with the known AgNP absorbance peak range 
(Elechiguerra et al., 2005; Sivaraman and Elango, 2009). Measurements from different AgNP 
preparations after different storage times (Figure 5.2b) indicate that the process slowly 
evolves, tending towards more aggregation and larger AgNPs a process known to occur 
during NP sample storage. These data (Figure 5.2b) indicate no significant shift in peak 
absorbance between 1 day and 3 months, meaning that the PVP-stabilized AgNPs that were 
synthesised were stable and could be kept for at least 3 months. TEM images also confirmed 
this, indicating only a slight (2-4 nm) increase in the overall average AgNP size distribution, 
which was considered insignificant for the purposes of this thesis. Furthermore, the overall 
size distribution range (~2-12 nm) was considered as an exceptionally narrow range for NP 
production, outperforming several other NP production methods tested (data not shown).   
Nanoparticle stability was tested under different storage conditions. Freshly prepared samples 
were wrapped in tinfoil to limit light exposure and stored at 4°C or at room temperature for 1 
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week. Analysis, using TEM to inspect for nanoparticle size and level of aggregation, was 
then performed on the stored samples (Figure 5.3). 
 
Figure 5.3: TEM images of AgNPs stored for 1 week at 4°C (a) and at room temperature (b). Less 
nanoparticle aggregation is observed for room temperature samples (b). This is consistent for all 
images taken using TEM at all different magnifications used. Size distribution graphs indicate more 
AgNPs > 26 nm in samples stored at 4°C. 
 
Storage at room temperature appears to be less prone to aggregation after 1 week (Figure 
5.3). Consequently, all AgNP samples used in enzymatic experiments were those stored at 
room temperature. This could possibly be due to lower solubility of PVP at lower storage 
temperatures thereby allowing for increased aggregation. A study investigating dipole and 
tripole formation from electrostatic energy fields around AgNPs and the effects of NP size on 
these energy fields may provide further insight into AgNP aggregation. This study goes on to 
explain the creation of rods, triangles or prisms in AgNP solutions by investigating the 
energy fields of AgNPs with reference to electromagnetic theory for spherical particles also 
known as Mie Theory (Hao and Schatz, 2004).  
5.3.2 Effect of AgNPs on αG3PDH 
A key aspect to ensure the validity of all the TIM assays that were carried out was to establish 
the concentrations of AgNPs that have an effect on the coupled αG3PDH, as this enzymatic 
reaction is critical for monitoring the TIM activity of the two TIMs being studied. The 
following results (Figure 5.4) indicate the range of AgNP concentrations tested, and their 
relative effect on αG3PDH activity.  
 
(a) (b) 
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Figure 5.4: The interaction of AgNP, at different concentrations, with αG3PDH. The ‘Standard’ 
represents the full negative control (i.e. the standard assay). The sample labelled ‘PVP + EtOH’ is a 
negative AgNP control (i.e. it contains PVP + EtOH, but no Ag) in an equivalent dilution as that of 
the 150 µM AgNP sample. Samples run in triplicate. 
 
 
Data presented in Figure 5.4 indicate that αG3PDH is not affected by 20 µM AgNPs. 
Furthermore, at two-times concentration (40 µM AgNPs), over 60% activity still remained. 
The activity of αG3PDH was more significantly affected by 60 µM AgNPs, albeit with a 
large margin of error, implying that active disruption of enzyme activity is occurring. At 80 
µM AgNPs no activity remains. The PVP and EtOH control — tested using an equivalent 
dilution level to that of the 150 µM AgNP sample — indicates that, at this concentration, 
PVP and EtOH have no significant effect on αG3PDH activity (Figure 5.4). Therefore, the 
observed loss in activity is entirely due to the presence of the AgNPs and not due to PVP or 
EtOH.   
This experiment — which specifically tested the effects of AgNPs on the coupled enzyme 
reaction, using αG3PDH — established the upper AgNP concentration limit that could be 
tolerated by αG3PDH under assay conditions without losing any noticeable level of activity 
(Section 5.2.2). Results illustrated in Figure 5.4 indicate that this limit is 20 µM AgNPs.  
While the TIM assay is different to the αG3PDH assay used here, the determined limits (Fig. 
5.4) are still applicable to TIM assays because the αG3PDH assay is more sensitive to 
changes in αG3PDH activity than is the TIM assay. This is because the TIM assay uses 
significantly more αG3PDH: 20 x more under normal conditions or 40 x more for kinetics. 
This excess is critical, to ensure that αG3PDH activity is not rate-limiting and also serves to 
mitigate fluctuations in the activity of αG3PDH, making the coupled reaction in TIM assays 
very robust.  
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The timing, incubation temperature and buffers of the αG3PDH assay with AgNPs were all 
standardised to ensure that any observed effects in this test would translate objectively to tests 
done using the TIM assay. A final notable aspect of importance is that, in the TIM assay, 
samples containing TIM were prepared separately and only added to the rest of the assay 
mixture after the pre-assay incubations. This further minimises αG3PDH exposure to AgNPs 
and also results in an additional dilution. This test established that the coupling TIM assay 
enzyme αG3PDH is highly resilient to AgNPs at concentrations of up to 20 µM.  
During TIM-AgNP interactions the highest AgNP concentration to achieve full TIM 
inhibition was only 2 µM for both TIM variants. This confirms the original suspicions about 
TIM that it would be susceptible to inhibition by AgNPs. At this concentration (2 µM) the 
αG3PDH, in the TIM assays, is well within this limit. After the necessary dilutions for the 
other TIM assay reagents, the AgNP concentration ‘exposure level’, to αG3PDH, drops to 
0.065 µM. From these data and dilution factors it was therefore concluded that the AgNPs do 
not affect the coupling enzymatic reaction of αG3PDH in TIM assays (Figure 3.2; pg. 50).  
These results indicate that any observed changes in TIM activity are entirely due to the AgNP 
effect on the relevant TIM enzyme (hTIM or PfTIM) used for the TIM assays. These data 
thus confirm that it is acceptable and scientifically valid to test the effects of AgNPs on TIM 
enzymes, using the assay methodology described (Sections 5.2.2, 5.2.3 and 5.2.4).   
5.3.3 AgNP interactions with TIM enzyme variants 
After characterising the two different TIM variants being studied (hTIM and PfTIM) and 
optimizing protocols, the inhibitory effects of AgNP on these two enzymes were investigated.  
A set of comparative enzyme inhibition experiments was performed (Section 5.2.3). Data on 
the AgNP inhibition effects after immediate introduction of AgNPs (0 min) and after 45 min 
are shown in Figures 5.5 to 5.8. Samples immediately taken for assay (0 min samples) were 
technically exposed to AgNPs during pre-incubation (5 min), which was standardised across 
all assay experiments.  
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Figure 5.5: Bar graph showing relative percentage activity of PfTIM when incubated with different 
concentrations of AgNPs for T0 min. The 0 sample represents the full –ve control and is also used as 
reference for 100% standard when calculating relative % activity. Samples run in triplicate and error 
bars indicate standard deviation. 
 
 
An examination of Figure 5.5 indicates that the PVP and EtOH negative controls, run at 
dilutions equivalent to 0.12, 0.25 and 0.5 µM AgNP samples, did not affect PfTIM activity in 
any statistically significant manner. Several PVP and EtOH control concentrations were 
assayed and it was shown that, at higher concentrations, PVP and EtOH can affect TIM 
enzyme activity. This phenomenon was investigated in a separate set of experiments (Section 
5.3.5) which revealed some interesting observations regarding the PVP and EtOH controls. 
For the purposes of these experiments, under the AgNP concentrations used here, only the 
relevant PVP and EtOH controls are shown. Dilution calculation examples, to determine 
concentrations of PVP and EtOH in the AgNPs samples and in the ‘equivalent’ dilutions, are 
available in Appendix N.  
Figure 5.5 indicates that 0.03 µM AgNPs reduced PfTIM activity to 74% +/- 6%, as 
compared to the negative control (0 µM). This decrease in activity continues as AgNP 
concentrations increase. At 0.25 µM AgNPs the PfTIM activity decreased to only 8% +/- 
1.9% relative percentage activity and at 0.5 µM virtually no detectable activity remains. The 
PVP and ethanol controls at these equivalent dilutions (0.25 µM and 0.5 µM) are completely 
unaffected in any statistically significant manner, compared to the 0 µM negative control. 
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This indicates that the observed decrease in PfTIM activity is entirely due to the presence of 
the AgNPs, which appear to have significant inhibitory effects on PfTIM at final AgNP 
concentrations of 0.03 µM and higher. This inhibitory effect appears to occur relatively 
rapidly, considering the brief time (5 min) of exposure to AgNPs experienced by the T0 min 
PfTIM samples. 
 
Figure 5.6: Bar graph showing relative percentage activity of hTIM when incubated with different 
concentrations of AgNPs for T0 min. The 0 sample represents the full –ve control and is also used as 
reference for 100% standard when calculating relative % activity. Samples run in triplicate and error 
bars indicate standard deviation. 
 
A comparison of Figure 5.5 (PfTIM) and Figure 5.6 (hTIM) indicates some key differences. 
Inhibition by AgNPs is notably less pronounced for hTIM than for PfTIM, with hTIM 
showing only statistically-insignificant effects by AgNPs concentrations of up to 0.06 µM. At 
0.25 µM AgNPs around 56% +/- 1.3% activity remains, which is significantly greater than 
the 8% +/- 1.9% observed for PfTIM samples at the same AgNP concentration. This trend is 
similar at higher AgNP concentrations, from 0.5 µM to 1.0 µM AgNPs, where hTIM is still 
active in a statistically-significant way, while PfTIM is not, with 0% being within its margin 
of error. This indicates that activity had been affected, even after the briefest possible 
exposure to AgNPs.  
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A detailed investigation into the PVP and EtOH controls was also done, because of the 
observed increase in activity, of approximately 18%, which was seen only in the hTIM 
control samples, using 0.5 µM equivalent PVP and EtOH dilutions (Figure 5.6 and 5.8). This 
increase in activity could not be accounted for by the error bars so it was investigated 
separately. This was done by setting up a range of PVP and EtOH controls, to investigate this 
observation. These control experiments are described in detail in Section 5.3.5.  
Figures 5.7 and 5.8 show the relative percentage inhibition by AgNPs after a 45 min exposure 
at optimum conditions (Section 5.2.3). The two exposure times chosen (0 min and 45 min) 
are in accordance with the optimal stability determined in pH and temperature experiments 
outlined in Chapter 4 (Sections 4.3.1 and 4.3.2; pgs. 79 and 80). 
 
 
Figure 5.7: Bar graph showing relative percentage activity of PfTIM when incubated with different 
concentrations of AgNPs for T45 min. The 0 sample represents the full –ve control and is also used as 
reference for 100% standard when calculating relative % activity. Samples run in triplicate and error 
bars indicate standard deviation. 
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As with the T0 min sample (Figure 5.5) the trend of inhibition is consistent for T45 min 
samples for PfTIM (Figure 5.7). Complete loss of activity for PfTIM samples (Figure 5.7), is 
observed for 0.25 µM AgNP concentrations, while the PVP and EtOH controls at this 
equivalent dilution (PVP EtOH 0.25) are unaffected, compared to the 0 µM negative controls.  
Figure 5.8: Bar graph showing relative percentage activity of hTIM when incubated with different 
concentrations of AgNPs for T45 min. The 0 sample represents the full –ve control and is also used as 
reference for 100% standard when calculating relative % activity. Samples run in triplicate and error 
bars indicate standard deviation. 
 
 
Inhibition of hTIM samples at concentrations up to 0.03 µM is statistically insignificant 
(error bars overlap with 0 control) however, at concentrations of 0.06 µM, notable significant 
level of inhibition (error bars do not overlap with the 0 control) is observed after 45 min 
incubations with AgNPs for hTIM samples (Figure 5.8). Complete inhibition for hTIM is 
achieved with 0.75 µM AgNPs, while the closest equivalent control sample (PVP EtOH 0.5) 
shows an increased level of activity of approximately 117% which appears to be significant 
(error bars do not overlap with the 0 control). Across all AgNP concentrations a greater level 
of enzyme inhibition is observed after 45 minutes incubation with AgNPs (Figures 5.5 to 
5.8). This indicates that the relative level of inhibition by AgNP increases with incubation 
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exposure time. This implies a destructive or ‘inactivating’ nature of the AgNPs to both of the 
TIM enzymes, something that would not likely occur with a standard competitive inhibitor 
and emphasises that protein-AgNP interactions are different to conventional (i.e. competitive, 
uncompetitive, non-competitive and mixed) inhibitors.  
The results from the 45 minute AgNP incubations, hTIM (Figure 5.8) and PfTIM (Figure 
5.7), indicate that hTIM samples can maintain approximately 47% +/- 2.7% of activity after 
45 minutes of exposure to 0.12 µM AgNP concentrations and 31% +/- 4% activity with 0.25 
µM AgNP concentrations. PfTIM samples for these AgNP concentrations, on the other hand, 
show activity levels 35% +/- 4.6% and 1% (considered inactive) respectively. This indicates 
that AgNPs appear to selectively inhibit PfTIM over hTIM.  
To assess this level of inhibition as an IC50 value a linear regression was performed on the 45 
minute incubation data (Figures 5.7 and 5.8) only selecting the linear decrease range i.e. (0.03 
to 0.025 µM AgNP) for hTIM samples and (0.03 to 0.12 µM AgNP) for PfTIM samples. The 
regression line equation was then used to determine an IC50 concentration level for both 
hTIM and PfTIM. These determined IC50 values were 0.158 µM AgNPs for hTIM and 0.095 
µM AgNPs for PfTIM – see Appendix N, Equations N1 and N2 for calculations. These IC50 
levels were only determined with a limited set of data points and the inhibition curve may not 
actually be linear, even though it may appear so (Figures 5.7 and 5.8). These IC50 values 
therefore can only provide a rough estimate of the true IC50 values. That said, the IC50 data 
indicate that an almost 2-fold greater AgNP concentration is required to reach the IC50 for 
hTIM samples compared to PfTIM samples.   
These results indicate that the hypothesis, “Due to amino acid sequence and structural 
differences between Human and Plasmodium falciparum triosephosphate isomerases, silver 
nanoparticles, of less than 20 nm in size, will selectively inhibit the parasite enzyme over its 
Human counterpart.”, must be true.  
5.3.4 Kinetics studies with AgNPs on TIM variants 
Kinetics experiments conducted on the two TIM variants were done after determining 
inhibition levels at different AgNP concentrations (Section 5.3.3). Initially AgNP 
concentration of 0.12 µM was chosen for kinetics as this was thought to represent the ~50% 
inhibition level desired for kinetics tests across both TIM samples. Tests using this 
concentration for PfTIM samples however produced unreadable kinetic data at low substrate 
concentrations (data not shown). For this reason a lower AgNP concentration level, of 0.06 
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µM AgNPs, had to be used. Kinetics assays were performed as described in Section 5.2.4. To 
analyse kinetics data the Hanes-Woolf, Lineweaver-Burk, and non-linear regression analyses 
were performed with the use of the Michaelis-Menten equation (Equation 4.1; pg. 78) - see 
Appendix M.  
To see the kinetic plots of Lineweaver-Burk, Hanes-Woolf and the Michaelis-Menten plot - 
with the Non-Linear regression curve incorporated - see Figures 5.9 and 5.10 for hTIM 
samples and Figures 5.11 and 5.12 for PfTIM samples.  
Calculated kinetic parameters from all the plots (Figures 5.9 to 5.12) are presented in Table 
5.1. The negative kinetic controls used for comparative inhibition kinetics were run 
concurrently with the AgNP inhibition kinetics samples as detailed in Section 5.2.4.  
Figure 5.9: The Lineweaver-Burk plot (a), and Hanes-Woolf plot (b) for enzyme kinetic inhibition 
studies on hTIM using 0.06 µM AgNPs. Samples run in triplicate and error bars indicate standard 
deviation.  
 
Figure 5.10: Kinetic activity of hTIM indicating velocity versus substrate concentration. Km and Vmax 
values, determined by non-linear regression computation, were used to plot the solid line graphs using 
the Michaelis-Menten equation (Equation 4.1) The hTIM samples used 0.06 µM AgNPs and controls 
had PVP and EtOH at an equivalent dilution level. Samples run in triplicate and error bars indicate 
standard deviation. 
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At the 0.06 µM AgNP concentrations used, kinetics data indicate the occurrence of only 
minimal inhibition for hTIM samples (Figures 5.9 and 5.10), while the PfTIM samples 
(Figures 5.11 and 5.12) appear to be experiencing relatively strong inhibition in comparison. 
All calculated kinetic parameters; Vmax, Km, Kcat, and Km/Kcat are reported in Table 5.1.  
 
Figure 5.11: The Lineweaver-Burk plot (a), and Hanes-Woolf plot (b) for enzyme kinetic inhibition 
studies on PfTIM using 0.06 µM AgNPs. Samples run in triplicate and error bars indicate standard 
deviation. 
 
 
Figure 5.12: Kinetic activity of PfTIM showing velocity versus substrate concentration. Km and Vmax 
values, determined by non-linear regression computation, were used to plot the solid line graphs using 
the Michaelis-Menten equation (Equation 4.1) PfTIM samples used 0.06 µM AgNPs and controls had 
PVP and EtOH at an equivalent dilution level. Samples run in triplicate and error bars indicate 
standard deviation. 
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Kinetics data from PfTIM samples (Figures 5.11 and 5.12) indicate that comparatively far 
more inhibition is occurring for PfTIM samples than for hTIM samples when run under 
identical conditions relative to the negative controls containing PVP and EtOH. The 
Lineweaver-Burk plot (Figure 5.11a) indicates the type of inhibition which probably follows 
a mixed or non-competitive inhibition model. The Hanes-Woolf and the Michaelis-Menten 
graphs with non-linear regression analysis are considered to give the most accurate Km and 
Vmax values. The Lineweaver-Burk values, although included, are considered significantly 
less accurate. These data are presented for comparative purposes in Table 5.1. 
 
Table 5.1: Kinetic parameters calculated from the three graphical plots: Lineweaver-Burk, Hanes-
Woolf and Non-linear regression using Michaelis-Menten (Figures 5.9 to 5.12). Analysis of human 
(hTIM) and Plasmodium falciparum (PfTIM) in the presence and absence (control) of silver 
nanoparticles (AgNPs), (Units presented under each parameter). 
Plot Type 
and Sample human TIM Plasmodium falciparum TIM 
Lineweaver-
Burk Km (mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
Km 
(mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
AgNPs 4.65 0.7968 2.89 x 104
 
6.22 x 106 10.26 0.3717 7.92 x 103 7.72 x 105 
Control 5.34 0.9719 3.52 x 104 6.59 x 106 10.63 0.9065 1.93 x 104 1.82 x 106 
Hanes-
Woolf Km (mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
Km 
(mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
AgNPs 7.23 1.1039 4.00 x 104 5.53 x 106 11.5 0.4057 8.65 x 103 7.52 x 105 
Control 8.22 1.3481 4.89 x 104 5.95 x 106 13.09 1.0784 2.30 x 104 1.76 x 106 
Non-linear 
Regression Km (mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
Km 
(mM) 
Vmax 
(µmol.ml-
1min-1) 
Kcat 
(min-1) 
Kcat/Km 
(Mol-1.min-1) 
AgNPs 7.73 1.1362 4.12 x 104 5.33 x 106 12.8 0.4299 9.16 x 103 7.16 x 105 
Control 8.78 1.3894 5.04 x 104 5.74 x 106 14.21 1.1299 2.41 x 104 1.70 x 106 
 
Hanes-Woolf and Non-linear regression data correlate reasonably well, indicating that these 
data are reliable, since these two methods are considered to be the most accurate and were 
derived from completely different mathematical methods. Good correlation can be taken as 
an indication that a good data set was obtained. It is noted that a theoretically perfect data set 
should produce identical results. Thus, the production of similar results from two different 
methods (Table 5.1) indicates that the quality of these data can be considered good. The non-
linear regression analysis of data is still regarded as the most powerful method, producing the 
most accurate results. For this reason, results from this method will be used when a single set 
of values needs to be quoted. The non-linear regression method data is considered more 
accurate than the Hanes-Woolf plot data - (which is considered the most accurate of the linear 
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plots). This is because the Hanes-Woolf plot is flawed, in that it uses substrate concentration 
in the abscissa (x-axis) and the ordinate (y-axis), meaning neither axis is independent as it 
should be. This in turn means that the R2-value, typically used to determine the accuracy or 
‘goodness of fit’ for linear regressions, is not applicable to Hanes-Woolf plots (Voet and 
Voet, 2004). The non-linear regression method does not suffer from this issue or any of the 
other issues that are associated with the linearization of the Michaelis-Menten equation. For 
this reason it is considered the most accurate (Greco and Hakala, 1979). Lineweaver-Burk 
plots are considered even less accurate because, by dividing by 1/S and 1/V, any inaccuracies 
in substrate concentration, particularly in velocity readings at low substrate concentrations, 
are amplified dramatically when using this methodology (Voet and Voet, 2004).   
As indicated in Table 5.1 for all the plots, Vmax clearly decreases in the presence of AgNPs, 
compared to negative controls. The effects of this are far more pronounced in PfTIM samples 
than in hTIM samples. Km values also appear to change, decreasing in all the plots when 
compared to negative controls, even though the decrease is not as significant as that seen for 
Vmax values. This suggests that the inhibition that is occurring here is most similar to a mixed 
inhibition model rather than a non-competitive model. It should however be noted that, due to 
the different nature of inhibition occurring with AgNPs, these conventional models of 
inhibition are not necessarily even relevant when considering enzyme inhibition by AgNPs. 
Evidence, discussed above, suggesting that there is a mixed mode of inhibition emphasises 
this conclusion.   
The Lineweaver-Burk plot (Figure 5.11a) provides a clearer indication that inhibition is 
occurring and it appears to be operating in a non-competitive, or possibly mixed, manner. 
Enzyme inhibition using nanoparticles is a relatively new technique that is not fully 
understood. What is known, however, is that this unconventional method can either enhance 
or decrease enzyme activity and that factors, such as of nanoparticle size, concentration, 
nanoparticle functionalization and the type of nanoparticle used, can greatly affect the 
outcome of nanoparticle enzyme interactions (Paciotti et al., 2006; Wilner et al., 2007; Lynch 
and Dawson, 2008; Rana et al., 2010). It is clear from these data that the AgNPs do target and 
interact with the TIM enzymes, regardless of whether or not the substrate is bound. In this 
way they act in a similar manner as a non-competitive inhibitor. The binding mechanisms of 
nanoparticles however operate in a vastly different manner and it is likely that they induce 3D 
conformational changes when they bind. This makes it unlikely that enzyme activity may be 
restored after AgNP binding has occurred (You et al., 2005; Willner et al., 2007; Lynch and 
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Dawson, 2008; Wu et al., 2009; Rana et al., 2010). Any conformational changes induced 
during AgNP binding would need to be reversed if activity were to be restored. This is 
discussed in further detail in Chapter 6, with reference to 3D protein models of the two TIM 
enzymes being studied. These data further support the hypothesis (Section 1.7; pg. 27). 
5.3.5 Unforeseen observations from control experiments 
 For the inhibition experiments (Section 5.3.2) a series of additional PVP and ethanol controls 
were prepared and assayed (Section 5.2.3). This was done because during testing it was 
shown that, depending on concentration, the presence of PVP and ethanol could have a 
statistically significant effect on hTIM activity, most notably at dilution levels equivalent to 
the (2 µM AgNP) concentrations (Figure 5.13).  
Figure 5.13: Analysis of all PVP and EtOH controls run for both hTIM (Blues) and PfTIM (Reds) at 
T0- and T45- minute sample times versus the negative controls (Bright colours),  used to determine 
relative percentage activity. Samples run in triplicate and error bars indicate standard deviation.  
 
For hTIM samples (blue), higher concentrations — equivalent to 2.0 µM AgNP dilutions of 
PVP and EtOH (see Appendix N for actual PVP and EtOH concentrations) — resulted in an 
approximate doubling of hTIM activity (Figure 5.13). Additionally, at PVP and EtOH 
dilutions that were equivalent to the 0.5 µM AgNP samples (Section 5.3.3), a statistically 
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significant increase, of approximately 18% +/- 3%, was observed for both incubation times 
(Figures 5.6 and 5.8). This did not occur for PfTIM samples (red), where PVP and EtOH 
controls at 2.0 µM-equivalent dilutions maintained approximately the same level of activity 
as the T0 negative control samples (Figure 5.13). For PfTIM at T0 time (2.0 µM) a slight, but 
statistically significant (i.e. error bars don’t overlap), decrease in activity was observed, while 
for 45 minute samples no statistically-significant change was observed (i.e. error bars overlap 
with those of the T0, negative control). 
These control experiments were repeated several times and conducted under carefully 
controlled conditions, using fresh reagents, dilutions and new negative controls for each set 
of experiments. Results from all repeats of these PVP and EtOH control experiments were 
identical (Figure 5.13). This indicates that hTIM and PfTIM are affected differently by the 
presence of PVP and EtOH at the concentrations investigated (Appendix N). This observation 
emphasises that the differences between the two TIM variants (PFTIM and hTIM) are indeed 
important with noticeable variations observed for pH optima, temperature optima, AgNP 
concentrations and now PVP and EtOH concentrations. This strongly supports the notion that 
a selective PfTIM inhibitor could be designed. Ironically it appears that a selective enzyme 
activator/enhancer, (PVP and EtOH at the tested concentrations – see Appendix N), for hTIM 
appears to have also been found by serendipity. Fortunately, for the relevant AgNP 
concentrations required to achieve noticeable enzyme inactivation (0.25 µM AgNPs) – 
Figures 5.7 and 5.8, the equivalent controls, (0.25 PVP EtOH), showed no statistically 
significant (i.e. error bars overlap) differences compared to the 0 µM negative control (which 
contained no AgNPs, PVP or EtOH in it) – see Figure 5.13. This indicates that the two 
enzymes are affected differently by AgNPs and the PVP and EtOH solution used to create the 
AgNPs.  
Therefore the controls that were prepared and assayed were able to rule out the possibility - 
that this observed enhancement in activity (Figure 5.13) may have resulted in interference 
with the AgNP inhibition experiments (Figures 5.5 to 5.8). Indeed complete enzyme 
inhibition by 1.0 µM AgNPs for both TIM samples was observed (Figures 5.7 and 5.8) 
irrespective of any possible PVP and EtOH enhancements. As such it appears that the ability 
of AgNPs to inhibit activity superseded and enhancement activity of PVP and EtOH (Figures 
5.5-5.8).  
  
108 
 
5.4 Conclusions 
Firstly, the TEM and spectral analyses (Figures 5.1 to 5.3) were able to confirm that the 
AgNPs obtained were well within the desired size range desired (of < 20 nm), with the 
majority of AgNPs being ~4-12 nm in size and stable during storage. At this size the range 
the AgNPs are of a size comparable to that of the TIM enzymes being studied, i.e.  
Approximately 7.8 nm x 5.2 nm x 5.0 nm as measured by PyMol: pdb files; {1HTI-(hTIM); 
1YDV-(PfTIM)}. The AgNPs therefore have sufficient ‘curvature’ to interact with the natural 
surface curvature of the TIM enzymes and probe the exposed sulphur atoms of the targeted 
residues (Figures 1.7a, b, c; pg. 16) (You et al., 2005; Willner et al., 2007; Lynch and 
Dawson, 2008; Wu et al., 2009; Rana et al., 2010).   
On analysing the most accurate kinetic data, obtained from the non-linear regression (Table 
5.1), it becomes apparent that both Km and Vmax values are affected by the presence of AgNPs, 
indicating that a complex type of inhibition is occurring. After further study of the kinetics 
‘turn over’ values, (Kcat values), it becomes apparent that - at the 0.06 µM AgNP 
concentration tested - AgNPs had a noticeably greater effect on PfTIM than on hTIM (Table 
5.1). It is noted that for PfTIM a ~62% decrease in ‘enzymatic turnover’ (Kcat), is observed 
while for hTIM the decrease in Kcat is only ~18% (Table 5.1), (Plaut and Knowles, 1972; 
Blacklow et al., 1988; Mann et al., 1990). If one further considers Kcat/Km, also known as the 
enzyme ‘catalytic efficiency’ value, which incorporates any observed shifts in Km as well, and 
is therefore more accurate, an even greater difference between PfTIM and hTIM is observed 
(Plaut and Knowles, 1972; Blacklow et al., 1988; Mann et al., 1990). With 0.06 µM AgNPs 
there was a decrease of ~58% in ‘catalytic efficiency’ for the PfTIM enzyme while only a 
~7% decrease was observed for the hTIM enzyme – see Table 5.1. This clearly indicates that 
AgNPs inhibit PfTIM selectively over hTIM by a significant margin of approximately 8 fold, 
as based on Kcat/Km values determined from kinetics data of the non-linear regression analysis 
(Table 5.1) for both enzymes when inhibited with 0.06 µM AgNPs. This selective inhibition 
trend is consistent across the range of AgNPs tested, when incubated at both the time 
durations tested (Figures 5.5 to 5.8).   
Data indicating that the PVP and ethanol controls at equivalent dilutions (to 2.0 µM AgNPs) 
resulted in selective activity enhancement for hTIM, but and not for PfTIM, supports the idea 
that these two variants of the same enzyme (TIM) are sufficiently different for selective 
enzyme inhibition or activation to be induced by foreign substances, namely AgNPs (Figures 
5.5 to 5.12) and the PVP and EtOH solution (Figure 5.13), discovered by serendipity. 
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6.	Final	discussion,	conclusions	and	
recommended	future	work	
6.1 Final discussion and conclusions 
From the experimental data presented it is clear that AgNPs selectively inhibit PfTIM over 
hTIM and that this has the potential to be utilised in drug design and development. 
Considering the recently-discovered propensity for NPs and macro-molecules of the same 
size studied, (4-12 nm), to associate with red blood cells and persist in the blood stream due 
to the complicated fluid dynamics of the human vascular system (Charoenphol et al., 2010; 
Huang et al., 2010; Charoenphol et al., 2011).  
Given the discovery that erythrocytes infected with Plasmodium falciparum have been shown 
to uptake ferritin/apoferritin protein cages – which have also subsequentially been shown to 
have the capacity to encapsulate Au and Ag NPs (Fan et al., 2010; Kasyutich et al., 2010) – 
this offers a realistic and achievable means, of targeting, and deliving NPs to infected 
erythrocytes (Burns and Pollack, 1988). It is noted that the AgNPs used in these studies were 
functionalized or stabilized with the PVP during the AgNP preparation and synthesis 
procedure. PVP acts as a stabilizing agent to the AgNPs by loosely associating with the 
AgNPs and preventing aggregation (Pal et al., 2009). Considereing that the PVP and EtOH 
solution also appeared to have an interesting enhancing effect on hTIM activity when 
incubated with the enzyme by itself, this indicates that the PVP and EtOH solution also has a 
notable level of interaction with the hTIM enzyme and this should not be overlooked.  
PVP shells associated with stabilizing the AgNPs only weakly associate with the AgNP 
surface through van der Waals forces which are sufficiently strong enough to greatly limit 
and reduce AgNP aggregation but not strong enough to compete with the relatively stronger 
bonding associated with AgNP and atomic sulphur on the TIM surface which can more 
accurately be viewed as similar to a CH3-S—AgNP bond. PVP binds to the AgNP via its 
thiol group forming an Ag thiol bond while the CH3-S—Ag shows similar bond strength to 
CH3-S—Au/Ag bonds as reported by (Sellers et al., 1993) who also made comparisons 
between hydrogen bonds and CH3-S—Ag/Au bonds as well as disulphide bonds indicating 
their relative strength. Another paper (Ramachandran et al., 2003) indicates the bond 
dissociation energies for an Au-S under optical testing was 1.6 eV while that of the thiol-Au 
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bond was 0.1 eV (Ramachandran et al., 2003; Jain et al., 2006). Indicating that Sulphur binds 
are at least an order of magnitude greater than that of thiol type bonds (Ramachandran et al., 
2003). This would likely also be the case when tested with AgNPs as the data from Sellers et 
al., (1993), indicates that Ag and Au CH3-S—Ag/Au bonds are comparable in terms of 
strength only differing by a relatively small percentage typically less than 10% (Sellers et al., 
1993). Thus it is assumed that in the presence of the surface sulphur atoms of PfTIM in 
particular the predicted S-Ag bonds created with AgNPs will displace any thiol bonds present 
between the PVP stabilizing molecules and the AgNPs due to sulphurs greater affinity. This 
is further supported by the fact that the PVP only controls exhibited no detectable changes in 
either of the TIM activities when tested at equivalent concentrations to strongly inhibiting 
AgNP experiments. If PVP were playing a noticeable role in inhibition when in conjunction 
with AgNPs it would be logical to assume some trace of this effect might be detectable in the 
PVP controls, the experimental data however indicates this is not the case. 
The targeting of P. falciparum infected erythrocytes using ferritin/apoferritin which become 
incorportated into the erythrocytes via endocytosis and ultimately digested (Burns and 
Pollack, 1988). Offer an intriguing possible drug delivery mechanism as anything captured 
inside the ferritin/apoferritin cage would presumably be released inside the infected 
erythrocyte upon digestion of the protein cage by the parasites biochemical digestive 
processes (Burns and Pollack, 1988). 
In this study, AgNPs successfully inhibited both hTIM and PfTIM enzymes. The inhibition 
observed was also significantly higher for PfTIM samples as compared to hTIM samples, 
across all AgNP concentrations tested. For the inhibition kinetics experiments, performed 
using 0.06 µM AgNPs, an 8-fold higher level of inhibition was observed in the enzyme 
catalytic efficiency (Kcat/Km) for PfTIM samples, compared to hTIM samples, which were 
barely affected (i.e. ~8% decrease observed at this level) – see Table 5.1 (Blacklow et al., 
1988; Mann et al., 1990).  
AgNPs were hypothesised to exhibit this selective inhibition on PfTIM, due to the exposed 
sulphur atoms, prevalent on the surface of PfTIM and at its dimer interface – see (Figures 
1.7a, b, c; pg. 16). Most of these exposed sulphur atoms are not present on hTIM, which only 
has one exposed sulphur atom on its surface (Figure 1.7d; pg. 16). It is known that silver 
interacts strongly with sulphur atoms, forming a relatively strong bond with sulphur 
chemisorption (SH and SCH3 sulphur) occurring at a bond length of 2.337 Å and 2.332 Å 
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respectively with a silver surface (Sellers et al., 1993). This is smaller than the bond length of 
disulphide bonds lengths which are considered highly influential in protein tertiary structure 
formation (Sellers et al., 1993; Rafique et al., 2010). Furthermore, it is known that, when 
nanoparticles are able to interact strongly with enzymes, they tend to induce conformational 
changes in the 3D tertiary structures of those enzymes, which in turn can affect enzyme 
activity (Fischer et al., 2002; You et al., 2005; Lynch and Dawson, 2008; Rana et al., 2010). 
When strong interactions occur, with short bond lengths, or when bonds occur at multiple 
sites, it is more likely that such proteins will join up with the nanoparticle and become a part 
of the ‘hard corona’ of proteins directly conjugated to the nanoparticle. When this happens, 
the affected proteins typically experience a large degree of protein deformation, resulting in a 
loss of enzymatic activity (Fischer et al., 2002; You et al., 2005; Lynch and Dawson, 2008; 
Rana et al., 2010). This is because any significant conformational changes will likely change 
the tertiary conformation of the enzyme to such a degree that the key catalytic residues will 
shift in position, enough to render them ineffective. It is known from literature that, for TIM, 
the positioning of the key catalytic residues (His95 and Glu165) within the TIM active site is 
critical and finely tuned for efficient enzyme function (Knowles and Albery, 1977). As 
indicated by Knowles and Albery (1977) and Knowles (1991), any minor shift in TIM 
structure – an enzyme he describes as “honed to perfection” – could likely reposition these 
key residues and thereby alter catalytic efficiency. Considering Knowles’s argument – about 
this enzyme being a “perfect enzyme” to start with – it is likely that such an alteration will 
destroy this “perfection”.  
The selectivity of the AgNPs to PfTIM comes from both the exposure level of cysteine 
sulphur atoms on the surface of PfTIM and the fact that there are more of them present on the 
surface of PfTIM compared to hTIM. The Cys13, which resides in the dimer interface, is 
theoretically shielded from AgNP exposure but it is known that enzymes, particularly 
multimeric enzymes, are in a constant state of flux, essentially having a constant ‘wobble’ to 
them as they continually associate and disassociate and interact with their surrounding 
environment (Lynch and Dawson, 2008). This essentially means that protein dimer interfaces 
can be targeted because, while the dimer interface of each monomer is generally protected by 
the other monomer, the dynamic flux interactions with the exposed surface may cause a shift 
that weakens dimer stability allowing the dimer itself to be targeted. This has already been 
shown for TIM enzymes by the selective inhibition of Trypanosoma cruzi TIM by Olivares-
Illana et al. (2007) where the dimer interface was targeted. This showed that the dimer 
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interface of TIM is not effectively as shielded in practice as one might expect when studying 
3D protein structures. Hypothetically, if the AgNPs interact with the already exposed surface 
sulphur atoms on PfTIM, it is likely that this initial interaction could cause conformational 
changes that would result in the exposure of the dimer interface. This would raise the 
possibility of further AgNP interactions and binding with the TIM dimer interface that, in the 
case of PfTIM, will likely bind AgNPs with the dimer interface Cys13 via the highly-exposed 
sulphur atom present at the dimer interface (Figure 1.7d; pg. 16). Olivares-Illana et al. 
(2007), noted that this residue (Cys13) is also present on the T. cruzi TIM, which was 
selectively inhibited using 2,2´-dithiodianiline (DTDA) and also interacts with the sulphur 
atom of Cys13. 
6.2 Recommended future works 
The work done here has raised interesting possibilities with regards to the design of selective 
nanodrugs. A lot more work, however, would be required to advance this research to a point 
where such an objective could become a real possibility. To start with, the kinetics studies 
could be extended, to study the forward and reverse reactions of TIM and also to study the 
kinetic effects of AgNPs under a wider range of concentrations. The effects observed with 
enhanced activity of hTIM, in the presence of greater than 2.0 µM PVP, should be further 
investigated as well as the differences between the non-PVP kinetics and kinetics of the 
controls done in the presence of PVP. Other stabilizing and functionalising options, aside 
from PVP, should also be investigated. These would include the use of 2,2´-dithiodianiline 
(DTDA), which was shown to selectively inhibit T. cruzi TIM (Olivares-Illana et al., 2007). 
If this was associated with AgNPs as an outer functional layer it could possibly further 
enhance the selective inhibition of the AgNPs and theoretically reduce nanoparticle toxicity.  
Further research and comparison testing could be done using iron, platinum, gold and copper 
nanoparticles. In addition to this, the option of functionalizing the nanoparticles in various 
ways with multiple layers could be investigated and tested, which would add great value to 
the research, especially if the ultimate goal – of creating a viable nanodrug – is kept in mind. 
Functionalisations to allow for red blood cell targeting could be investigated, such as using 
infected erythrocyte endocytosis of ferritins, apoferritins or transferritins – which have been 
demonstrated to occur in P. falciparum-infected erythrocytes – could be a powerful selective 
delivery mechanism (Burns and Pollack, 1988). The toxicity of the nanodrugs could also be 
investigated, by performing tissue-culture experiments with various human cell lines or 
possibly in mice, as carried out by Lasagna-Reeves et al. (2010), using gold nanoparticles.  
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The lethal nature of any developed nanoparticle system could be tested against live P. 
falciparum parasite cultures. The toxicity of selected nanoparticle-based systems can then be 
each investigated by testing their interactions with human tissue cultures and on live rats or 
mice.   
From these data and knowledge from literature, a proposed hypothesis for a possible future 
research project is as follows. “Silver nanoparticles encapsulated in ferritin or apoferritin will 
become incorporated into P. falciparum infected erythrocytes releasing the silver 
nanoparticles and result in decreased parasite proliferation”.     
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Appendices 
Appendix  A 
Equipment and Reagents             Suppliers 
EcoRI 
NdeI 
XhoI 
E. coli BL21(DE3) 
E. coli JM109 
pMK-T 
pRARE2 
pET28(b+) 
Phusion Hot start II Pfu DNA Polymerase  
T4 DNA Ligase and 10 x buffer 
pJET1.2 Kit 
QiaPrep Miniprep Kit 
Viva-Spin2 columns 10K MWCO 
EDTA free protease inhibitor tablet 
PageRuler™ protein ladder  
GeneRuler DNA ladder mix 
All primers were synthesised by Integrated 
DNA Technologies (IDT, USA) 
SDS-PAGE and agarose gel Equipment 
2-Methyl-2-butanol 
B-mercaptoethanol 
Acetic Acid 
Adenosine diphosphate (sodium salt) 
Adenosine triphosphate (disodium salt) 
Agar (Bacteriological) 
Agarose 
Ammonium per sulphate 
Ampicillin 
30%/0.8% Acrylamide/Bis-Acrylamide  
Bovine Serum Albumin 
Bradford's Reagent 
Calcium chloride 
Chloramphenicol 
Coomassie Brilliant Blue R250 
Diethiothreitol 
Dimethyl sulfoxide (DMSO) 
dNTP mix 
EDTA, sodium salt 
Ethanol 
Ethidium bromide 
α-Glycerol-3-phosphate dehydrogenase 100U 
Glacial acetic acid 
Glycerol 
HEPES 
MES 
TAPS 
MOPS 
Hydrochloric Acid 
Imidazole 
Kanamycin sulphate 
Lysozyme 
ThermoFisher Scientific, USA 
ThermoFisher Scientific, USA 
ThermoFisher Scientific, USA 
Promega, USA 
Promega, UK 
Life Technologies, USA 
Novagen, USA 
Novagen, USA 
ThermoFisher Scientific, USA 
ThermoFisher Scientific, USA 
ThermoFisher Scientific, USA 
Roche Applied Sciences,  
Sartorius Stedim 
Roche, Germany 
Inqaba Biotechnology, RSA 
Inqaba Biotechnology, RSA 
- 
IDT, USA  
Bio-Rad, USA 
Sigma-Aldrich, USA 
Merck, South Africa 
Saarchem, South Africa 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 
Biolab, South Africa 
Whitesci, USA 
Bio-Rad, South Africa 
Roche, Germany 
Bio-Rad, South Africa 
Bio-Rad, South Africa 
Sigma-Aldrich, Germany 
Sigma-Aldrich, Germany 
Sigma-Aldrich, USA 
Merck, South Africa 
Merck, South Africa 
Sigma-Aldrich, USA 
ThermoFisher Scientific, USA 
Saarchem, South Africa 
Saarchem, South Africa 
Merck, South Africa 
Sigma-Aldrich, USA 
Saarchem, South Africa 
Saarchem, South Africa 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 
Saarchem, South Africa 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 
Sigma-Aldrich, USA 
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Methanol 
Magnesium chloride (MgCl2) 
Magnesium Sulphate (MgSO4) 
Polyethylene Glycol 3000 (PEG-3000) 
Polyvinylpyrrolidone (PVP) 
Potassium acetate (KOAc) 
Potassium chloride (KCI) 
Potassium hydroxide (KOH) 
Potassium phosphate (K2HPO4) 
Potassium dihydrogen phosphate (KH2PO4) 
Sodium carbonate (Na2CO3 / NaHCO3) 
Sodium chloride (NaCl) 
Sodium dodecyi sulphate (SDS) 
Sodium phosphate (NaH2PO4/ Na2HPO4) 
Sodium hydroxide (NaOH) 
Silver nitrate (AgNO3) 
Snake-skin 10 kDa MWCO 
TEMED(N,N,N’,N'~tetramethylethylenediamine) 
Tris (Tris-2-amino-2-hydroxymethyl-1,3-
propanol) 
Triton X-100 
Tween 20 
Yeast extract 
Pancreatic digent of casein (tryptone) 
Biospin gel extraction kit 
Biospin plasmid DNA extraction kit 
DNA Sequencing  
hTIM gene in pMK-T vector 
FPLC System UPC-900 AKTA 
Zeiss Libra 120 TEM 
365 nm gel doc #ECX-15-L 
Centrivap Cold trap and DNA concentrator 
Saarchem, South Africa 
Saarchem, South Africa 
Saarchem, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Merck, South Africa 
Sigma-Aldrich, Germany 
Sigma-Aldrich, Germany 
- 
Sigma-Aldrich, USA 
Merck, South Africa 
Biolab, South Africa 
Biolab, South Africa 
Bioer, China 
Bioer, China 
Inqaba biotechnology, RSA 
Life Sciences, USA 
GE Healthcare, USA 
Zeiss, Germany 
Vilber Lourmat 
Vacutec, RSA 
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Appendix B 
 
List of preparation procedures for buffers, growth media, agar plates, gels and other basic 
preparations.  
 
Luria Broth (LB-Broth), 1 l, pH 7.0 (pH checked but no adjustments ever required) 
10 g/l Tryptone (pancreatic digest of casein)  
5 g Yeast Extract 
5 g NaCl 
(Autoclave 121°C at 1.21 kg/cm2 for 20 min) 
 
TB-Buffer, 250 ml 
10 mM HEPES 
15 mM CaCl2  
250 mM KCl 
55 mM MnCl2 
(Mix all components except the MnCl2 then adjust to pH 6.7 with KOH or HCl and add the 
MnCl2 and filter sterilize with a 0.22 µm filter and store at 4°C) 
 
Super Optimal broth (SOB) Medium, 1 l 
20 g/l Tryptone (pancreatic digest of casein) 
5 g Yeast extract 
0.584 g/l NaCl 
0.186 g/l KCl 
2.034 g/l MgCl2-6H2O 
2.464 g/l MgSO4-7H2O 
(Autoclave 121°C at 1.21 kg/cm2 for 20 min) 
 
Super Optimal broth with Catabolite repression (SOC)-Broth 
To 1 l of SOB broth after autoclaving add under sterile conditions 
20 ml of 1 M glucose (filter sterilized) 
 
LB-Agar plates (With or without antibiotics) 
Add 15 g/l agar to 1 l LB-Broth medium before autoclaving. 
After autoclaving allow to cool to approximately 55°C and add any necessary antibiotics, mix 
by swirling and gently inverting several times and then pour about 20 ml per sterile petri dish 
plate. Allow to cool to 4°C in fridge and store inverted. 
 
 
10x TAE Electrophoresis Buffer, 1 l 
48.4 g of Tris base [tris(hydroxymethyl)aminomethane] 
11.4 mL of glacial acetic acid (17.4 M) 
3.7 g of EDTA, disodium salt 
Deionized water 
(Tris, glacial acetic acid and EDTA are dissolved in 800 ml of deionized water and then the 
buffer is made up to 1 L. This was autoclaved and stored at room temperature. The solution is 
diluted to 1X  from the 10X stock with deionized water prior to use). 
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Lysis by boiling procedure 
The Dirty prep Lysis by boiling procedure started by adding 1.5 ml of broth culture to a 1.5 
ml tube and centrifuging at 14000 rpm for 30 sec discarding the supernatant. Pelleted cells 
are resuspended in 350 µl STET buffer (5% {v/v} Triton X-100, 50 mM Tris-HCl, 50 mM 
EDTA, and 8% {w/v} sucrose at pH 8.0). To this 25 µl lysozyme (10 mg/ml) was added and 
the sample was vortexed for 3 sec. Tubes were placed in 100°C heat block for 40 sec and 
then centrifuged at 14000 rpm for 10 min at room temperature in a micro centrifuge. Pellet 
debris was removed using a toothpick and 40 µl of 2.5 M sodium acetate at pH 5.2 was added 
along with 420 µl of isopropanol. Sample was vortexed and left to precipitate at RT for 5 
min. This was then centrifuged at 14000 rpm for 5 min and the supernatant carefully 
discarded. To the tube 1 ml of ice cold 70% ethanol was added and it was centrifuged at 
14000 rpm for 2 min. Supernatant was discarded and the sample dried by placing it in a 45°C 
heat block with the lid open for 10 min. Sample was then dissolved in 50 µl 10 mM Tris-HCl 
buffer pH 8.0 using an auto-pipette. This sample was then used in double digest reactions and 
run on a 0.8% agarose gel for screening.  
 
ZY medium, 1l 
10 g pancreatic digest of casein (tryptone)  
5 g of yeast extract  
(Fill to 1 l of dddH2O and autoclaving).  
 
20x NPS solution, 200 ml 
0.5 M (NH4)2SO4 ,  
1 M of KH2PO4  
1 M Na2HPO4  
(Filter sterilized using a 0.22 µm sterile filter into a pre-autoclaved bottle) 
 
50x, (505)/(5052), 100 ml 
250 g/l glycerol,  
25 g/l glucose,  
100 g/l α-lactose  
(Filter sterilized using a 0.22 µm sterile filter into a pre-autoclaved bottle) 
 
1 M MgSO4, 10 ml 
1.2 g in 10 ml dddH2O 
(Filter sterilized using a 0.22 µm sterile filter into a pre-autoclaved bottle) 
 
ZYP505/5052, 1l 
50 ml of 20x NPS,  
20 ml of 50x 505/5052,  
2 ml of 1 M MgSO4 and  
1 l of ZY media.  
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KHPO4 Working buffer 
1 M K2HPO4 (base) 1 l prepared and autoclaved 
1 M KH2PO4 (acid) 500 ml prepared and autoclaved  
(The above 2 buffers were mixed approximately 77(base):23(acid) while monitoring pH until 
pH 7.4 was reached, 100 ml of this was then mixed with 900 ml deionised H2O to make the 
0.1 M Working buffer). 
 
FPLC Running buffer, 1 l  
20 mM KHPO4 (pH 7.4) 
40 mM imidazole  
0.5 M NaCl 
 
FPLC Elution buffer, 500 ml 
20 mM KHPO4 (pH 7.4) 
500 mM imidazole  
0.5 M NaCl 
 
FPLC 4x loading buffer, 100 ml 
80 mM KHPO4 (pH 7.4) 
160 mM imidazole  
2.0 M NaCl 
 
FPLC dddH2O, 1 l  
FPLC 20% Ethanol, 1 l 
(Note: All FPLC buffers filtered through 0.45 µM filtration membrane and degassed)  
 
FPLC Gel filtration running buffer  
50 mM KHPO4 
50 mM NaCl 
(Adjusted to pH 7.4, then degassed and autoclaved) 
 
SDS-PAGE Resolving gels 12.5% 
1.518 ml 30%/0.8% Acrylamide/Bis-Acrylamide,  
485 µl 3 M Tris-HCl, pH 8.8 
1.641 ml sterile dddH2O 
91 µl 10% SDS 
12.5 µl 10% ammonium persulphate (APS)  
2.5 µl Tetramethylethylenediamine (TEMED)  
(APS and TEMED added just prior to pouring of the gel. Once poured a few drops of H2O 
saturated Tert-Amyl alcohol (2-Methyl-2-butanol) were added to prevent oxygen access and 
ensure it set level. Gels were allowed 1 h to set before pouring the stacking gel).  
 
SDS-PAGE Stacking gels 4% 
0.2 ml 30%/0.8% Acrylamide/Bis-Acrylamide 
105 µl 0.5 M Tris-HCl, pH 6.8 
1.185 ml sterile dddH2O 
15 µ l 10% SDS 
15 µl 10% APS 
 2.5 µl  TEMED 
(After pouring 10 tooth combs were inserted into the gels and left to set for 1 h). 
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SDS-PAGE 10x running buffer, 1l  
30.28 g Tris 
144 g Glycine 
10 g SDS 
(Buffer sterilised and diluted down to 1x using dddH2O prior to running SDS-PAGE). 
 
SDS-PAGE TD solution  
1 ml 10% SDS  
50 µl β-mercaptoethanol  
(Always prepared fresh) 
 
SDS-PAGE TS solution  
13.3 ml 3 M Tris-HCl, pH 8.8 
2 ml 0.5 M Ethylenediaminetetraacetic acid (EDTA) 
40 ml Glycerol  
20 mg bromophenol blue.  
 
SDS-PAGE loading solution TD + TS  
200 µl TS solution  
50 µl of TD solution  
(This constituted the loading solution which was mixed 1:1 with protein sample heated on a 
heat block (100°C, 10 min) and 25 µl loaded per well). 
 
SDS-PAGE Fairbanks destaining solutions 
Fairbanks A, 0.05% coomassie blue R-250, 25% isopropanol, and 10% acetic acid 
Fairbanks B, 0.005% coomassie blue R-250, 10% isopropanol, and 10% acetic acid 
Fairbanks C, 0.002% coomassie blue R-250, and 10% acetic acid 
Fairbanks D, 10% acetic acid 
 
Triethanolamine HCl (TEA) buffer for α-G3PDH and TIM assays, 500 ml 
300 mM Triethanolamine HCl (TEA)  
(Adjusted to pH 7.4 for α-G3PDH assays and pH 7.6 for TIM assays with KOH or HCl) 
 
DHAP substrate for αG3PDH assays 
76 mM Dihydroxyacetone phosphate (DHAP)  
(Prepared in sterile MilliQ H2O and frozen in aliquots)  
 
β-Nicotinamide Adenine Dinucleotide in reduced form (β-NADH) 
8 mM β-Nicotinamide Adenine Dinucleotide (reduced form)  
(Prepared fresh in TEA buffer, pH 7.4 or 7.6, dependant on assay being performed). 
 
DL-GAP Substrate for TIM assays 
20 mM of DL-Glyceraldehyde-3-phosphate dilithium salt (DL-GAP) 
(Prepared in sterile MilliQ H2O and frozen in aliquots)  
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αG3PDH enzyme preparation for αG3PDH and TIM assays  
Lyophilised αG3PDH in 100 U vials (Sigma-Aldrich) were re-suspended in TEA buffer (300 
mM, pH 7.4, 1 ml, 0.05 µl β-mercaptoethanol, 6-7 drops 50% glycerol) and stored (4°C, up 
to 2-weeks). This helped maintain the αG3PDH enzyme in reduced form which has been 
shown to improve stability and freezing this enzyme is known to result in a total loss of 
activity (Albertyn et al., 1992; De la Roche et al., 2012). The (100 U/ml) stock was diluted 
down to working concentrations (1 U/ml) for αG3PDH assays, (20 U/ml) for TIM assays and 
(40 U/ml) for TIM kinetics assays. Dilutions made just prior to performing relevant assay.  
 
pH Buffer cocktail 
Four buffers in all were used in the buffer cocktail to achieve the pH range 3.5 to 9.0. These 
were, sodium acetate for pH (3.5 to 5.5), 2-(N-morpholino) ethanesulfonic acid (MES) for pH 
(5.6 to 6.7), 2-[4-(2-hydroxyethyl)piperazin-1-yl] ethanesulfonic acid (HEPES) for pH (6.8 to 
8.2) and finally 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propane-1-sulfonic 
acid (TAPS) for pH (7.7 to 9.1).  
 
A 500 ml stock solution (20 mM) of each of these four buffers was prepared. The pH of the 
stock buffer was adjusted using KOH or HCl to create individual buffers (20 ml each) 
covering pH 5.5 to 9.1. For buffers covering pH 3.5 to 5.0 pH adjustments were done using 
acetic acid. After preparation, each of the individual buffers was filter sterilised using a 
syringe and a 0.45 µm filter. Overall 12 pH buffers were prepared in 0.5 pH increments 
covering values from pH 3.5 to pH 9.0.  
 
Testing for change in pH due to buffer  
Both purified enzymes were stored in KHPO4 buffer (100 mM, pH 7.4). To test if this buffer 
may have altered the pH of the buffer cocktail being used, an identical KHPO4 buffer (100 
mM, pH 7.4) was prepared. This was diluted 1/300 (the lowest dilution used in tests) with 
buffer cocktail samples at pH values 3.5, 7.0 and 9.0. Change in pH level was then measured 
for each and it was shown that no significant pH change occurred (i.e. +/- <0.05 pH units).  
An additional pH evaluation was done to test for pH changes when buffer cocktail mixed 
with the TIM assay buffer Triethanolamine HCl (TEA) (300 mM, pH 7.6). This was 
performed using (1:20 ratio pH 3.5 buffer cocktail to TEA). The observed pH change 
recorded was -0.12 which was deemed would not affect the activity assay. 
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Appendix C 
 
Plasmodium falciparum cDNA sequence, Primer design and analysis. 
Forward 
 
5'-atggctagaaaatattttgtcgcagc-3' 
Length=26 A=8.0 G=6.0 T=8.0 C=4.0 CG=38.5% 
Complexity = 91% 
Primer's PCR Efficiency = 72% 
  
Tm = 56.3°C (Allawi's thermodynamics parameters) 
Tm = 64.7°C (Sugimoto's thermodynamics parameters) 
Tm = 57.1°C (SantaLucia's thermodynamics parameters) 
Tm = 55.3°C (Tm = 75.1 + 11.7Log[K+] + 0.41(GC%) - 528/L) 
Tm = 54.8°C (Tm = 64.9 + 41(nG + nC - 16.4)/L) 
 
IDT Analysis  
LENGTH: 26 
GC CONTENT: 38.5 % 
MELT TEMP: 56.3 ºC 
MOLECULAR 
WEIGHT: 8009.3 g/mole 
 
pDraw Analysis 
Tm 59.8 
 
Reverse 
5'-ttacatagcactttttattatatcaacaaaagattc-3' 
Length=36 A=14.0 G=2.0 T=14.0 C=6.0 CG=22.2% 
Complexity = 70% 
Primer's PCR Efficiency = 77% 
  
Tm = 52.8°C (Allawi's thermodynamics parameters) 
Tm = 62.3°C (Sugimoto's thermodynamics parameters) 
Tm = 51.2°C (SantaLucia's thermodynamics parameters) 
Tm = 54.3°C (Tm = 75.1 + 11.7Log[K+] + 0.41(GC%) - 528/L) 
Tm = 55.3°C (Tm = 64.9 + 41(nG + nC - 16.4)/L) 
 
IDT Analysis 
LENGTH: 36 
GC CONTENT: 22.2 % 
MELT TEMP: 54.0 ºC 
MOLECULAR 
WEIGHT: 10975.2 g/mole 
 
pDraw Analysis 
Tm 56.5 
 
FINAL Primers with restriction endonucleases added. 
Forward with NdeI 
CATATGatggctagaaaatattttgtcgcagc 
Final - Forward with removal of 2nd ATG 
CATatggctagaaaatattttgtcgcagc 
Final - Reverse with EcoRI 
GAATTCttacatagcactttttattatatcaacaaaagattc 
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BLAST Scores and Top 3 results (Primer BLAST against all known sequences)  
 
Forward 
Plasmodium falciparum 3D7 triosephosphate isomerase (PF14_0378) mRNA, complete cds 
Score 52.0 Total Score 74.3 Coverage 100% E-Val 9e-08 
Plasmodium falciparum 3D7 chromosome 14, complete sequence 
Score 52.0 Total Score 2.977e+04 Coverage 100% E-Val 9e-08 
Plasmodium falciparum 3D7 chromosome 12, complete sequence 
Score 30.2 Total Score 1.703e+04 Coverage 88% E-Val 0.34 
 
Reverse 
Plasmodium falciparum 3D7 triosephosphate isomerase (PF14_0378) mRNA, complete cds 
Score 71.9 Total Score 163 Coverage 100% E-val 2e-13  
Plasmodium falciparum 3D7 chromosome 14, complete sequence 
Score 71.9 Total Score 7.418e+04 Coverage100% E-val 2e-13  
Plasmodium falciparum 3D7 chromosome 7 
Score 36.2 Total Score 3.078e+04 Coverage 100% E-val 0.010 
 
Plasmodium falciparum cDNA sequence from NCBI translated into DNA code from mRNA 
sequence. The coding sequence from 318 to 1064 starting with ATG and ending in TAA is 
highlighted. 
 
LOCUS    XM_001348516   1486 bp    mRNA 
ORIGIN   Plasmodium falciparum 3D7 triosephosphate isomerase (PF14_0378)  
        1 taaattataa tttttataat tgaccacttt ttttcttaat aaagtgaaaa taataaaaaa 
       61 aatattccgt atataaaaga aaaacatatc aacaaaaata tattataata tttgcttaat 
      121 ttttttaata taatatatta tttttattat atcttccctt cattaaagaa attataatat 
      181 tttaaaaaac taatattata agtatataat tttattatta ttattttaaa gtgctaaccc 
      241 aaaaaaaatt taattactaa gttttttatt tttttatttt tttattttat tattttttaa 
      301 ttttttcttt ttacaaaatg gctagaaaat attttgtcgc agcaaactgg aaatgtaatg 
      361 gaactttaga aagtattaaa tctttaacaa acagttttaa caatttggat tttgatccaa 
      421 gcaaattaga cgttgttgtt tttcctgttt ccgtacatta tgatcataca aggaaattac 
      481 ttcagagtaa gttttctact ggtattcaga atgtatcaaa attcggaaat ggatcataca 
      541 caggtgaagt aagtgcagaa attgccaagg atttaaatat tgaatatgtt attattggtc 
      601 attttgaaag aagaaaatat ttccatgaaa ccgatgaaga tgttcgtgaa aaattacaag 
      661 cttcattaaa aaataattta aaagccgttg tatgttttgg tgaatcttta gaacaaagag 
      721 aacaaaataa aactatcgaa gttattacaa aacaagttaa agcatttgtt gatttaattg 
      781 ataattttga taatgttatt ttggcttatg aacctttatg ggctattggt actggtaaaa 
      841 cagctacacc tgaacaagct caattagtac acaaagaaat cagaaaaatt gtaaaagata 
      901 catgcggaga aaaacaagct aaccaaataa gaatattata tggaggtagt gttaatactg 
      961 aaaactgctc ttcattaatt caacaagaag atattgatgg tttcttagtt ggaaatgctt 
     1021 ccttaaaaga atcttttgtt gatataataa aaagtgctat gtaaaatata tatatatata 
     1081 ttacaaatga ataatgaata gatatacata tatatatatt tgataacatt tttcttttat 
     1141 atatatttta taaatgcatt tacgacttta aaaaaaaatg aggtgaacgt attctatata 
     1201 tatatatata tatatatgtt gcattcaaat tttgaaaaac tatttctcat ttttatcata 
     1261 tttatttatt ttatcatatt cgtgttttct cattttctta tttttttatt catcgtcatg 
     1321 ttccgaactt ttctcgcaaa agtgtattta taatatttat gcctttatga ttttatcact 
     1381 taccaacata taataataat aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa tcaaactctc 
     1441 aacattttta acacataaat aaaatttgtg ataagggaaa tgtaaa 
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Appendix D 
 
Gels of PfTIM samples  
 
Figure D1: Gradient PCR reactions of PfTIM (lane 1) using cDNA as template  
 
Figure D2: Optimised gradient PCR using cDNA PCR product as template strongest bands seen at 
62°C and 57°C double annealing temperature procedure. 
PfTIM, 750 bp 
PfTIM, 750 bp 
1      2       3       4       5      6      7 
1   2     3    4     5    6    7     8    9   10   11  12 
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Figure D3: PCR from cDNA using the optimized protocols  
 
 
Figure D4: Image of the gel run on the double digest reaction of the pJET1.2 vector (3 Kbp) 
containing PfTIM (lanes 2 to 4). Note: Image taken after DNA visualization at 365 nm and excision 
of the PfTIM (cut at 750 bp) sequence for purification using the gel extraction kit. The last 3 lanes (6 
to 8) indicate the double digest of the pET28(b+) expression vector (cut at 5.4 Kbp) indicating that it 
was in linear form. Note this was also extracted and the linearized purified PfTIM and pET28b+ 
vector were then used for sticky end ligations as they had being digested using the same restriction 
endonucleased (NdeI and EcoRI). 
 
 
 
PfTIM, 750 bp
Excised pET28(b+) 
Excised PfTIM 
1        2         3         4        5        6        7        8 
1           2         3         4         1             2   
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Appendix E 
Figure E1: Plasmid Map of pMK-T plasmid and essential data about the plasmid provided by life 
sciences.  
 
Figure E2: Chromatogram of DNA sequenced data for the purchased hTIM sequence. 
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Figure E3: Purchased hTIM DNA sequenced translated into an Amino acid sequence. 
 
Below is the BLAST of the translated hTIM amino acid sequence alignment obtained versus the 
known hTIM amino acid sequence (from NCBI) this had to be done this way because the purchased 
DNA sequence was codon optimised for E. coli and therefore differed from the human sequence. The 
DNA sequence arrived in the pMK-T plasmid (Figure E3). 
 
Length=250 
Score =  511 bits (1317),  Expect = 0.0, Method: Compositional matrix 
adjust. 
Identities = 250/250 (100%), Positives = 250/250 (100%), Gaps = 0/250 (0%) 
 
Query MAPSRKFFVGGNWKMNGRKQSLGELIGTLNAAKVPADTEVVCAPPTAYIDFARQKLDPKI  60 
Sbjct MAPSRKFFVGGNWKMNGRKQSLGELIGTLNAAKVPADTEVVCAPPTAYIDFARQKLDPKI  60 
Query AVAAQNCYKVTNGAFTGEISPGMIKDCGATWVVLGHSERRHVFGESDELIGQKVAHALAE  120 
Sbjct AVAAQNCYKVTNGAFTGEISPGMIKDCGATWVVLGHSERRHVFGESDELIGQKVAHALAE  120 
Query GLGVIACIGEKLDEREAGITEKVVFEQTKVIADNVKDWSKVVLAYEPVWAIGTGKTATPQ  180 
Sbjct GLGVIACIGEKLDEREAGITEKVVFEQTKVIADNVKDWSKVVLAYEPVWAIGTGKTATPQ  180 
Query QAQEVHEKLRGWLKSNVSDAVAQSTRIIYGGSVTGATCKELASQPDVDGFLVGGASLKPE  240 
Sbjct QAQEVHEKLRGWLKSNVSDAVAQSTRIIYGGSVTGATCKELASQPDVDGFLVGGASLKPE  240 
Query FVDIINAKQ*  250 
Sbjct FVDIINAKQ*  250 
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Figure E4: Gel of double digest reactions done on the p-MK-T and pET28(b+) plasmids, which were 
visualised at 365 nm and the bands corresponding to the hTIM gene at 750 bp (lanes 3 to 5) and the 
linearised pET28(b+) vector at 5.4 Kbp (lanes 9 to 11) were excised from the gel for DNA gel 
extraction and then ligation of the hTIM gene into pET28(b+) vector. 
 
Figure E5: Agarose gel of the ‘dirty prep’ Lysis by boiling procedure followed by a double digest 
reaction (Section 2.2.5) used to screen transformed colonies for positive inserts, from this lanes 2 and 
8 were selected to undergo a clean preparation procedure using the kit (Section 2.2.4). 
  
1       2     3     4     5     6     7     8      9    10   11  12   13   14   15 
1       2       3       4       5      6       7       8       9     10     11     12 
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Appendix F  
 
Figure F1: Chromatogram of the DNA sequencing result for the sub-cloned PfTIM DNA sent in for 
sequencing in the pJet1.2 cloning vector using the pJet1.2 primers that came with the kit. The 
resulting DNA sequence is shown. 
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Plasmodium falciparum 3D7 triosephosphate isomerase (PF14_0378) mRNA, complete cds  
Sequence ID: ref|XM_001348516.2|Length: 1486Number of Matches: 1 
Related Information 
Gene-associated gene details 
Range 1: 318 to 1064GenBankGraphics Next Match Previous Match First Match  
Alignment statistics for match #1 
Score Expect Identities Gaps Strand Frame 
1380 bits(747) 0.0() 747/747(100%) 0/747(0%) Plus/Plus 
 
Features: 
Query  1     ATGGCTAGAAAATATTTTGTCGCAGCAAACTGGAAATGTAATGGAACTTTAGAAAGTATT  60                                                                                                                  
Sbjct  318   ATGGCTAGAAAATATTTTGTCGCAGCAAACTGGAAATGTAATGGAACTTTAGAAAGTATT  377 
 
Query  61    AAATCTTTAACAAACAGTTTTAACAATTTGGATTTTGATCCAAGCAAATTAGACGTTGTT  120           
Sbjct  378   AAATCTTTAACAAACAGTTTTAACAATTTGGATTTTGATCCAAGCAAATTAGACGTTGTT  437 
 
Query  121   GTTTTTCCTGTTTCCGTACATTATGATCATACAAGGAAATTACTTCAGAGTAAGTTTTCT  180           
Sbjct  438   GTTTTTCCTGTTTCCGTACATTATGATCATACAAGGAAATTACTTCAGAGTAAGTTTTCT  497 
 
Query  181   ACTGGTATTCAGAATGTATCAAAATTCGGAAATGGATCATACACAGGTGAAGTAAGTGCA  240           
Sbjct  498   ACTGGTATTCAGAATGTATCAAAATTCGGAAATGGATCATACACAGGTGAAGTAAGTGCA  557 
 
Query  241   GAAATTGCCAAGGATTTAAATATTGAATATGTTATTATTGGTCATTTTGAAAGAAGAAAA  300           
Sbjct  558   GAAATTGCCAAGGATTTAAATATTGAATATGTTATTATTGGTCATTTTGAAAGAAGAAAA  617 
 
Query  301   TATTTCCATGAAACCGATGAAGATGTTCGTGAAAAATTACAAGCTTCATTAAAAAATAAT  360           
Sbjct  618   TATTTCCATGAAACCGATGAAGATGTTCGTGAAAAATTACAAGCTTCATTAAAAAATAAT  677 
 
Query  361   TTAAAAGCCGTTGTATGTTTTGGTGAATCTTTAGAACAAAGAGAACAAAATAAAACTATC  420           
Sbjct  678   TTAAAAGCCGTTGTATGTTTTGGTGAATCTTTAGAACAAAGAGAACAAAATAAAACTATC  737 
 
Query  421   GAAGTTATTACAAAACAAGTTAAAGCATTTGTTGATTTAATTGATAATTTTGATAATGTT  480           
Sbjct  738   GAAGTTATTACAAAACAAGTTAAAGCATTTGTTGATTTAATTGATAATTTTGATAATGTT  797 
 
Query  481   ATTTTGGCTTATGAACCTTTATGGGCTATTGGTACTGGTAAAACAGCTACACCTGAACAA  540           
Sbjct  798   ATTTTGGCTTATGAACCTTTATGGGCTATTGGTACTGGTAAAACAGCTACACCTGAACAA  857 
 
Query  541   GCTCAATTAGTACACAAAGAAATCAGAAAAATTGTAAAAGATACATGCGGAGAAAAACAA  600           
Sbjct  858   GCTCAATTAGTACACAAAGAAATCAGAAAAATTGTAAAAGATACATGCGGAGAAAAACAA  917 
 
Query  601   GCTAACCAAATAAGAATATTATATGGAGGTAGTGTTAATACTGAAAACTGCTCTTCATTA  660           
Sbjct  918   GCTAACCAAATAAGAATATTATATGGAGGTAGTGTTAATACTGAAAACTGCTCTTCATTA  977 
 
Query  661   ATTCAACAAGAAGATATTGATGGTTTCTTAGTTGGAAATGCTTCCTTAAAAGAATCTTTT  720           
Sbjct  978   ATTCAACAAGAAGATATTGATGGTTTCTTAGTTGGAAATGCTTCCTTAAAAGAATCTTTT  1037 
 
Query  721   GTTGATATAATAAAAAGTGCTATGTAA  747 
Sbjct  1038  GTTGATATAATAAAAAGTGCTATGTAA  1064 
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Appendix G 
Bradfords assay standard curve 
To determine concentrations of protein from absorbance readings using the Bradfords method 
(Bradfords, 1976) a standard curve (Figure G1) was constructed using 11 points of known 
BSA concentrations (0-1.2 mg/ml) and the protocol provided by the Sigma-Aldrich, (2012). 
All data points were measured in hexlicate (n=6), and the linear equation from Figure G1 
reorganised (Equation G1) for the determination of concentration from absorbance readings 
at 595 nm. 
 
Figure G1: Bradfords assay standard curve made using known concentrations of Bovine 
Serum Albumin (BSA), error bars (standard deviation), linear equation and R2 values 
included.  
 
 
Equation G1 
x = (y + 0.0126) / (0.3101) 
 
When samples had readings out of range they were diluted 1:1 using distilled H2O where 
necessary. If samples required concentration a 10 fold increase was achieved by using 50 µl 
per well instead of 5 µl (strictly speaking this concentration method is not correct) as it uses 
less Bradfords reagent per well however due to lower protein concentration (of samples that 
require concentration) and sufficient Bradfords reagent in the protocol for over 1 mg/ml 
protein full colour development does in fact occur using this method and an accurate result is 
produced. 
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Appendix H 
Optimizing assay protocols 
To optimize the TIM standard assay different concentrations of αG3PDH were tested. Figure 
H1 and Table H1 indicate the decrease in absorbance at 340 nm and the activity of rTIM 
when (13 U/ml, 20 U/ml and 40 U/ml) of αG3PDH are used. Standard concentrations for all 
other relevant reagents were used. These data indicate no significant increase in activity when 
13 U/ml, 20 U/ml and 40 U/ml of αG3PDH are used. This was expected as the assay uses a 
large excess of αG3PDH. From these data it was decided that 20 U/ml of αG3PDH would be 
used for standard TIM assays and only kinetics assays which use large substrate 
concentrations would require 40 U/ml αG3PDH.  
 
Figure H1: The activity of set rTIM concentrations using different concentrations (13 U/ml, 20 U/ml 
and 40 U/ml) of coupling αG3PDH (n=3). 
 
 
Table H1: Calculated TIM activity using (13 U/ml, 20 U/ml and 40 U/ml) of αG3PDH 
αG3PDH 
concentration 
Calculated 
activity 
13 U  0.704 mM/min 
20 U 0.738 mM/min 
40 U 0.636 mM/min 
 
Averaged assay data on identical samples revealed the assay has an inherent margin of error 
of +/- 5-10%. Careful refinement of the operating steps and standardising conditions such as: 
timing and mixing procedures, brought this margin of error down to approximately +/- 5%. 
As such results within this margin of error range are considered to be equivalent in assays. 
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The other important optimization was to find the correct dilutions of the different 
recombinant TIM enzymes. Each of which showed different protein concentrations and 
activity levels after purification. Standardised running conditions recommended for this assay 
(Bergmeyer, 1974; Plaut and Knowles, 1972), require the assay to ‘complete’ or deplete 
NADH supply, in 5-8 min. This time range is optimally suited to allow increased or 
decreased enzymatic activity to be observed satisfactorily during experimentation. Many 
different dilutions of hTIM and PfTIM were attempted until a 1/2000 dilution for hTIM and a 
1/300 dilution for PfTIM were able to achieve these optimal time constraints. These 
obviously represented different enzyme concentrations but to optimize the assay this was 
required. Activity per mg could then easily be calculated using the protein concentration data 
obtained for each TIM by Bradfords method assays and multiplying out by these set dilution 
ratios. These dilution ratios were used for all subsequent experiments and done as a two-step 
serial dilution, to achieve the highest possible level of consistency. Additionally they were 
always done fresh and comparisons which varied other parameters always used dilutions 
made from the same stock and prepared on the same day.  
 
Optimizing assays also involved determining a negative control system for each and every 
individual well sample, to ensure no contamination was present. This was possible due to the 
coupled nature of the assay in which the monitoring of wells prior to the addition of the 
reaction initiating enzyme (TIM) could be used as a negative enzyme control for TIM assays. 
Change in absorbance monitored during pre-incubation steps was analysed over many 
samples and shown to be zero which was used in the equations to determine activity. This 
was done for a few key reasons. First: initial inconsistency in the 2 min incubation period 
resulted in a slight but practically insignificant gradient that could be either positive or 
negative, before the system equilibrated and levelled off. Second: gradient readings taken 
were all very low and bordering on insignificant. Third: analysis of this process over an 
extended period of time (~15 min) using many samples, showed that after an initial gradient 
change, samples would equilibrate until the gradient would level off forming a straight line of 
a gradient of zero. Forth: The process could be accelerated in reaching this point by using a 
pipette to initiate more rapid mixing by pipetting up and down, (replicating the inversion step 
of the 3 ml assay). Fifth: at the point of starting the enzymatic assay this level off point had 
being reached. For practical reasons pipette mixing could not be done on all sample wells as 
this would likely have increased the chance of cross contamination, exposure to other 
contaminants and altered very carefully measured volumes. The 2 min incubation of the 
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negative controls for each well also proved effective in monitoring for contamination and in 
cases where controls showed residual activity during pre-incubation those samples were 
repeated and/or eliminated from the data set. 
  
 
Figure H2: The activity of set rTIM versus hTIM (1/2000 dilution) and PfTIM (1/300 dilution) 
(n=3). 
 
 
Figure H2 indicates that the purified recombinant TIM enzymes are both active. Activity 
cannot be compared to that of the +ve control rTIM as the concentrations were not the same. 
This assay proved activity was present in both samples and the assay was functional and 
running to completion within the desired time duration of 5-10 min as it should. The fact that 
the recommended concentration of rTIM ran this assay to completion in approximately 10 
min also indicates that all concentrations, dilutions and mixing procedures were effective and 
functioning. 
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Figure H3: NADH linear response range versus volume of 8 mM NADH added, samples run in 
triplicate and error bars calculated using standard deviation.  
 
 
From these data it was assumed that NADH produced a linear response curve in the Synergy 
MX spectrophotometer used up to and absorbance reading at 340 nm of 2.5. The R2 value 
indicated on the graph of 0.9977 confirms the strong linear correlation of the response.  
Appendix I 
Activity assays to determine the activity at each step during the purification of hTIM (Figures 
I1 and I2) and PfTIM (Figures I3 and I4) samples to draw up the purification tables are 
indicated. Activity was calculated using Equation 3.1 (chapter 3). The gradient of each curve 
(Figures I1 and I2) was determined by linear regression in MS Excel, taking only the most 
linear portion of each curve into consideration and samples were all done in triplicate.  
Further details such as dilution factors used and calculations for each and every sample are 
included in the laboratory note books handed in with this thesis.  
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Figure I1: Coupled activity assay for hTIM with linear graph equations for the determination of 
activity. Legend indicates which purification step it was taken from (n=3). 
 
Figure I2: Coupled activity assay for hTIM with linear graph equations for the determination of 
activity. Legend indicates which purification step it was taken from (n=3). 
 
Figure I3: Coupled activity assay for PfTIM with linear graph equations for the determination of 
activity. Legend indicates which purification step it was taken from (n=3). 
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Figure I4: Coupled activity assay for PfTIM with linear graph equations for the determination of 
activity. Legend indicates which purification step it was taken from (n=3). 
 
 
For all TIM assays conducted used this method of deriving curve gradients and Equation 3.1 
to calculate the activity. An example of Equation 3.1 is indicated below for the PfTIM post 
2700 x g centrifugation step (Figure I3, purple x). 
 
Equation 3.1 example:     Activity =  (dA/min*0.3 ml)/(6.22 µM*0.01 ml) x df 
    Activity  = (0.0556*0.03)/(6.22*0.01) x 1000 
      = 0.2681672 mM/min/ml x 1000 
      = 268.2 µmol-1.ml-1.min-1  
    Or  = 268.2 Units of activity. 
 
Appendix J 
pH and temperature tests   
A full breakdown of all the experiments conducted in the pH study is shown in Appendix K. 
All tests were done in triplicate and error bars were calculated with standard deviation. These 
data were then pooled for select time frames of 15 min and 45 min and there activities 
converted into a relative activity value based on the highest activity recording level across all 
tests. 
 
Substrate concentrations in these assays were adjusted accordingly to determined Km values 
for each TIM, because these tests are only ever compared with themselves to determine 
optimum parameters, and this was standardised for all the temperature and pH tests this does 
not affect the relative percentage activity or the determined pH or temperature optima as it is 
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always only relevant or compared with identically assayed samples. 
The setup was as follows for pH and temp assays was as before, in a first set of wells: 10 µl 
of NADH (8 mM) and 10 µl of αG3PDH (20 U/ml) and 25 µl of DL-Glyceraldehyde-3-
Phosphate (DL-GA3P) (20 mM) for hTIM assays and 30 µl of DL-GA3P (20 mM) for PfTIM 
assays, was added per a well. Lastly 205 µl or 200 µl respectively of TEA buffer at pH 7.6 
was added, totalling 300 µl. In a second set of wells 10 µl of the diluted TIM enzyme being 
tested was added (dilutions, PfTIM 1/300 and hTIM 1/2000) prepared as 2 ml volumes and 
incubated in 2 ml tubes at the tested pH or temperature. Samples were then assayed using the 
following procedure. 
Micro-titre plates were monitored in a Synergy MX spectrophotometer at (340 nm, 25°C). 
The system shook the micro-titre plates for 30 sec and monitored the first set of wells for 
change in absorbance (340 nm, 2 min, 15 sec intervals). The tray was then ejected, 290 µl 
taken from first set of wells and pipetted into the second set of wells containing 10 µl of the 
TIM enzyme being tested. The tray was immediately sent back into the machine and shaken 
variably for 3 sec then monitored for changes in absorbance at 340 nm for 10 min taking 
readings every 15 sec. 
Kinetics 
A drop in NADH absorbance at 340 nm was observed at highest substrate concentrations 
which were later eliminated from tests. This was due to small amounts of DHAP within the 
DL-GA3P solution reacting with the αG3PDH and oxidising NADH. This might be expected 
however as these two molecules are structural isomers and have identical chemical formulae, 
C3H7O6P and molecular weight of 170.06 g/mol. Any DHAP impurities in the assay are 
rapidly reacted away by the high concentrations (40 U/ml) of αG3PDH used for the coupled 
assay, meaning it wouldn’t interfere with the assay, but still oxidises NADH. The concern 
introduced by this however was whether enough NADH was still left to monitor the coupled 
assay reaction when run. An additional 2 µl NADH could alleviate this problem however.  
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Appendix K 
Calculated ‘in assay’ enzyme activity for all pH study tests, for activity of undiluted TIM 
samples, multiply by the dilution factor, 2000 x (for hTIM) and 300 x (for PfTIM).  
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Figure K1: Activity over time for hTIM (red) and PfTIM (blue) samples assayed from pH 3.5- pH 
9.0 (n=3). Error bars use standard deviation. 
 
Appendix L 
Temperature study 
Calculated ‘in assay’ enzyme activity for all temperature study experiments done in triplicate. 
Again to determine the activity of the undiluted purified TIM, the values in the graphs should 
be multiplied by the dilution factors used for the different TIMs, 2000 x (for hTIM) and 300 x 
(for PfTIM). 
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Figure L1: Activity over time for hTIM (blue) and PfTIM (red) samples assayed at temperatures 
ranging from 20°C to 65°C (n=3). Error bars use standard deviation  
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Appendix M 
It is noted that for kinetics experiments the highest substrate concentrations planned (20 mM) 
were unable to be used due to noticeable NADH depletion observed at the highest 
concentrations prior to the addition of TIM. This was due to a small amount of DHAP being 
present in the DL-GA3P purchased from Sigma-Aldrich, note – DHAP and DL-GA3P are 
structural isomers. That said excellent results up to 10 mM DL-GA3P concentrations were 
obtained which could then be extrapolated. 
From the graphs of Figure 4.5 and using the linear regression equations determined and 
shown in the Lineweaver-Burk plot Figure 4.5a values for Km and Vmax were calculated as 
indicated in Equations M1 below. 
 
Equation M1: Lineweaver-Burk calculations 
Km/Vmax=grad = 3.3788   
  -1/Km = x-int = -1.2884/3.3788 
Hence   x-int = -0.38132 
Km  = -1/ x-int   
Km    = 2.622477 mM 
Vmax  = 1/y-int   
 Vmax   = 1/1.2884   
Vmax   = 0.776156 µMol.ml-1.min-1 (conversion to l to drop volume) 
 Vmax  = 776.1565 µMol.min-1 
 
As with the Lineweaver-Burk the Hanes-Woolf plot was also used to derive Km and Vmax 
values for the hTIM graph indicated in the right of Figure 4.5. Equation M2 below details the 
calculations to obtain Km and Vmax values from the Hanes-Woolf plot of Figure 4.5b.  
 
Equation M2: Hanes-Woolf calculations 
x-int = -Km = -3.2973/1.3705 
Therefore     
Km   = 2.405910252 mM  
y-int   = Km/Vmax   
Vmax   = Km/y-int   
Vmax   = 0.729660708 µMol.ml-1.min-1 (conversion to l to drop volume) 
 Vmax  = 729.6607078 µMol.min-1 
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Equation M3: Non-linear regression calculation methodology  
First off the difference of squares is calculated as follows using experimental data and an 
unsolved Michaelis-Menten equation with Km and Vmax values of 1.   
1. Squared difference {V- [Vmax [S]/(Km+[S])]}2  
2. The above is calculated and added for all substrate concentration values. 
3. Starting with undetermined Km and Vmax values set to 1 in MS-Excel. 
4. The squared differences are added to give a single ‘test’ value. 
5. The solver tool in MS-Excel is used to minimise the ‘test’ result (sum of squared values) by 
altering the value of Km and Vmax cells that were set to 1. 
6. The solver algorithm iterates as long as necessary (probably in the millions) repeating the 
above equation by altering values of Km and Vmax and evaluating against its test, (the sum of 
difference of squares) each time until the lowest possible test value is obtained. 
7. The resulting Km and Vmax represent the absolute best fit curve to the experimental data 
which follows the Michaelis-Menten equation and returns the resulting Km and Vmax to the 
cells that were each set to 1 earlier. 
 
 
Equation M4   Kcat = Vmax/ET (Concentration of enzyme catalytic sites in µmols) 
Example Kcat = Vmax (µMol/min) / ET (µmol) Therefore: (units are in min-1) 
To calculate   ET    = n x (# catalytic sites per enzyme) 
 
Note for hTIM (df =2000; Conc = 1.49 mg-1.ml-1; Mw = 54 Kda; a 27 Kda dimer with 2 active sites) 
hTIM =  n  = M/Mw = (1.49 g-1. l-1) / 54000 g-1.l-1.mol-1 
  n = 27.592 x 10-6 mols in undiluted hTIM 
  n  = 27.592 x 10-6 / 2000 (df for hTIM assays) 
  n = 13.796 x 10-9 mols 
Therefore ET     = n x (#catalytic sites) TIM is 2 x 27 Kda monomers (as a 54 Kda Dimer) 
  ET     = 13.796 x 10-9 mols x 2 catalytic sites/molecule (TIM is a homodimer) 
  ET     = 27.592 x 10-9 mols convert to µmols 
  ET     = 27.592 x 10-3 µmols for hTIM 
Therefore  Kcat  = Vmax (µMol/min) / ET (µMol) 
E.g.
 (non-linear reg hTIM control from AgNP experiment) 
Kcat  = 1389.4 µmols.min-1 / 27.592 x 10-3 µmols  
Kcat = 5.04 x 10-4 .min-1 
Likewise the Kcat for PfTIM samples was also calculated.  
Note for PfTIM (df = 300; Conc = 0.38 mg/ml; Mw = 54 Kda; a 27 Kda dimer with 2 active sites) 
 
 
For easy reference a copy of Equation 4.1: Michaelis-Menten equation is provided below. 
 
Equation 4.1   V = Vmax [S]/(Km+[S])  
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Appendix N 
AgNP, PVP and ethanol concentration calculations for inhibition studies 
The AgNPs were made using a 0.1 M solution of AgNO3 and 0.2 ml of this was added to a 10 
ml volume. Nanoparticle concentrations are calculated in terms of molar concentrations and 
also referred to as containing a size distribution of NPs. An actual count of nanoparticles was 
never attempted as such this would be either extremely inaccurate or impossible. 
Thus 0.1 M x 0.2 ml / 10 ml = 0.002 M of AgNO3 and therefore Ag+ ions present 
Concentration   = 0.002 M x1000 
    = 2 mM AgNO3 in the NP solution 
From the standard 2 mM stock a 1/100 dilution was prepared by serially performing two 1/10 
dilutions using 100 µl AgNPs in 900 µl optimised pH buffer used for either hTIM or PfTIM 
dilutions done separately for each solution. This gave a 0.02 mM or 20 µM stock. This was 
incorporated into the 2 ml tubes used to dilute the respective TIM enzymes to obtain the 
working concentrations of NPs used for the AgNP interaction incubations that were 
performed at 25°C and readings were taken at T0 min and T45 min. 
Final concentrations of AgNPs made were 0, 0.015, 0.03, 0.06, 0.12, 0.25, 0.5, 0.75, 1.0, 1.5, 
2.0 µM. An example equation, shown below indicated how one of these concentrations was 
prepared. 
Equation 
For a final AgNP concentration of 0.12 µM AgNPs the following calculations and dilutions 
were performed. 
To obtain this concentration using the 20 µM/ml stock the 20 µM/ml needs to be diluted by 
an unknown amount this unknown is calculated below. 
 20 µM / 0.12 µM = 166.667 (this is how much it must be diluted) 
So given the above and a desired final volume of 2000 µl we can calculate how many µl of 
the 20 µM AgNP stock needs to be added to the 2000 µl tube. This calculation is shown 
below. 
2000 µl / 166.667 (dividing factor) = 12 µl. 
The mathematics of this calculation can be easily verified by the standard C1V1 = C2V2 
equation as indicated below. 
C2 = (12 µl x 20 µM) / 2000 µl  
 C2 = 0.12 µM (this is what was desired) 
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Similarly a separate divisor was calculated for each desired final concentration as described 
above and all the different AgNP incubation concentrations were prepared. EtOH and 
polyvinylpyrrolidone (PVP) containing controls were made using for equivalent 
concentration values of 0.12, 0.25, 0.5 and 2.0 µM. The dilutions for these controls were 
done exactly as described using a PVP and EtOH sample with no Ag in it. The controls were 
prepared identically to the AgNP containing samples and even included the microwaving step 
required for AgNP seed creation. This ensured control samples were completely consistent 
with the AgNP samples.  
As the controls with PVP and EtOH were created in the exact same manner as that of the 
AgNP samples their concentration of relevant materials PVP and ethanol are also calculated 
in a similar manner to the above calculations. 
PVP is a complex branched polymer with a chemical formula of (C6H9NO)n as such molar 
Mr values are estimated averages (i.e. Sigma-Aldrich reports an average mol weight as 
360000 g/mol). For this reason I refer to PVP concentration in g/ml. In the 10 ml solution 0.1 
g was used this made it 0.01 g/ml. 
As before  
 0.001 x 1/100 = 0.00001 g/ml or 0.01 mg/ml of 10 µg/ml in the stock 
For the 0.12 µM AgNP equivalent dilution which used 12 µl in 2000 µl solution the same 
was done for this control with PVP. (1/166.667 dilution). Thus 
10 µg/ml PVP / 166.667 = 0.05999 µg/ml PVP or approximately 60 ng/ml PVP in this 
dilution. 
Thus the 4 controls dilution equivalents contained 60, 125, 250 and 1000 ng/ml PVP in the 
incubation with nanoparticles. This became 1.94, 4.03, 8.06 and 32.25 ng/ml PVP within the 
assay volume after dilution with other assay reagents and enzymes. 
Likewise the absolute ethanol was 95% vol (190 proof). Thus its concentration in the AgNP 
TIM incubations was therefore  
0.95 /100 / 166.667 = 0.00570 % EtOH in the 0.12 µM/ml AgNP sample 
Thus EtOH concentrations were 0.00071, 0.00123, 0.00285, 0.00570, 0.01188, 0.02375, 
0.033563, 0.0475, 0.07125 and 0.095 % over the 10 different AgNP dilutions used, namely 0, 
0.015, 0.03, 0.06, 0.12, 0.25, 0.5, 0.75, 1.0, 1.5, 2.0 µM and also in the relevant equivalently 
diluted control samples. The term ‘equivalent dilutions’ was used to simplify the comparisons 
as it is easier to understand what the equivalent PVP and ethanol control is relevant to that to 
use the ng/ml concentrations of PVP and obscurely low % ethanol values relevant.   
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IC50 calculations  
These are very basically done using a linear regression and the inhibition data from 45 minute 
incubations with AgNPs, because of the rapid drops in activity seen with increasing 
concentrations only 4 data points for hTIM and 3 data points for PfTIM could be used. 
Figure N1: Linear range of decrease in relative percentage activity for hTIM (blue) and PfTIM (red), 
linear regression equations were reorganised to determine IC50 levels as Equations N1 and N2 
(below). 
 
 
Equations: N1 and N2 
For hTIM 
Equation N1 
For PfTIM 
Equation N2 
if y = 50% if y = 50% 
then x = (0.5-0.9292)/-2.7105 then x = (0.5-1.155)/-6.881 
x = 0.158347 µM AgNPs x = 0.09519 µM AgNPs 
IC50 0.158347 µM AgNPs IC50 0.09519 µM AgNPs 
 
 
The above calculations are only considered as a rough estimate of IC50 AgNP concentration 
levels. 
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Appendix O 
Spectral scans taken immediately after the microwave process had slight peaks with an 
absorbance of less than 0.2 prior to any dilution. This is compared to a week old sample with 
an absorbance peak of 1.6 using a 1:3 dilution (Figure O1). 
Figure O1: Fresh AgNPs versus one week old AgNPs. 
 
The above figure demonstrates that AgNP seeds need time to mature after removal from the 
microwave. This confirms that AgNP growth occurs through a seeded growth process, other 
experiments done over the 1st few hour after removal from the microwave confirmed that this 
seeded growth period mainly occurs within the 1st 2 hours after removal from the microwave. 
Further experiments indicated barely any detectable change occurs from 1 day old AgNPs to 
3 month old AgNPs, with only a slight level of aggregation occurring during this time. Thus 
it was concluded that as long as the AgNPs had being allowed to mature overnight the seeded 
growth phase was assumed to have finished and they were ready for use.    
This indicated that the seeded growth period also completed overnight. In addition to this a 
test was conducted making spectral scans after 30 min 1, 2 and 3 hours. These scans tracked 
an increasing peak height which increased rapidly over the first 2 hours after microwaving 
(data not shown). This indicated nanoparticle growth was still occurring for at least a couple 
of hours after removal from the microwave, but confirmed no further growth of the 
nanoparticles occurred after day 1. Consequently all nanoparticle samples were allowed a 
period of at least 1 day for seed growth after microwaving before use. This also helped ensure 
no free Ag+ ions remained in AgNP solutions.  
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